

# Clonal Hematopoiesis and Blood-Cancer Risk Inferred f

New England Journal of Medicine

371, 2477-2487

DOI: [10.1056/nejmoa1409405](https://doi.org/10.1056/nejmoa1409405)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Acute myeloid leukaemia. <i>Hematology</i> , 2014, 19, 493-494.	0.7	2
2	Clone Wars – The Emergence of Neoplastic Blood-Cell Clones with Aging. <i>New England Journal of Medicine</i> , 2014, 371, 2523-2525.	13.9	19
3	The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 299-307.	0.9	72
4	Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 308-316.	0.9	16
5	Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 19-25.	0.9	32
6	Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 294-298.	0.9	34
7	Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology. <i>Stem Cells</i> , 2015, 33, 2887-2892.	1.4	8
8	DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. <i>Haematologica</i> , 2015, 100, e438-e442.	1.7	105
10	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. <i>Blood</i> , 2015, 126, 2484-2490.	0.6	207
11	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. <i>Blood</i> , 2015, 125, 1367-1376.	0.6	747
12	What came first: MDS or AML?. <i>Blood</i> , 2015, 125, 1357-1358.	0.6	5
13	Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 445-453.	0.6	126
14	Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner. <i>Blood</i> , 2015, 126, 1172-1183.	0.6	117
15	Clinical and molecular response to interferon- $\gamma$ therapy in essential thrombocythemia patients with CALR mutations. <i>Blood</i> , 2015, 126, 2585-2591.	0.6	127
16	Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. <i>Blood</i> , 2015, 126, 2362-2365.	0.6	157
17	MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. <i>Blood</i> , 2015, 126, 2355-2361.	0.6	280
18	Cytopenias + mutations $\hat{=}$ dysplasia = what?. <i>Blood</i> , 2015, 126, 2349-2351.	0.6	21
19	Premalignant cell dynamics in indolent B-cell malignancies. <i>Current Opinion in Hematology</i> , 2015, 22, 388-396.	1.2	13

#	ARTICLE	IF	CITATIONS
20	The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications. <i>Current Opinion in Oncology</i> , 2015, 27, 551-559.	1.1	8
21	Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. <i>BMC Genomics</i> , 2015, 16, 727.	1.2	42
22	Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2015, 27, 532-539.	1.1	19
23	New data shed light on Yâ€lossâ€related pathogenesis in myelodysplastic syndromes. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 717-724.	1.5	42
24	Clonal Evolution Models of Tumor Heterogeneity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e662-e665.	1.8	28
25	Gene Mutations in Acute Myeloid Leukemia â€” Incidence, Prognostic Influence, and Association with Other Molecular Markers. , 0, , .		2
27	Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm. <i>Mediators of Inflammation</i> , 2015, 2015, 1-6.	1.4	36
28	Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis. <i>Cell Reports</i> , 2015, 10, 1239-1245.	2.9	443
29	High burden and pervasive positive selection of somatic mutations in normal human skin. <i>Science</i> , 2015, 348, 880-886.	6.0	1,431
30	Loss of Dnmt3a and endogenous KrasG12D/+ cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis. <i>Leukemia</i> , 2015, 29, 1847-1856.	3.3	38
31	High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). <i>Leukemia</i> , 2015, 29, 1928-1938.	3.3	36
32	Next-Generation Sequencing-Based Panel Testing for Myeloid Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 104-111.	1.2	35
33	Ageing-Induced Stem Cell Mutations as Drivers for Disease and Cancer. <i>Cell Stem Cell</i> , 2015, 16, 601-612.	5.2	149
34	Minimal Residual Disease in Acute Myeloid Leukemiaâ€”Current Status and Future Perspectives. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 132-144.	1.2	31
35	Personalized Therapy of Cancer. , 2015, , 199-381.		1
37	Low frequency of mutations in Chinese with acute myeloid leukemia: Different disease or different aetiology?. <i>Leukemia Research</i> , 2015, 39, 646-648.	0.4	7
38	Stem Cell-Specific Mechanisms Ensure Genomic Fidelity within HSCs and upon Aging of HSCs. <i>Cell Reports</i> , 2015, 13, 2412-2424.	2.9	48
39	Stem cells and healthy aging. <i>Science</i> , 2015, 350, 1199-1204.	6.0	268

#	ARTICLE	IF	CITATIONS
40	Mitochondrial dysfunction and longevity in animals: Untangling the knot. <i>Science</i> , 2015, 350, 1204-1207.	6.0	213
41	Leveraging Distant Relatedness to Quantify Human Mutation and Gene-Conversion Rates. <i>American Journal of Human Genetics</i> , 2015, 97, 775-789.	2.6	77
42	Aging, clonal hematopoiesis and preleukemia: not just bad luck?. <i>International Journal of Hematology</i> , 2015, 102, 513-522.	0.7	27
43	Modeling Normal and Disordered Human Hematopoiesis. <i>Trends in Cancer</i> , 2015, 1, 199-210.	3.8	10
44	Multistep tumorigenesis in peripheral T cell lymphoma. <i>International Journal of Hematology</i> , 2015, 102, 523-527.	0.7	31
45	DNMT3A in haematological malignancies. <i>Nature Reviews Cancer</i> , 2015, 15, 152-165.	12.8	379
46	Do Mutational Dynamics in Stem Cells Explain the Origin of Common Cancers?. <i>Cell Stem Cell</i> , 2015, 16, 111-112.	5.2	7
47	Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals. <i>Leukemia</i> , 2015, 29, 1600-1602.	3.3	16
48	Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. <i>Cancer Genetics</i> , 2015, 208, 115-128.	0.2	102
49	Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 282-291.	1.2	35
50	Functional abnormalities and changes in gene expression in fibroblasts and macrophages from the bone marrow of patients with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2015, 102, 278-288.	0.7	5
51	DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1041-1047.	0.4	4
52	Evolutionary Determinants of Cancer. <i>Cancer Discovery</i> , 2015, 5, 806-820.	7.7	350
53	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. <i>Oncologist</i> , 2015, 20, 1069-1076.	1.9	20
54	Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis. <i>Experimental Hematology</i> , 2015, 43, 609-624.	0.2	47
55	Bone marrow niche in the myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 1020-1027.	0.4	61
56	Cancer in the parasitic protozoans <i>Trypanosoma brucei</i> and <i>Toxoplasma gondii</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8835-8842.	3.3	42
57	Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8914-8921.	3.3	96

#	ARTICLE	IF	CITATIONS
58	Systems Epigenomics and Applications to Ageing and Cancer. <i>Translational Bioinformatics</i> , 2015, , 161-185.	0.0	0
59	Advances in the diagnosis and classification of myelodysplastic syndromes. <i>Diagnostic Histopathology</i> , 2015, 21, 203-211.	0.2	2
60	Application of single-cell genomics in cancer: promise and challenges. <i>Human Molecular Genetics</i> , 2015, 24, R74-R84.	1.4	60
61	Insights into cell ontogeny, age, and acute myeloid leukemia. <i>Experimental Hematology</i> , 2015, 43, 745-755.	0.2	28
62	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. <i>New England Journal of Medicine</i> , 2015, 373, 35-47.	13.9	508
63	New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide. <i>Experimental Hematology</i> , 2015, 43, 661-672.	0.2	7
64	Wnt activity and basal niche position sensitize intestinal stem and progenitor cells to <scp>DNA</scp> damage. <i>EMBO Journal</i> , 2015, 34, 624-640.	3.5	82
65	Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. <i>Seminars in Hematology</i> , 2015, 52, 150-164.	1.8	55
66	Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 184-192.	1.8	32
67	Distinguishing clonal evolution from so-called secondary acute myelogenous leukemia: Adhering to unifying concepts of the genetic basis of leukemogenesis. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 1-2.	0.6	3
68	TET proteins and the control of cytosine demethylation in cancer. <i>Genome Medicine</i> , 2015, 7, 9.	3.6	176
69	Whole-exome sequencing as a diagnostic tool: current challenges and future opportunities. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 749-760.	1.5	62
70	Paroxysmal nocturnal hemoglobinuria revisited: news on pathophysiology, clinical course and treatment. <i>Laboratoriums Medizin</i> , 2015, 39, 87-96.	0.1	0
71	Annotation of Sequence Variants in Cancer Samples. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 339-351.	1.2	9
72	Textbook of Personalized Medicine. , 2015, , .		27
73	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> , 2015, 126, 9-16.	0.6	1,493
74	Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment. <i>Leukemia and Lymphoma</i> , 2015, 56, 3022-3030.	0.6	7
75	Myeloproliferative Neoplasms. <i>JAMA Oncology</i> , 2015, 1, 97.	3.4	266

#	ARTICLE	IF	CITATIONS
76	Telomerase abrogates aneuploidy-induced telomere replication stress, senescence and cell depletion. <i>EMBO Journal</i> , 2015, 34, 1371-1384.	3.5	65
77	Inferring mutational timing and reconstructing tumour evolutionary histories. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 264-275.	3.3	48
78	Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2015, 27, 502-515.	7.7	191
79	Genetics and genomics of psychiatric disease. <i>Science</i> , 2015, 349, 1489-1494.	6.0	337
80	Somatic mutation in cancer and normal cells. <i>Science</i> , 2015, 349, 1483-1489.	6.0	996
81	Aging as a driver of leukemogenesis. <i>Science Translational Medicine</i> , 2015, 7, 306fs38.	5.8	42
82	Why germline variations in ALL can matter. <i>Lancet Oncology</i> , The, 2015, 16, 1577-1578.	5.1	1
84	Frequent Somatic Mutation in Adult Intestinal Stem Cells Drives Neoplasia and Genetic Mosaicism during Aging. <i>Cell Stem Cell</i> , 2015, 17, 663-674.	5.2	79
85	Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 55.	3.5	12
86	Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse. <i>Frontiers of Medicine</i> , 2015, 9, 412-420.	1.5	10
87	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. <i>New England Journal of Medicine</i> , 2015, 373, 1673-1676.	13.9	32
88	Clonal Hematopoiesis and Blood-Cancer Risk. <i>New England Journal of Medicine</i> , 2015, 372, 1071-1072.	13.9	57
89	The Fanconi anemia pathway is required for efficient repair of stress-induced DNA damage in haematopoietic stem cells. <i>Cell Cycle</i> , 2015, 14, 2734-2742.	1.3	18
90	Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. <i>Journal of Experimental Medicine</i> , 2015, 212, 1833-1850.	4.2	145
91	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the $\beta$ -secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000539.	0.5	47
92	Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus. <i>Leukemia</i> , 2015, 29, 2069-2074.	3.3	13
93	A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. <i>Leukemia</i> , 2015, 29, 2101-2104.	3.3	32
94	Incidence and Burden of the Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 272-281.	1.2	108

#	ARTICLE	IF	CITATIONS
95	Molecular Pathogenesis of Peripheral T Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 429-437.	1.2	13
96	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. <i>Nature Genetics</i> , 2015, 47, 1334-1340.	9.4	152
97	Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML. <i>International Journal of Hematology</i> , 2015, 102, 553-557.	0.7	16
98	Next-Generation Sequencing and Detection of Minimal Residual Disease in Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 778.	3.8	14
99	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. <i>Nature Genetics</i> , 2015, 47, 1131-1140.	9.4	107
100	Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1034-1040.	0.4	8
101	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 811.	3.8	302
102	Preventing clonal evolutionary processes in cancer: Insights from mathematical models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8843-8850.	3.3	17
103	Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1136-1152.	13.9	2,466
104	Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. <i>Blood Cancer Journal</i> , 2015, 5, e337-e337.	2.8	100
105	Reasons for optimism in the therapy of acute leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 69-72.	0.7	9
106	AML evolution from preleukemia to leukemia and relapse. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 81-89.	0.7	20
107	Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. <i>Cancer Cell</i> , 2015, 28, 552-554.	7.7	132
108	Somatic mutations linked to future disease risk. <i>Nature Reviews Genetics</i> , 2015, 16, 69-69.	7.7	8
109	Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. <i>Blood Advances</i> , 2016, 1, 160-169.	2.5	12
110	Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. <i>Blood Advances</i> , 2016, 1, 193-204.	2.5	63
111	Obesity and neoplasms of lymphohematopoietic cells. <i>Blood Advances</i> , 2016, 1, 101-103.	2.5	4
114	Stem Cell Epigenetics in Medical Therapy. , 2016, , 877-887.		0

#	ARTICLE	IF	CITATIONS
115	Molecular landscape in acute myeloid leukemia: where do we stand in 2016. <i>Cancer Biology and Medicine</i> , 2016, 13, 474.	1.4	9
116	Novel diagnostic tools: implication for the diagnosis, prognosis and understanding of haematological malignancies. <i>Hematologie</i> , 2016, 22, 66-72.	0.0	0
117	Myelodysplastic Syndromes and Other Precursor Myeloid Neoplasms in the Era of Genomic Medicine (Mini Review). <i>Journal of Leukemia (Los Angeles, Calif )</i> , 2016, 04, .	0.1	0
118	Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. <i>Oncotarget</i> , 2016, 7, 26724-26738.	0.8	16
119	Clonal Hematopoiesis of Indeterminate Potential. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2016, 113, 317-22.	0.6	65
120	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. <i>Frontiers in Immunology</i> , 2016, 7, 94.	2.2	26
121	Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 502.	2.2	272
122	Personalized Cancer Risk Assessments for Space Radiation Exposures. <i>Frontiers in Oncology</i> , 2016, 6, 38.	1.3	10
123	DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders. <i>Frontiers in Oncology</i> , 2016, 6, 187.	1.3	38
124	Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic. <i>International Journal of Molecular Sciences</i> , 2016, 17, 553.	1.8	12
125	Loss of Y Chromosome in Peripheral Blood of Colorectal and Prostate Cancer Patients. <i>PLoS ONE</i> , 2016, 11, e0146264.	1.1	79
126	The Emerging Potential for Epigenetic Therapeutics in Noncancer Disorders. , 2016, , 437-456.		2
127	Therapy-related myeloid neoplasms. <i>Current Opinion in Hematology</i> , 2016, 23, 161-166.	1.2	17
128	Regulation of hematopoietic stem cell integrity through p53 and its related factors. <i>Annals of the New York Academy of Sciences</i> , 2016, 1370, 45-54.	1.8	23
129	Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer. <i>EBioMedicine</i> , 2016, 10, 117-123.	2.7	153
130	Novel therapeutic strategies in myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2016, 23, 79-87.	1.2	2
131	Molecular landscapes of human hematopoietic stem cells in health and leukemia. <i>Annals of the New York Academy of Sciences</i> , 2016, 1370, 5-14.	1.8	24
132	Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance. <i>Modern Pathology</i> , 2016, 29, 1183-1199.	2.9	14



#	ARTICLE	IF	CITATIONS
133	Aging, Clonality, and Rejuvenation of Hematopoietic Stem Cells. Trends in Molecular Medicine, 2016, 22, 701-712.	3.5	135
134	Exome sequencing a review of new strategies for rare genomic disease research. Genomics, 2016, 108, 109-114.	1.3	23
135	Genetically distinct leukemic stem cells in human CD34 <sup>hi</sup> acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. Journal of Experimental Medicine, 2016, 213, 1513-1535.	4.2	120
136	New challenges in evaluating anemia in older persons in the era of molecular testing. Hematology American Society of Hematology Education Program, 2016, 2016, 67-73.	0.9	15
137	New insights into the generation and role of de novo mutations in health and disease. Genome Biology, 2016, 17, 241.	3.8	339
138	Impaired haematopoietic stem cell differentiation and enhanced skewing towards myeloid progenitors in aged caspase-2-deficient mice. Cell Death and Disease, 2016, 7, e2509-e2509.	2.7	28
139	Molecular pathogenesis of chronic myelomonocytic leukemia. Memo - Magazine of European Medical Oncology, 2016, 9, 172-177.	0.3	2
140	<i>SETD2</i> and <i>DNMT3A</i> screen in the Sotos-like syndrome French cohort. Journal of Medical Genetics, 2016, 53, 743-751.	1.5	54
141	Analysis of cancer genomes reveals basic features of human aging and its role in cancer development. Nature Communications, 2016, 7, 12157.	5.8	81
142	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 15084-15089.	3.3	96
143	Somatic mosaicism in chronic myeloid leukemia in remission. Blood, 2016, 128, 2863-2866.	0.6	13
144	Mutations in AML: prognostic and therapeutic implications. Hematology American Society of Hematology Education Program, 2016, 2016, 348-355.	0.9	136
146	Case 37-2016. New England Journal of Medicine, 2016, 375, 2273-2282.	13.9	3
147	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	0.9	32
148	Aplastic anemia and clonal evolution: germ line and somatic genetics. Hematology American Society of Hematology Education Program, 2016, 2016, 74-82.	0.9	35
149	Hematopoietic Cell Transplantation for Myelodysplastic Syndromes. Journal of Oncology Practice, 2016, 12, 786-792.	2.5	10
150	A physical mechanism of cancer heterogeneity. Scientific Reports, 2016, 6, 20679.	1.6	25
151	Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nature Communications, 2016, 7, 12484.	5.8	523

#	ARTICLE	IF	CITATIONS
152	Role of TET enzymes in DNA methylation, development, and cancer. <i>Genes and Development</i> , 2016, 30, 733-750.	2.7	781
153	DNMT3A Haploinsufficiency Transforms <i>FLT3</i> ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2016, 6, 501-515.	7.7	73
154	Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. <i>Experimental Hematology</i> , 2016, 44, 740-744.	0.2	48
155	Pathogenesis of Myeloproliferative Disorders. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 101-126.	9.6	38
156	DNA methylation in hematopoietic development and disease. <i>Experimental Hematology</i> , 2016, 44, 783-790.	0.2	18
157	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. <i>Modern Pathology</i> , 2016, 29, 854-864.	2.9	104
158	Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. <i>American Journal of Human Genetics</i> , 2016, 98, 1208-1219.	2.6	164
159	Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of <i>inv(16)</i> AML in a CBL mutated clonal hematopoiesis. <i>Leukemia Research</i> , 2016, 47, 41-46.	0.4	12
160	The curious origins of angioimmunoblastic T-cell lymphoma. <i>Current Opinion in Hematology</i> , 2016, 23, 434-443.	1.2	49
161	Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, e157-e161.	1.7	55
162	The Conundrum of Genetic "Drivers" in Benign Conditions. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw036.	3.0	113
163	External signals shape the epigenome. <i>Genome Biology</i> , 2016, 17, 18.	3.8	1
164	Epigenetic drift, epigenetic clocks and cancer risk. <i>Epigenomics</i> , 2016, 8, 705-719.	1.0	101
165	Mosaic loss of chromosome Y is associated with common variation near <i>TCL1A</i> . <i>Nature Genetics</i> , 2016, 48, 563-568.	9.4	134
166	Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic <i>TP53</i> mutations in noncancerous tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6005-6010.	3.3	135
168	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. <i>Nature Medicine</i> , 2016, 22, 672-678.	15.2	301
169	Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2016, 145, 497-506.	0.4	36
170	Clinical significance of acquired somatic mutations in aplastic anaemia. <i>International Journal of Hematology</i> , 2016, 104, 159-167.	0.7	13

#	ARTICLE	IF	CITATIONS
171	Frequent reconstitution of IDH2R140Q mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia. <i>Leukemia</i> , 2016, 30, 1946-1950.	3.3	10
172	Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. <i>Blood</i> , 2016, 128, 1121-1128.	0.6	200
173	Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. <i>Blood</i> , 2016, 127, 29-41.	0.6	356
174	Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. <i>Blood</i> , 2016, 127, 1575-1586.	0.6	38
175	Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. <i>Blood</i> , 2016, 127, 333-342.	0.6	149
176	An update of current treatments for adult acute myeloid leukemia. <i>Blood</i> , 2016, 127, 53-61.	0.6	444
177	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. <i>Blood</i> , 2016, 127, 893-897.	0.6	94
178	Uncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2. <i>Blood</i> , 2016, 127, 1512-1515.	0.6	38
179	Clonal hematopoiesis in acquired aplastic anemia. <i>Blood</i> , 2016, 128, 337-347.	0.6	158
180	Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. <i>Blood</i> , 2016, 128, 686-698.	0.6	456
181	Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated?. <i>Leukemia</i> , 2016, 30, 2127-2130.	3.3	14
183	Leukemia. <i>Progress in Tumor Research</i> , 2016, 43, 87-100.	0.1	141
184	Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. <i>Blood</i> , 2016, 128, 1246-1259.	0.6	111
185	New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 279-280.	0.7	0
186	The Evolution of Lifespan and Age-Dependent Cancer Risk. <i>Trends in Cancer</i> , 2016, 2, 552-560.	3.8	83
187	Biology of peripheral T cell lymphomas “ Not otherwise specified: Is something finally happening?. <i>Pathogenesis</i> , 2016, 3, 9-18.	0.8	12
188	Detection and characterization of circulating cell free tumor DNA in cancer patients with malignant solid tumors. Liquid biopsy: a new tool in molecular pathology?. <i>Laboratoriums Medizin</i> , 2016, 40, 313-322.	0.1	2
189	Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). <i>American Journal of Clinical Pathology</i> , 2016, 146, 408-422.	0.4	30

#	ARTICLE	IF	CITATIONS
190	Epigenetics and Cancer. Energy Balance and Cancer, 2016, , 1-28.	0.2	2
191	Tissue-specific mutation accumulation in human adult stem cells during life. Nature, 2016, 538, 260-264.	13.7	759
192	Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nature Neuroscience, 2016, 19, 1433-1441.	7.1	427
193	Molecular Testing in Patients with Suspected Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2016, 11, 441-448.	1.2	6
194	Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome. Haematologica, 2016, 101, e129-e132.	1.7	22
195	Correlation of an epigenetic mitotic clock with cancer risk. Genome Biology, 2016, 17, 205.	3.8	197
196	Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations. Haematologica, 2016, 101, 1074-1081.	1.7	15
197	Human blood cell levels of 5-hydroxymethylcytosine (5hmC) decline with age, partly related to acquired mutations in TET2. Experimental Hematology, 2016, 44, 1072-1084.	0.2	40
198	Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 226-236.	1.2	49
199	Can exome scans be expected to be part of real-time decision-making in patients with haematological cancers?. British Journal of Haematology, 2016, 174, 486-492.	1.2	0
200	Chronic lymphocytic leukemia: Time to go past genomics?. American Journal of Hematology, 2016, 91, 518-528.	2.0	13
201	Aging of hematopoietic stem cells: DNA damage and mutations?. Experimental Hematology, 2016, 44, 895-901.	0.2	65
202	Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome. Leukemia, 2016, 30, 2422-2426.	3.3	6
203	Cancer Prevention in the Older Individual. Seminars in Oncology Nursing, 2016, 32, 314-324.	0.7	15
204	The Role of Additional Sex Combs-Like Proteins in Cancer. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026526.	2.9	48
205	Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2041-2049.	1.2	13
206	Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms. Current Hematologic Malignancy Reports, 2016, 11, 408-415.	1.2	19
207	MicroRNAs in Control of Stem Cells in Normal and Malignant Hematopoiesis. Current Stem Cell Reports, 2016, 2, 183-196.	0.7	20

#	ARTICLE	IF	CITATIONS
208	Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. <i>Nature Genetics</i> , 2016, 48, 1193-1203.	9.4	952
209	Prognosis of Primary Myelofibrosis in the Genomic Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S105-S113.	0.2	12
210	Molecular Pathology. <i>Surgical Pathology Clinics</i> , 2016, 9, 475-488.	0.7	4
211	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2100-2103.	2.0	42
212	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	13.9	663
213	Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. <i>American Journal of Hematology</i> , 2016, 91, 1234-1238.	2.0	32
214	Critical Updates to the Leukemia Stem Cell Model. , 2016, , 101-119.		2
215	Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission. <i>Leukemia Research</i> , 2016, 49, 102-107.	0.4	18
216	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <i>Blood</i> , 2016, 127, 2391-2405.	0.6	7,429
217	Established and emerging targeted therapies in the myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2016, 9, 997-1005.	1.0	2
218	Evaluating Elevated Hemoglobin. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1114.	3.8	0
219	Evaluating Elevated Hemoglobin—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1115.	3.8	0
220	Understanding the regulation of vertebrate hematopoiesis and blood disorders — big lessons from a small fish. <i>FEBS Letters</i> , 2016, 590, 4016-4033.	1.3	32
221	Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways. <i>Histopathology</i> , 2016, 69, 1055-1065.	1.6	9
222	DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. <i>Nature Genetics</i> , 2016, 48, 1014-1023.	9.4	200
223	TP53 mutations on circulating cell-free DNA. <i>EBioMedicine</i> , 2016, 10, 15-16.	2.7	3
224	Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. <i>British Journal of Haematology</i> , 2016, 174, 847-858.	1.2	25
225	How I diagnose and manage individuals at risk for inherited myeloid malignancies. <i>Blood</i> , 2016, 128, 1800-1813.	0.6	149

#	ARTICLE	IF	CITATIONS
226	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. <i>Nature Communications</i> , 2016, 7, 10767.	5.8	177
227	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	15.2	195
228	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. <i>Nature Communications</i> , 2016, 7, 11843.	5.8	86
229	Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. <i>Nature Communications</i> , 2016, 7, 12475.	5.8	95
230	The fetal thymus has a unique genomic copy number profile resulting from physiological T cell receptor gene rearrangement. <i>Scientific Reports</i> , 2016, 6, 23500.	1.6	3
231	Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 2209-2221.	13.9	3,067
232	â€˜CHIPâ€™ping away at clonal hematopoiesis. <i>Leukemia</i> , 2016, 30, 1633-1635.	3.3	48
233	Dynamics of an Aging Genome. <i>Cell Metabolism</i> , 2016, 23, 949-950.	7.2	9
234	Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women. <i>Experimental Hematology</i> , 2016, 44, 857-865.e5.	0.2	5
235	Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development. <i>Cancer Cell</i> , 2016, 30, 92-107.	7.7	130
236	Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. <i>Modern Pathology</i> , 2016, 29, 996-1003.	2.9	12
237	Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. <i>Haematologica</i> , 2016, 101, 757-763.	1.7	75
238	Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 89-95.	0.6	37
239	When Genome Maintenance Goes Badly Awry. <i>Molecular Cell</i> , 2016, 62, 777-787.	4.5	64
240	BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. <i>Annals of Hematology</i> , 2016, 95, 1211-1221.	0.8	72
241	Incorporating measurable (â€˜minimalâ€™) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1527-1533.	0.6	7
242	Mutations of myelodysplastic syndromes (MDS): An update. <i>Mutation Research - Reviews in Mutation Research</i> , 2016, 769, 47-62.	2.4	87
243	JAK2 V617F mutation in immune thrombocytopenia. <i>Thrombosis Research</i> , 2016, 144, 149-151.	0.8	5

#	ARTICLE	IF	CITATIONS
244	Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?. <i>Human Gene Therapy</i> , 2016, 27, 108-116.	1.4	92
245	The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 10107-10114.	0.8	20
246	Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 3-16.	1.1	66
247	Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. <i>Expert Review of Hematology</i> , 2016, 9, 447-469.	1.0	12
248	Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. <i>Leukemia</i> , 2016, 30, 248-250.	3.3	51
249	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. <i>JAMA Oncology</i> , 2016, 2, 104.	3.4	270
250	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	7.7	372
251	Age-related mutations and chronic myelomonocytic leukemia. <i>Leukemia</i> , 2016, 30, 906-913.	3.3	119
252	Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation. <i>Leukemia</i> , 2016, 30, 1756-1759.	3.3	25
253	Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia?. <i>Acta Haematologica</i> , 2016, 135, 39-42.	0.7	6
254	Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation. <i>Leukemia</i> , 2016, 30, 1742-1745.	3.3	39
255	Understanding the physiology of the ageing individual: computational modelling of changes in metabolism and endurance. <i>Interface Focus</i> , 2016, 6, 20150079.	1.5	49
256	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
257	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. <i>Cancer Discovery</i> , 2016, 6, 479-491.	7.7	1,087
258	Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. <i>Nature Neuroscience</i> , 2016, 19, 571-577.	7.1	388
259	Leukaemia 'firsts' in cancer research and treatment. <i>Nature Reviews Cancer</i> , 2016, 16, 163-172.	12.8	67
260	The molecular pathogenesis of chronic lymphocytic leukaemia. <i>Nature Reviews Cancer</i> , 2016, 16, 145-162.	12.8	227
261	Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. <i>Leukemia</i> , 2016, 30, 1916-1920.	3.3	79

#	ARTICLE	IF	CITATIONS
262	Laboratory Test Utilization Management. <i>Surgical Pathology Clinics</i> , 2016, 9, 1-10.	0.7	4
263	Somatic mosaicism underlies X-linked acrogeria syndrome in sporadic male subjects. <i>Endocrine-Related Cancer</i> , 2016, 23, 221-233.	1.6	75
264	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2016, 17, 496-508.	5.1	142
265	Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1050-1055.	3.3	28
266	When stem cells grow old: phenotypes and mechanisms of stem cell aging. <i>Development (Cambridge)</i> , 2016, 143, 3-14.	1.2	267
267	Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. <i>Leukemia and Lymphoma</i> , 2016, 57, 520-536.	0.6	96
268	Ultra-fast local-haplotype variant calling using paired-end DNA-sequencing data reveals somatic mosaicism in tumor and normal blood samples. <i>Nucleic Acids Research</i> , 2016, 44, e25-e25.	6.5	12
269	Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. <i>Leukemia</i> , 2016, 30, 666-673.	3.3	177
270	Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive <i>TNIP1</i> - <i>PDGFRB</i> fusion gene. <i>Leukemia</i> , 2016, 30, 1402-1405.	3.3	8
271	Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. <i>Leukemia</i> , 2016, 30, 545-554.	3.3	41
272	Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. <i>Annual Review of Medicine</i> , 2016, 67, 59-72.	5.0	42
273	Ordering of mutations in acute myeloid leukemia with partial tandem duplication of <i>MLL</i> ( <i>MLL-PTD</i> ). <i>Leukemia</i> , 2017, 31, 1-10.	3.3	63
274	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	0.8	339
275	Clonal hematopoiesis associated with <i>TET2</i> deficiency accelerates atherosclerosis development in mice. <i>Science</i> , 2017, 355, 842-847.	6.0	999
276	Recent advances in understanding clonal haematopoiesis in aplastic anaemia. <i>British Journal of Haematology</i> , 2017, 177, 509-525.	1.2	52
277	Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. <i>Cancer Genetics</i> , 2017, 211, 5-8.	0.2	45
278	Biological and clinical consequences of <i>NPM1</i> mutations in AML. <i>Leukemia</i> , 2017, 31, 798-807.	3.3	134
279	Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. <i>Leukemia</i> , 2017, 31, 1238-1240.	3.3	37



#	ARTICLE	IF	CITATIONS
280	Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms. Archives of Pathology and Laboratory Medicine, 2017, 141, 341-354.	1.2	6
281	Absence of <i>CALR</i> mutations in <i>JAK2</i> -negative polycythemia. Haematologica, 2017, 102, e15-e16.	1.7	13
282	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2017, 23, 612-617.	2.0	17
283	The ageing genome, clonal mosaicism and chronic disease. Current Opinion in Genetics and Development, 2017, 42, 8-13.	1.5	28
284	Coexisting and cooperating mutations in <i>NPM1</i> -mutated acute myeloid leukemia. Leukemia Research, 2017, 56, 7-12.	0.4	51
285	Changing mutational and adaptive landscapes and the genesis of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 84-94.	3.3	27
286	Gain-of-function <i>SAMD9L</i> mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood, 2017, 129, 2266-2279.	0.6	152
287	Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 51.	6.9	85
288	Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer, 2017, 17, 223-238.	12.8	1,786
289	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell, 2017, 168, 801-816.e13.	13.5	177
290	Myelodysplastic Syndromes. Medical Clinics of North America, 2017, 101, 333-350.	1.1	9
291	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell, 2017, 20, 315-328.e7.	5.2	114
292	<i>RUNX1</i> cooperates with <i>FLT3-ITD</i> to induce leukemia. Journal of Experimental Medicine, 2017, 214, 737-752.	4.2	38
293	Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. Journal of Clinical Oncology, 2017, 35, 934-946.	0.8	372
294	Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica, 2017, 102, 320-326.	1.7	53
295	The origin and evolution of the term "clone". Leukemia Research, 2017, 57, 97-101.	0.4	3
296	Pathogenic <i>ASXL1</i> somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome. Human Mutation, 2017, 38, 517-523.	1.1	49
297	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Reviews, 2017, 31, 185-192.	2.8	83

#	ARTICLE	IF	CITATIONS
298	The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications. <i>Blood</i> , 2017, 129, 1617-1626.	0.6	99
299	Somatic clonal evolution: A selection-centric perspective. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 139-150.	3.3	61
300	Myeloproliferative neoplasm stem cells. <i>Blood</i> , 2017, 129, 1607-1616.	0.6	133
301	Biology and relevance of human acute myeloid leukemia stem cells. <i>Blood</i> , 2017, 129, 1577-1585.	0.6	328
302	Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2017, 177, 55-66.	1.2	3
303	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.	13.9	586
304	Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. <i>Bone Marrow Transplantation</i> , 2017, 52, 634-637.	1.3	1
305	Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection. <i>Cell</i> , 2017, 168, 571-574.	13.5	302
306	Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 2587-2591.	0.6	44
307	Liquid Biopsies, What We Do Not Know (Yet). <i>Cancer Cell</i> , 2017, 31, 172-179.	7.7	395
308	Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1059-1063.	2.0	3
309	The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 131-135.	2.3	7
310	Clinical significance of somatic mutation in unexplained blood cytopenia. <i>Blood</i> , 2017, 129, 3371-3378.	0.6	379
311	Therapy-related myeloid neoplasms. <i>Current Opinion in Hematology</i> , 2017, 24, 152-158.	1.2	30
312	Clonal evolution in myelodysplastic syndromes. <i>Nature Communications</i> , 2017, 8, 15099.	5.8	118
313	Generalized palisaded neutrophilic and granulomatous dermatitis—a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases. <i>Human Pathology</i> , 2017, 64, 198-206.	1.1	14
314	Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar DNMT3A R882 mutation. <i>Journal of Medical Genetics</i> , 2017, 54, 805-808.	1.5	30
315	Implications of molecular genetic diversity in myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2017, 24, 73-78.	1.2	44

#	ARTICLE	IF	CITATIONS
316	Evolution of Premalignant Disease. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026542.	2.9	23
317	Mutational signatures and mutable motifs in cancer genomes. Briefings in Bioinformatics, 2017, 19, 1085-1101.	3.2	32
319	Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood, 2017, 130, 91-94.	0.6	78
320	Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood, 2017, 130, 742-752.	0.6	582
321	Differences between germline and somatic mutation rates in humans and mice. Nature Communications, 2017, 8, 15183.	5.8	309
322	Telomere length is an independent prognostic marker in <scp>MDS</scp> but not in <i>de novo</i> </i><scp>AML</scp>. British Journal of Haematology, 2017, 178, 240-249.	1.2	21
323	Diagnosis and treatment of macrocytic anemias in adults. Journal of General and Family Medicine, 2017, 18, 200-204.	0.3	78
324	Assessment of the ExAC data set for the presence of individuals with pathogenic genotypes implicated in severe Mendelian pediatric disorders. Genetics in Medicine, 2017, 19, 1300-1308.	1.1	58
325	Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature, 2017, 545, 229-233.	13.7	409
326	Epigenetics in normal and malignant hematopoiesis: An overview and update 2017. Cancer Science, 2017, 108, 553-562.	1.7	44
327	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.4	25
328	A common ancestral DNMT3A-mutated preleukemic clone giving rise to AML and MDS in an adolescent girl. Leukemia and Lymphoma, 2017, 58, 718-721.	0.6	3
329	Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes. Methods in Molecular Biology, 2017, 1541, 209-222.	0.4	5
330	Preleukemia: one name, many meanings. Leukemia, 2017, 31, 534-542.	3.3	51
331	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncology, The, 2017, 18, 100-111.	5.1	296
332	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncology, The, 2017, 18, 112-121.	5.1	249
333	Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. Blood Reviews, 2017, 31, 139-150.	2.8	9
334	Therapy of older persons with acute myeloid leukaemia. Leukemia Research, 2017, 60, 1-10.	0.4	11

#	ARTICLE	IF	CITATIONS
335	DNA-damage response in hematopoietic stem cells: an evolutionary trade-off between blood regeneration and leukemia suppression. <i>Carcinogenesis</i> , 2017, 38, 367-377.	1.3	39
336	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nature Communications</i> , 2017, 8, 15429.	5.8	55
337	<i>IDH2</i> Mutation in a Patient with Metastatic Colon Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1991-1992.	13.9	12
338	Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 111-121.	13.9	1,738
339	Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. <i>Nature Communications</i> , 2017, 8, 15869.	5.8	83
340	Turning the tide in myelodysplastic/myeloproliferative neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 425-440.	12.8	117
341	CHIP, ICUS, CCUS and other four-letter words. <i>Leukemia</i> , 2017, 31, 1869-1871.	3.3	71
342	Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes. <i>Journal of Leukocyte Biology</i> , 2017, 102, 209-219.	1.5	12
343	Myelodysplasia in younger adults: outlier or unique molecular entity?. <i>Haematologica</i> , 2017, 102, 967-968.	1.7	5
344	Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia. <i>Experimental Hematology</i> , 2017, 53, 48-58.	0.2	15
345	Targeting Aberrant Signaling in Myeloid Malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 565-576.	0.9	3
346	Myeloid neoplasms with germ line RUNX1 mutation. <i>International Journal of Hematology</i> , 2017, 106, 183-188.	0.7	26
347	Epigenetic dysregulation of hematopoietic stem cells and preleukemic state. <i>International Journal of Hematology</i> , 2017, 106, 34-44.	0.7	24
348	Li-Fraumeni versus Pseudo-Li-Fraumeni Syndrome: Key Insights for Interpreting Next-Generation Sequencing Reports in Patients with Suspected Cancer Predisposition Syndromes. <i>Oncologist</i> , 2017, 22, 1084-1085.	1.9	0
349	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. <i>Blood</i> , 2017, 130, 440-452.	0.6	66
350	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. <i>Haematologica</i> , 2017, 102, 968-971.	1.7	28
353	Measurable residual disease testing in acute myeloid leukaemia. <i>Leukemia</i> , 2017, 31, 1482-1490.	3.3	197
354	Detecting and Monitoring Circulating Stromal Cells from Solid Tumors Using Blood-Based Biopsies in the Twenty-First Century: Have Circulating Stromal Cells Come of Age?. <i>Cancer Drug Discovery and Development</i> , 2017, , 81-104.	0.2	2

#	ARTICLE	IF	CITATIONS
355	CTCs and ctDNA: Two Tales of a Complex Biology. <i>Cancer Drug Discovery and Development</i> , 2017, , 119-137.	0.2	1
356	Runx Family Genes in Tissue Stem Cell Dynamics. <i>Advances in Experimental Medicine and Biology</i> , 2017, 962, 117-138.	0.8	6
357	The cancer epigenome: Concepts, challenges, and therapeutic opportunities. <i>Science</i> , 2017, 355, 1147-1152.	6.0	289
358	Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1227-1237.	1.7	45
359	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	13.7	229
360	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	0.6	4,375
361	PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias. <i>Leukemia</i> , 2017, 31, 1975-1986.	3.3	10
362	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. <i>Blood</i> , 2017, 129, 667-679.	0.6	444
363	Genomics of chronic neutrophilic leukemia. <i>Blood</i> , 2017, 129, 715-722.	0.6	74
364	Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. <i>Haematologica</i> , 2017, 102, 7-17.	1.7	74
365	How "precise" is precision medicine in hematology?. <i>Haematologica</i> , 2017, 102, 4-6.	1.7	7
366	Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 107-118.	1.1	40
367	Mosaicism in health and disease " clones picking up speed. <i>Nature Reviews Genetics</i> , 2017, 18, 128-142.	7.7	200
368	Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 97-99.	0.2	3
369	Dynamics of clonal evolution in myelodysplastic syndromes. <i>Nature Genetics</i> , 2017, 49, 204-212.	9.4	348
370	Looking beyond drivers and passengers in cancer genome sequencing data. <i>Annals of Oncology</i> , 2017, 28, 938-945.	0.6	27
371	DNMT3A in Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a030320.	2.9	135
372	Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant. <i>Future Oncology</i> , 2017, 13, 935-944.	1.1	3

#	ARTICLE	IF	CITATIONS
373	A novel class of somatic mutations in blood detected preferentially in CD8 + cells. <i>Clinical Immunology</i> , 2017, 175, 75-81.	1.4	35
374	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 4-23.	1.2	1,267
375	Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	19
376	Individual risk assessment in MDS in the era of genomic medicine. <i>Seminars in Hematology</i> , 2017, 54, 133-140.	1.8	2
377	Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. <i>Cell Stem Cell</i> , 2017, 21, 547-555.e8.	5.2	71
378	E Pluribus Unum (‘‘Out of Many, One’’): CRISPR Modeling of Myeloid Expansion. <i>Cell Stem Cell</i> , 2017, 21, 415-416.	5.2	0
379	The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. <i>Journal of Translational Internal Medicine</i> , 2017, 5, 139-143.	1.0	50
380	Methods of Detection of Measurable Residual Disease in AML. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 557-567.	1.2	31
381	The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 295-300.	0.7	7
382	Distinguishing CHIP from Myeloid Neoplasia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S215-S216.	0.2	0
383	Clonal evolution in leukemia. <i>Nature Medicine</i> , 2017, 23, 1135-1145.	15.2	93
384	Selective and Sensitive Detection of Methylcytosine by Aerolysin Nanopore under Serum Condition. <i>Analytical Chemistry</i> , 2017, 89, 11685-11689.	3.2	52
385	Discrimination of Germline <i>EGFR</i> T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 7351-7359.	3.2	74
386	Bad blood promotes tumour progression. <i>Nature</i> , 2017, 549, 465-466.	13.7	4
387	The spectrum of <i>DNMT3A</i> variants in Tatton-Brown-Rahman syndrome overlaps with that in hematologic malignancies. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 3022-3028.	0.7	42
388	Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 424-431.	1.2	11
389	The Prognostic Significance of Measurable (‘‘Minimal’’) Residual Disease in Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 547-556.	1.2	19
390	Clonality in context: hematopoietic clones in their marrow environment. <i>Blood</i> , 2017, 130, 2363-2372.	0.6	74

#	ARTICLE	IF	CITATIONS
391	The potential of liquid biopsies for the early detection of cancer. <i>Npj Precision Oncology</i> , 2017, 1, 36.	2.3	126
392	Cytogenetic changes in the Bhopal population exposed to methyl isocyanate (MIC) in 1984: Then and 30 years later. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2017, 824, 9-19.	0.9	8
393	Therapy-related myeloid neoplasms: when genetics and environment collide. <i>Nature Reviews Cancer</i> , 2017, 17, 513-527.	12.8	270
394	ICUS/CCUS/CHIP: basics & beyond. <i>Expert Review of Hematology</i> , 2017, 10, 915-920.	1.0	14
395	Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. <i>Nature</i> , 2017, 549, 476-481.	13.7	398
396	Genomic and functional integrity of the hematopoietic system requires tolerance of oxidative DNA lesions. <i>Blood</i> , 2017, 130, 1523-1534.	0.6	29
397	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	2.2	132
398	Exonic Mosaic Mutations Contribute Risk for Autism Spectrum Disorder. <i>American Journal of Human Genetics</i> , 2017, 101, 369-390.	2.6	151
399	Detection of structural mosaicism from targeted and whole-genome sequencing data. <i>Genome Research</i> , 2017, 27, 1704-1714.	2.4	44
400	Mutations in myeloproliferative neoplasms – their significance and clinical use. <i>Expert Review of Hematology</i> , 2017, 10, 961-973.	1.0	19
401	Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history. <i>Human Mutation</i> , 2017, 38, 1723-1730.	1.1	40
402	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	3.3	438
403	State of the Art Update: Molecular Genetics of MPN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S88-S90.	0.2	0
404	Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 604-612.	0.7	9
405	Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. <i>Cell Reports</i> , 2017, 20, 572-585.	2.9	99
406	Design and Application of Multiplex PCR Seq for the Detection of Somatic Mutations Associated with Myeloid Malignancies. <i>Methods in Molecular Biology</i> , 2017, 1633, 87-99.	0.4	1
407	Acquired Overlap Bone Marrow Failure Disorders. , 2017, , 51-56.		1
408	Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. <i>Nature Neuroscience</i> , 2017, 20, 1217-1224.	7.1	212

#	ARTICLE	IF	CITATIONS
409	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. <i>Cell Stem Cell</i> , 2017, 21, 374-382.e4.	5.2	578
410	The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression. <i>Immunity</i> , 2017, 47, 284-297.e5.	6.6	115
411	Characterization of breakpoint regions of large structural autosomal mosaic events. <i>Human Molecular Genetics</i> , 2017, 26, 4388-4394.	1.4	2
412	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	808
413	Prevalent premalignancy. <i>Blood</i> , 2017, 130, 695-696.	0.6	2
414	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	2.7	24
415	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2017, , .	3.3	9
416	Myeloproliferative neoplasms: from origins to outcomes. <i>Blood</i> , 2017, 130, 2475-2483.	0.6	107
417	Reducing medical comorbidities associated with long-term HIV infection. <i>Aids</i> , 2017, 31, 2547-2549.	1.0	1
418	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1736-1743.	2.0	44
419	Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer. <i>Oncology Research and Treatment</i> , 2017, 40, 409-416.	0.8	30
420	CHIPs and engraftment dips. <i>Blood</i> , 2017, 130, 7-9.	0.6	0
421	High prevalence of myeloid neoplasms in adults with non- $\alpha$ -Langerhans cell histiocytosis. <i>Blood</i> , 2017, 130, 1007-1013.	0.6	98
422	Mosaic mutations in blood DNA sequence are associated with solid tumor cancers. <i>Npj Genomic Medicine</i> , 2017, 2, 22.	1.7	10
423	Guest editorial: Connecting multiple aspects of hematologic malignancies toward creation of new therapeutics. <i>International Journal of Hematology</i> , 2017, 105, 547-548.	0.7	0
424	Acute myeloid leukaemia genomics. <i>British Journal of Haematology</i> , 2017, 179, 530-542.	1.2	82
425	DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. <i>Blood</i> , 2017, 130, 753-762.	0.6	283
426	Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma. <i>Biomarker Research</i> , 2017, 5, 6.	2.8	8



#	ARTICLE	IF	CITATIONS
427	Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life. <i>American Journal of Human Genetics</i> , 2017, 101, 50-64.	2.6	210
428	The role of mutations in the cohesin complex in acute myeloid leukemia. <i>International Journal of Hematology</i> , 2017, 105, 31-36.	0.7	17
429	The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. <i>Nature Reviews Cancer</i> , 2017, 17, 5-19.	12.8	542
430	Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. <i>Leukemia</i> , 2017, 31, 872-881.	3.3	87
431	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. <i>Annual Review of Cancer Biology</i> , 2017, 1, 223-240.	2.3	20
432	Dysregulation of TET2 in hematologic malignancies. <i>International Journal of Hematology</i> , 2017, 105, 17-22.	0.7	42
433	Clonal hematopoiesis. <i>Seminars in Hematology</i> , 2017, 54, 43-50.	1.8	100
434	Age-associated changes in human hematopoietic stem cells. <i>Seminars in Hematology</i> , 2017, 54, 39-42.	1.8	89
435	Do hematopoietic stem cells get old?. <i>Leukemia</i> , 2017, 31, 529-531.	3.3	5
436	Hematopoiesis in aging: Current concepts and challenges. <i>Seminars in Hematology</i> , 2017, 54, 1-3.	1.8	9
437	The epigenetic basis of hematopoietic stem cell aging. <i>Seminars in Hematology</i> , 2017, 54, 19-24.	1.8	37
438	Rapid parallel acquisition of somatic mutations after <i>NPM1</i> in acute myeloid leukaemia evolution. <i>British Journal of Haematology</i> , 2017, 176, 825-829.	1.2	3
440	Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications. <i>Stem Cell Reviews and Reports</i> , 2017, 13, 7-16.	5.6	198
441	Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. <i>Leukemia</i> , 2017, 31, 720-727.	3.3	105
442	Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing. <i>Leukemia and Lymphoma</i> , 2017, 58, 1008-1012.	0.6	26
443	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 7-13.	0.2	5
444	Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. <i>Blood Reviews</i> , 2017, 31, 63-75.	2.8	128
445	Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. <i>Leukemia</i> , 2017, 31, 861-871.	3.3	22

#	ARTICLE	IF	CITATIONS
446	Accumulation of DNA damage in the aged hematopoietic stem cell compartment. <i>Seminars in Hematology</i> , 2017, 54, 12-18.	1.8	41
447	Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. <i>Leukemia</i> , 2017, 31, 1286-1295.	3.3	44
448	Molecular mechanisms underlying lineage bias in aging hematopoiesis. <i>Seminars in Hematology</i> , 2017, 54, 4-11.	1.8	58
449	Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations. <i>Annual Review of Medicine</i> , 2017, 68, 127-137.	5.0	6
450	Identification of cell-type-specific mutations in nodal T-cell lymphomas. <i>Blood Cancer Journal</i> , 2017, 7, e516-e516.	2.8	66
451	Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 109-119.	0.3	23
452	Aging, hematopoiesis, and the myelodysplastic syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 73-78.	0.9	17
453	Not So Typical: Development of Atypical Chronic Myeloid Leukemia in a Patient With Chronic Myeloid Leukemia. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	1
454	Active Disclosure of Secondary Germline Findings to Deceased Research Participantsâ€™ Personal Representatives: Process and Outcomes. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	3
455	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. <i>Oncotarget</i> , 2017, 8, 29887-29905.	0.8	9
456	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 358-369.	1.8	9
457	Myeloproliferative neoplasms: from origins to outcomes. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 470-479.	0.9	29
458	How and when to decide between epigenetic therapy and chemotherapy in patients with AML. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 45-53.	0.9	28
459	Aging, hematopoiesis, and the myelodysplastic syndromes. <i>Blood Advances</i> , 2017, 1, 2572-2578.	2.5	35
460	Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 66-72.	0.9	13
461	Now I cuss less about ICUS. <i>Blood</i> , 2017, 129, 3282-3283.	0.6	0
462	Mosaic chromosome 20q deletions are more frequent in the aging population. <i>Blood Advances</i> , 2017, 1, 380-385.	2.5	15
463	JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. <i>Blood Advances</i> , 2017, 1, 968-971.	2.5	42

#	ARTICLE	IF	CITATIONS
464	Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?. <i>Journal of Clinical Medicine</i> , 2017, 6, 57.	1.0	28
465	Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2017, 7, 241.	1.3	21
466	RUNX1 Mutations in Inherited and Sporadic Leukemia. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 111.	1.8	62
467	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1618.	1.8	37
468	Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism—UK Single Center Experience. <i>Frontiers in Immunology</i> , 2017, 8, 1410.	2.2	109
469	Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2017, 7, 263.	1.3	39
470	Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience. <i>Frontiers in Pediatrics</i> , 2017, 5, 252.	0.9	16
471	Understanding the molecular basis of acute myeloid leukemias: where are we now?. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 43-53.	0.7	9
472	Erythropoietin Receptor Signaling and Lipid Rafts. <i>Vitamins and Hormones</i> , 2017, 105, 79-100.	0.7	16
473	Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies. <i>PLoS Genetics</i> , 2017, 13, e1006683.	1.5	35
474	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. <i>Genome Medicine</i> , 2017, 9, 89.	3.6	39
475	MosaicHunter: accurate detection of postzygotic single-nucleotide mosaicism through next-generation sequencing of unpaired, trio, and paired samples. <i>Nucleic Acids Research</i> , 2017, 45, e76-e76.	6.5	51
476	Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders. <i>Oncotarget</i> , 2017, 8, 111966-111978.	0.8	8
477	Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 37-44.	0.9	49
478	Ageing, Somatic Evolution, and Cancer. , 2017, , 193-209.		0
479	Somatic HLA mutations expose the role of class II-mediated autoimmunity in aplastic anemia and its clonal complications. <i>Blood Advances</i> , 2017, 1, 1900-1910.	2.5	69
480	Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches. <i>Oncotarget</i> , 2017, 8, 72621-72632.	0.8	51
481	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	0.8	153

#	ARTICLE	IF	CITATIONS
482	Precancerous Clonal Expansion: A New Therapeutic Target?. Journal of Clinical Oncology, 2017, 35, 1503-1505.	0.8	0
483	Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Advances, 2017, 1, 2032-2040.	2.5	53
484	Genomics of Myeloproliferative Neoplasms. Journal of Clinical Oncology, 2017, 35, 947-954.	0.8	62
485	Established and Novel Prognostic Biomarkers in Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 548-560.	1.8	21
486	Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. Journal of Clinical Oncology, 2017, 35, 968-974.	0.8	117
487	Liquid biopsies in lung cancer—time to implement research technologies in routine care?. Annals of Translational Medicine, 2017, 5, 278-278.	0.7	27
488	Dynamics and Function of DNA Methylation During Development. , 2017, , 65-94.		0
489	Uncoding the genetic heterogeneity of myelodysplastic syndrome. Hematology American Society of Hematology Education Program, 2017, 2017, 447-452.	0.9	26
490	Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1 <sup>β</sup> /NLRP3 Inflammasome. Journal of the American College of Cardiology, 2018, 71, 875-886.	1.2	452
491	Genetic profiling of cancer with circulating tumor DNA analysis. Journal of Genetics and Genomics, 2018, 45, 79-85.	1.7	26
492	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253.	1.2	120
493	Liquid biopsy to monitor melanoma patients. JDDG - Journal of the German Society of Dermatology, 2018, 16, 405-414.	0.4	19
494	Liquid biopsy for the identification of intravascular large B-cell lymphoma. Haematologica, 2018, 103, e241-e244.	1.7	53
495	The interplay of leukemia cells and the bone marrow microenvironment. Blood, 2018, 131, 1507-1511.	0.6	87
496	Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia, 2018, 32, 1908-1919.	3.3	137
497	Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing. Journal of the National Cancer Institute, 2018, 110, 863-870.	3.0	69
498	IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?. Endocrine Practice, 2018, 24, 453-459.	1.1	22
499	Attenuated DNA damage responses and increased apoptosis characterize human hematopoietic stem cells exposed to irradiation. Scientific Reports, 2018, 8, 6071.	1.6	25

#	ARTICLE	IF	CITATIONS
500	Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. <i>Blood</i> , 2018, 131, 2501-2505.	0.6	57
501	Ageing- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes. <i>Cell Transplantation</i> , 2018, 27, 754-764.	1.2	36
502	Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. <i>Stem Cell Reports</i> , 2018, 10, 1610-1624.	2.3	43
503	Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. <i>Experimental Hematology</i> , 2018, 63, 1-11.	0.2	12
504	Large-Scale Clonal Analysis Resolves Aging of the Mouse Hematopoietic Stem Cell Compartment. <i>Cell Stem Cell</i> , 2018, 22, 600-607.e4.	5.2	132
505	Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo. <i>Cell Reports</i> , 2018, 23, 1-10.	2.9	159
506	Genetic alterations crossing the borders of distinct hematopoietic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 64-79.	2.0	12
507	Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. <i>Journal of Experimental Medicine</i> , 2018, 215, 1729-1747.	4.2	113
508	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	299
509	The role of JAK2 inhibitors in MPNs 7 years after approval. <i>Blood</i> , 2018, 131, 2426-2435.	0.6	40
510	Liquid Biopsy zur Überwachung von Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 405-416.	0.4	6
511	IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies. <i>Leukemia</i> , 2018, 32, 1249-1253.	3.3	26
513	Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 975-982.	0.5	36
514	Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. <i>Cell Stem Cell</i> , 2018, 22, 157-170.	5.2	345
515	Bone Marrow Microenvironment in Normal and Deranged Hematopoiesis: Opportunities for Regenerative Medicine and Therapies. <i>BioEssays</i> , 2018, 40, 1700190.	1.2	17
516	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. <i>Nature Communications</i> , 2018, 9, 455.	5.8	150
517	ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics. <i>Leukemia and Lymphoma</i> , 2018, 59, 2439-2446.	0.6	20
518	Somatic Mutations and Clonal Hematopoiesis. <i>Circulation Research</i> , 2018, 122, 523-532.	2.0	129

#	ARTICLE	IF	CITATIONS
519	Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG. <i>Annals of Hematology</i> , 2018, 97, 977-988.	0.8	15
520	Donor Cellâ€Derived Hematologic Neoplasms after Hematopoietic Stem Cell Transplantation: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1505-1513.	2.0	22
521	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2018, 131, 1820-1832.	0.6	40
522	Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 687-694.	0.4	4
523	Cohesin mutations in myeloid malignancies made simple. <i>Current Opinion in Hematology</i> , 2018, 25, 61-66.	1.2	34
524	Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 153, 209-244.	0.9	40
525	Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53. <i>Leukemia</i> , 2018, 32, 850-854.	3.3	26
526	The emerging significance of secondary germline testing in cancer genomics. <i>Journal of Pathology</i> , 2018, 244, 610-615.	2.1	37
527	Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. <i>Current Opinion in Hematology</i> , 2018, 25, 120-128.	1.2	4
528	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. <i>Cancer Cell</i> , 2018, 33, 44-59.e8.	7.7	71
529	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018, 131, 1275-1291.	0.6	796
530	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 122-131.	6.6	21
531	Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 69, 10-22.	0.6	10
532	Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients. <i>Clinical Cancer Research</i> , 2018, 24, 1716-1726.	3.2	63
533	Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. <i>Blood</i> , 2018, 131, 1846-1857.	0.6	35
534	Management of older adults with myelodysplastic syndromes (MDS). <i>Journal of Geriatric Oncology</i> , 2018, 9, 302-307.	0.5	12
535	Haploidentical Transplants for Acute Myeloid Leukemia in Adults. , 2018, , 231-243.		0
536	BCR/ABL1-negative, triple-negative, myeloproliferative neoplasm with a hitherto undescribed, isolated, SH2B3 (LNK) gene mutation: A case report. <i>Human Pathology: Case Reports</i> , 2018, 13, 4-8.	0.2	0

#	ARTICLE	IF	CITATIONS
537	Causes and Consequences of Hematopoietic Stem Cell Heterogeneity. <i>Cell Stem Cell</i> , 2018, 22, 627-638.	5.2	233
538	CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease. <i>Circulation Research</i> , 2018, 123, 335-341.	2.0	282
539	De(bar)coding aged hematopoiesis in primates. <i>Blood</i> , 2018, 131, 1157-1159.	0.6	1
540	Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. <i>Molecular Cancer</i> , 2018, 17, 49.	7.9	146
541	Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs. <i>Breast Cancer Research</i> , 2018, 20, 3.	2.2	19
542	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. <i>Clinical Epigenetics</i> , 2018, 10, 42.	1.8	36
543	Age-related clonal hematopoiesis and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia: a new association?. <i>Haematologica</i> , 2018, 103, 751-752.	1.7	6
544	Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis. <i>International Journal of Hematology</i> , 2018, 108, 447-451.	0.7	7
545	Cancer stem cells modulate patterns and processes of evolution in cancers. <i>Biology and Philosophy</i> , 2018, 33, 1.	0.7	4
546	The Leukemic Stem Cell. , 2018, , 29-40.		0
547	Cohesin in haematopoiesis and leukaemia. <i>Current Opinion in Hematology</i> , 2018, 25, 259-265.	1.2	2
548	Current status and trends in the diagnostics of AML and MDS. <i>Blood Reviews</i> , 2018, 32, 508-519.	2.8	35
549	New Insights from Studies of Clonal Hematopoiesis. <i>Clinical Cancer Research</i> , 2018, 24, 4633-4642.	3.2	76
550	The emerging clinical relevance of genomics in cancer medicine. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 353-365.	12.5	351
551	Personalized prevention in high risk individuals: Managing hormones and beyond. <i>Breast</i> , 2018, 39, 139-147.	0.9	18
552	Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. <i>Haematologica</i> , 2018, 103, 1198-1208.	1.7	34
553	Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1244-1245.	13.9	17
554	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1189-1199.	13.9	605

#	ARTICLE	IF	CITATIONS
556	Diagnosis and Treatment of Acute Myeloid Leukemia in Children. , 2018, , 359-374.		0
557	JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. <i>Cancer Biology and Therapy</i> , 2018, 19, 664-668.	1.5	4
558	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. <i>Clinical Cancer Research</i> , 2018, 24, 4437-4443.	3.2	321
559	Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. <i>Nature Reviews Genetics</i> , 2018, 19, 269-285.	7.7	374
560	Immunobiology of Acute Leukemia. , 2018, , 237-279.		3
561	Mutation analysis of therapy-related myeloid neoplasms. <i>Cancer Genetics</i> , 2018, 222-223, 38-45.	0.2	11
562	Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. <i>Lab on A Chip</i> , 2018, 18, 1174-1196.	3.1	234
563	Cardiac stem cell aging and heart failure. <i>Pharmacological Research</i> , 2018, 127, 26-32.	3.1	12
564	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. <i>Leukemia</i> , 2018, 32, 139-148.	3.3	28
565	DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 30-37.	3.3	50
566	Big Bang Tumor Growth and Clonal Evolution. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a028381.	2.9	38
567	Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 69, 90-100.	0.6	24
568	Replication stress in hematopoietic stem cells in mouse and man. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2018, 808, 74-82.	0.4	13
569	Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. <i>Annals of Oncology</i> , 2018, 29, 145-153.	0.6	114
570	Clinical features and biological implications of different <i>U2AF1</i> mutation types in myelodysplastic syndromes. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 80-88.	1.5	55
571	Emerging molecular predictive and prognostic factors in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2021-2039.	0.6	8
572	Somatic mutations and clonal hematopoiesis in congenital neutropenia. <i>Blood</i> , 2018, 131, 408-416.	0.6	91
573	The GNASR201C mutation associated with clonal hematopoiesis supports transplantable hematopoietic stem cell activity. <i>Experimental Hematology</i> , 2018, 57, 14-20.	0.2	5



#	ARTICLE	IF	CITATIONS
574	Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis. <i>Seminars in Cancer Biology</i> , 2018, 51, 89-100.	4.3	21
575	Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor. <i>Annals of Hematology</i> , 2018, 97, 51-61.	0.8	13
576	Phenome and genome based studies into human ageing and longevity: An overview. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 2742-2751.	1.8	36
577	Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. <i>Leukemia</i> , 2018, 32, 550-553.	3.3	10
578	Genome-wide DNA methylation analysis of senescence in repetitively infected memory cytotoxic T lymphocytes. <i>Immunology</i> , 2018, 153, 253-267.	2.0	3
579	Mechanisms underlying the heterogeneity of myelodysplastic syndromes. <i>Experimental Hematology</i> , 2018, 58, 17-26.	0.2	16
580	Somatic TP53 variants frequently confound germ-line testing results. <i>Genetics in Medicine</i> , 2018, 20, 809-816.	1.1	91
581	Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. <i>Cancer Science</i> , 2018, 109, 490-496.	1.7	37
582	The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. <i>Nature Medicine</i> , 2018, 24, 103-112.	15.2	525
583	Modernizing Human Cancer Risk Assessment of Therapeutics. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 232-247.	4.0	17
584	<i>Hematopoietic Stem Cell Biology</i> . , 2018, , 95-110.e13.		0
585	A vicious interplay between genetic and environmental insults in the etiology of blood cancers. <i>Experimental Hematology</i> , 2018, 59, 9-13.	0.2	4
586	Modeling the Subclonal Evolution of Cancer Cell Populations. <i>Cancer Research</i> , 2018, 78, 830-839.	0.4	37
587	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 164-173.	7.7	243
588	Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow. <i>Blood</i> , 2018, 131, 577-581.	0.6	14
589	An inflammatory environment containing TNF± favors Tet2-mutant clonal hematopoiesis. <i>Experimental Hematology</i> , 2018, 59, 60-65.	0.2	141
590	Measuring mutation accumulation in single human adult stem cells by whole-genome sequencing of organoid cultures. <i>Nature Protocols</i> , 2018, 13, 59-78.	5.5	52
591	An evolutionary perspective on field cancerization. <i>Nature Reviews Cancer</i> , 2018, 18, 19-32.	12.8	316

#	ARTICLE	IF	CITATIONS
592	Aging and neurodegeneration are associated with increased mutations in single human neurons. <i>Science</i> , 2018, 359, 555-559.	6.0	496
593	Aging of hematopoietic stem cells. <i>Blood</i> , 2018, 131, 479-487.	0.6	266
594	Age-related clonal hematopoiesis. <i>Blood</i> , 2018, 131, 496-504.	0.6	215
595	Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. <i>Blood</i> , 2018, 131, 621-635.	0.6	64
596	The Loss of TET2 Promotes CD8+ T Cell Memory Differentiation. <i>Journal of Immunology</i> , 2018, 200, 82-91.	0.4	112
597	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. <i>Leukemia and Lymphoma</i> , 2018, 59, 1742-1745.	0.6	6
598	Tumor-associated <sc>DNA</sc> mutation detection in individuals undergoing colonoscopy. <i>Cancer Medicine</i> , 2018, 7, 167-174.	1.3	12
599	Readers of DNA methylation, the MBD family as potential therapeutic targets. , 2018, 184, 98-111.		54
600	DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. <i>Seminars in Cancer Biology</i> , 2018, 51, 68-79.	4.3	42
601	Novel epigenetic therapies in hematological malignancies: Current status and beyond. <i>Seminars in Cancer Biology</i> , 2018, 51, 198-210.	4.3	22
602	Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes. <i>Leukemia and Lymphoma</i> , 2018, 59, 803-812.	0.6	13
603	Premature Physiologic Aging as a Paradigm for Understanding Increased Risk of Adverse Health Across the Lifespan of Survivors of Childhood Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2206-2215.	0.8	99
604	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	0.8	156
605	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018, 36, 1631-1641.	0.8	668
607	Circulating Tumor DNAâ€œDefined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. <i>Journal of Clinical Oncology</i> , 2018, 36, 3437-3440.	0.8	47
608	Molecular Hematopathology. , 2018, , 712-760.e18.		4
610	A brief, but comprehensive, guide to clonal evolution in aplastic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 457-466.	0.9	20
611	I. Understanding the Pathogenesis of Acute Myeloid Leukemia through Leukemic Stem Cells. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 1272-1278.	0.0	0

#	ARTICLE	IF	CITATIONS
612	Coexisting genomic aberrations associated with lymph node metastasis in breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 2310-2324.	3.9	22
613	Somatic Sequencing Identifies Trametinib-Responsive Myelodysplastic Syndrome and Finds Acquired Clonal Hematopoiesis of Indeterminate Potential. <i>JCO Precision Oncology</i> , 2018, 2, 0-0.	1.5	0
614	Age-related clonal hematopoiesis: implications for hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2018, 25, 441-445.	1.2	6
615	Evaluating measurable residual disease in acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 1356-1366.	2.5	132
616	Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis. <i>Cell Reports</i> , 2018, 25, 2308-2316.e4.	2.9	170
617	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. <i>Genome Medicine</i> , 2018, 10, 85.	3.6	94
618	Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. <i>Blood Cancer Journal</i> , 2018, 8, 113.	2.8	90
619	Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in <i>Jak2</i> <sup>V617F</sup> Mice. <i>Circulation Research</i> , 2018, 123, e35-e47.	2.0	173
620	Ageing, inflammation and cancer. <i>Seminars in Immunology</i> , 2018, 40, 74-82.	2.7	103
621	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	670
622	Distinctive types of postzygotic single-nucleotide mosaicisms in healthy individuals revealed by genome-wide profiling of multiple organs. <i>PLoS Genetics</i> , 2018, 14, e1007395.	1.5	31
623	The Clinical and Laboratory Features of Clonal Hematopoiesis of Indeterminate Potential. <i>Advances in Molecular Pathology</i> , 2018, 1, 37-42.	0.2	1
624	Abnormal Morphological and Functional Nature of Bone Marrow Stromal Cells Provides Preferential Support for Survival of Acute Myeloid Leukemia Cells. <i>International Journal of Cancer</i> , 2018, 144, 2279-2289.	2.3	21
625	Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3850.	1.8	24
626	Myelodysplastic syndromes and acute myeloid leukemias in the elderly. <i>European Journal of Internal Medicine</i> , 2018, 58, 28-32.	1.0	5
627	Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis. <i>Cell Stem Cell</i> , 2018, 23, 833-849.e5.	5.2	242
628	Clonal Hematopoiesis Leading to AITL and <i>NPM1</i> -Mutated AML. <i>New England Journal of Medicine</i> , 2018, 379, 2184-2185.	13.9	0
629	Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging. <i>Cells</i> , 2018, 7, 237.	1.8	15

#	ARTICLE	IF	CITATIONS
630	The Progression of Severe Aplastic Anemia to Hypoplastic Leukemia in a Long-Term Observation after the Administration of Pegylated rHuMGDF. <i>Hematology Reports</i> , 2018, 10, 7679.	0.3	1
631	NLRP3 inflammasome activation in inflammaging. <i>Seminars in Immunology</i> , 2018, 40, 61-73.	2.7	109
632	Immunosenescence and lymphomagenesis. <i>Immunity and Ageing</i> , 2018, 15, 22.	1.8	30
633	Mechanisms of Hematopoietic Stem Cell Ageing and Targets for Hematopoietic Tumour Prevention. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1086, 117-140.	0.8	2
634	An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. <i>Oncotarget</i> , 2018, 9, 19079-19099.	0.8	11
635	Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. <i>BMC Medicine</i> , 2018, 16, 166.	2.3	181
636	Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms. <i>Blood</i> , 2018, 132, 2201-2205.	0.6	4
637	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2018, 379, 1416-1430.	13.9	442
638	De novo Mutations (DNMs) in Autism Spectrum Disorder (ASD): Pathway and Network Analysis. <i>Frontiers in Genetics</i> , 2018, 9, 406.	1.1	40
639	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
640	Selfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes. <i>Genome Research</i> , 2018, 28, 1779-1790.	2.4	56
641	High prevalence of focal and multi-focal somatic genetic variants in the human brain. <i>Nature Communications</i> , 2018, 9, 4257.	5.8	54
642	Radioactive Iodine Therapy Is Associated with Clonal Hematopoiesis, a Precursor for Hematologic Malignancies. <i>Clinical Thyroidology</i> , 2018, 30, 443-446.	0.0	0
643	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	13.7	907
644	Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene <i>U2af1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10437-E10446.	3.3	59
645	Somatic mutant clones colonize the human esophagus with age. <i>Science</i> , 2018, 362, 911-917.	6.0	805
646	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. <i>Cell Stem Cell</i> , 2018, 23, 700-713.e6.	5.2	272
647	Decelerated DNA methylation age predicts poor prognosis of breast cancer. <i>BMC Cancer</i> , 2018, 18, 989.	1.1	16

#	ARTICLE	IF	CITATIONS
648	Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 467-476.	1.2	4
649	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Adults. , 2018, , 970-980.e4.		0
650	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. <i>Cancer Genetics</i> , 2018, 228-229, 197-217.	0.2	25
651	Aging and Malignant Hemopathies: A Complex Multistep Process. , 2018, , 1-13.		1
652	CHIPing out PPM1D-mutant hematopoiesis. <i>Blood</i> , 2018, 132, 1087-1088.	0.6	1
653	Diagnosis of Li-Fraumeni Syndrome: Differentiating <i>TP53</i> germline mutations from clonal hematopoiesis. <i>Human Mutation</i> , 2018, 39, 2040-2046.	1.1	20
654	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , 2018, 132, 1703-1713.	0.6	237
655	How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes. <i>Blood</i> , 2018, 132, 1657-1663.	0.6	32
656	Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4216-4223.	1.8	33
657	Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. <i>Scientific Reports</i> , 2018, 8, 12316.	1.6	105
658	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879463.	1.4	317
659	Clonal Hematopoiesis and Its Impact on Cardiovascular Disease. <i>Circulation Journal</i> , 2018, 83, 2-11.	0.7	42
660	Disordered haematopoiesis and cardiovascular disease: a focus on myelopoiesis. <i>Clinical Science</i> , 2018, 132, 1889-1899.	1.8	14
661	Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. <i>PLoS ONE</i> , 2018, 13, e0204218.	1.1	23
662	Aging and Aging-Related Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	15
663	Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. <i>Cancer Cell</i> , 2018, 34, 674-689.e8.	7.7	71
665	Updates on Old and Weary Haematopoiesis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2567.	1.8	21
666	State of the Art Update: On the Origins of MPN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S30-S31.	0.2	0

#	ARTICLE	IF	CITATIONS
667	Circulating Tumor DNA for Early Cancer Detection. <i>Journal of applied laboratory medicine</i> , The, 2018, 3, 300-313.	0.6	25
668	Next-Generation Sequencing Assay Raises New Questions in a Case of Metastatic Prostate Cancer. <i>Journal of applied laboratory medicine</i> , The, 2018, 2, 960-964.	0.6	0
669	Evaluation of toxicity of functionalized graphene oxide with ginsenoside Rh2, lysine and arginine on blood cancer cells (K562), red blood cells, blood coagulation and cardiovascular tissue: In vitro and in vivo studies. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2018, 93, 70-78.	2.7	13
670	The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources. <i>Yearbook of Medical Informatics</i> , 2018, 27, 211-222.	0.8	21
671	Clinical consequences of clonal hematopoiesis of indeterminate potential. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 264-269.	0.9	83
672	Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. <i>Blood Advances</i> , 2018, 2, 481-491.	2.5	41
673	Cell-lineage level targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes. <i>Blood Advances</i> , 2018, 2, 2513-2521.	2.5	10
674	Clinical consequences of clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2018, 2, 3404-3410.	2.5	149
675	Impact of somatic and germline mutations on the outcome of systemic mastocytosis. <i>Blood Advances</i> , 2018, 2, 2814-2828.	2.5	42
676	NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. <i>Blood Advances</i> , 2018, 2, 3118-3125.	2.5	62
677	Nutritional Regulation of Intestinal Stem Cells. <i>Annual Review of Nutrition</i> , 2018, 38, 273-301.	4.3	44
678	Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. <i>Blood</i> , 2018, 132, 277-280.	0.6	101
679	Quantitative competitive allele-specific TaqMan duplex PCR (qCAST-Duplex PCR) assay: a refined method for highly sensitive and specific detection of <i>JAK2</i> V617F mutant allele burdens. <i>Haematologica</i> , 2018, 103, e450-e454.	1.7	4
680	Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic <i>TP53</i> Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 461-466.	2.3	19
681	A call to action in hematologic disorders: A report from the ASH scientific workshop on hematology and aging. <i>Journal of Geriatric Oncology</i> , 2018, 9, 287-290.	0.5	10
682	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018, 32, 2604-2616.	3.3	137
683	Consequences of mutant TET2 on clonality and subclonal hierarchy. <i>Leukemia</i> , 2018, 32, 1751-1761.	3.3	54
684	Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 495-500.	0.2	1

#	ARTICLE	IF	CITATIONS
685	Cellular and epigenetic drivers of stem cell ageing. <i>Nature Reviews Molecular Cell Biology</i> , 2018, 19, 594-610.	16.1	196
686	Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm—a comparison of 756 cases. <i>Leukemia</i> , 2018, 32, 2295-2298.	3.3	18
687	Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. <i>Nature</i> , 2018, 557, 580-584.	13.7	296
688	Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 636-647.	0.2	6
689	Diagnostic algorithm for lower-risk myelodysplastic syndromes. <i>Leukemia</i> , 2018, 32, 1679-1696.	3.3	10
690	Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. <i>Annals of Surgical Oncology</i> , 2018, 25, 2400-2408.	0.7	46
691	Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 686-702.	1.2	149
692	PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. <i>Blood</i> , 2018, 132, 1095-1105.	0.6	160
693	The Value of T-Cell Receptor $\beta$ (TRG) Clonality Evaluation by Next-Generation Sequencing in Clinical Hematolymphoid Tissues. <i>American Journal of Clinical Pathology</i> , 2018, 150, 193-223.	0.4	9
694	Stem Cell Model of Hematologic Diseases. , 2018, , 111-118.		0
695	Hematology in Aging. , 2018, , 2328-2331.		0
696	Acute myeloid leukaemia. <i>Lancet</i> , The, 2018, 392, 593-606.	6.3	512
697	AML: Predicting the Unpredictable. <i>Cell Stem Cell</i> , 2018, 23, 162-163.	5.2	1
698	Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1173-1186.	2.3	102
699	Lymphohematopoietic Stem Cells and Their Aging. , 2018, , 1-16.		0
701	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. <i>Blood</i> , 2018, 132, 1526-1534.	0.6	90
702	Mutation Detection in Tumor-Derived Cell Free DNA Anticipates Progression in a Patient With Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 306.	1.3	9
703	A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs. <i>Annals of Hematology</i> , 2018, 97, 2299-2308.	0.8	50

#	ARTICLE	IF	CITATIONS
704	Clonal Hematopoiesis in Aging. <i>Current Stem Cell Reports</i> , 2018, 4, 209-219.	0.7	18
705	A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. <i>Blood Advances</i> , 2018, 2, 825-831.	2.5	107
706	Incidence and survival of therapy related myeloid neoplasm in United States. <i>Leukemia Research</i> , 2018, 71, 95-99.	0.4	24
708	Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. <i>Blood Cancer Journal</i> , 2018, 8, 74.	2.8	67
709	Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 9.	1.2	96
710	Clonal Hematopoiesis. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001926.	1.6	43
711	Bridging Strategies to Allogeneic Transplant for Older AML Patients. <i>Cancers</i> , 2018, 10, 232.	1.7	6
712	Tuning of the Hematopoietic Stem Cell Compartment in its Inflammatory Environment. <i>Current Stem Cell Reports</i> , 2018, 4, 189-200.	0.7	2
713	Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 215.	1.7	22
714	Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations. <i>Diagnostics</i> , 2018, 8, 31.	1.3	94
715	Advances in understanding the pathogenesis of acquired aplastic anaemia. <i>British Journal of Haematology</i> , 2018, 182, 758-776.	1.2	91
716	Clinical Implications of Clonal Hematopoiesis. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1122-1130.	1.4	81
717	Diagnosis and Prognosis: Molecular. <i>Hematologic Malignancies</i> , 2018, , 15-37.	0.2	0
718	Prediction of acute myeloid leukaemia risk in healthy individuals. <i>Nature</i> , 2018, 559, 400-404.	13.7	617
719	Somatic mutations precede acute myeloid leukemia years before diagnosis. <i>Nature Medicine</i> , 2018, 24, 1015-1023.	15.2	447
720	Predicting progression to AML. <i>Nature Medicine</i> , 2018, 24, 904-906.	15.2	22
721	Microbiome metabolomics reveals new drivers of human liver steatosis. <i>Nature Medicine</i> , 2018, 24, 906-907.	15.2	25
722	Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. <i>Nature Communications</i> , 2018, 9, 2733.	5.8	88



#	ARTICLE	IF	CITATIONS
723	Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. <i>Nature Communications</i> , 2018, 9, 2670.	5.8	79
724	Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. <i>Nature</i> , 2018, 559, 350-355.	13.7	279
725	Myeloid Disease Mutations of Splicing Factor SRSF2 Cause G2-M Arrest and Skewed Differentiation of Human Hematopoietic Stem and Progenitor Cells. <i>Stem Cells</i> , 2018, 36, 1663-1675.	1.4	20
726	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018, 70, 1-8.	3.4	116
727	Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A mutated clone of patient origin. <i>Experimental and Molecular Pathology</i> , 2018, 105, 139-143.	0.9	2
728	Evolutionary Stem Cell Poker and Cancer Risks: the Paradox of the Large and Small Intestines. <i>Current Pathobiology Reports</i> , 2018, 6, 193-198.	1.6	2
729	Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 56.	1.8	54
730	Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. <i>Molecular Cancer</i> , 2018, 17, 40.	7.9	30
731	Identification of somatic mutations in monozygotic twins discordant for psychiatric disorders. <i>NPJ Schizophrenia</i> , 2018, 4, 7.	2.0	16
732	Signaling Pathways Regulating Hematopoietic Stem Cell and Progenitor Aging. <i>Current Stem Cell Reports</i> , 2018, 4, 166-181.	0.7	15
734	DNA Methylation Patterns in Normal Tissue Correlate more Strongly with Breast Cancer Status than Copy-Number Variants. <i>EBioMedicine</i> , 2018, 31, 243-252.	2.7	27
735	Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells. <i>Experimental Hematology</i> , 2018, 64, 33-44.e5.	0.2	17
736	Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion. <i>Leukemia</i> , 2018, 32, 2399-2411.	3.3	39
737	HLA-B gene somatic insertion/deletion mutations in patients with acute myelogenous leukaemia. <i>International Journal of Immunogenetics</i> , 2018, 45, 323-328.	0.8	1
738	Relationship between Aging and Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1965-1970.	2.0	10
739	Clonal hematopoiesis in patients with rheumatoid arthritis. <i>Blood Cancer Journal</i> , 2018, 8, 69.	2.8	62
740	Near Tetraploidy Acute Myeloid Leukemia in Long-term Remission with Persistent Clonal Hematopoiesis with del(20)(q12q13). <i>Internal Medicine</i> , 2018, , .	0.3	0
741	Impacts of demographic and laboratory parameters on key hematological indices in an adult population of southern Taiwan: A cohort study. <i>PLoS ONE</i> , 2018, 13, e0201708.	1.1	4

#	ARTICLE	IF	CITATIONS
742	Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 717-737.	1.2	49
743	New insights in the pathogenesis of T-cell lymphomas. <i>Current Opinion in Oncology</i> , 2018, 30, 277-284.	1.1	31
744	Cytopenias: Reactive and Neoplastic. , 2018, , 17-79.		1
745	Chronic Myelomonocytic Leukemia (CMML). <i>Hematologic Malignancies</i> , 2018, , 65-79.	0.2	0
746	Srsf2 P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells. <i>Blood</i> , 2018, 132, 608-621.	0.6	45
747	Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. <i>Haematologica</i> , 2018, 103, 1853-1861.	1.7	96
748	The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span. <i>GeroScience</i> , 2018, 40, 221-242.	2.1	15
749	Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil. <i>Stem Cells</i> , 2018, 36, 1287-1294.	1.4	60
750	Mixed Cytoses and Cytopenias. , 2018, , 257-279.		0
751	Somatic Mutations in Aplastic Anemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 595-607.	0.9	18
752	Anemia in the Elderly. <i>HemaSphere</i> , 2018, 2, e40.	1.2	71
753	Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. <i>Leukemia</i> , 2018, 32, 2046-2049.	3.3	37
754	Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. <i>Blood</i> , 2018, 132, 1225-1240.	0.6	168
755	Ageing and the rise of somatic cancer-associated mutations in normal tissues. <i>PLoS Genetics</i> , 2018, 14, e1007108.	1.5	162
756	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. <i>Leukemia Research</i> , 2018, 74, 137-143.	0.4	7
757	ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. <i>Pathobiology</i> , 2019, 86, 30-38.	1.9	71
758	Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients. <i>Frontiers of Medicine</i> , 2019, 13, 229-237.	1.5	18
759	Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification. <i>Leukemia</i> , 2019, 33, 191-204.	3.3	41

#	ARTICLE	IF	CITATIONS
760	Genetic and epigenetic determinants of AML pathogenesis. <i>Seminars in Hematology</i> , 2019, 56, 84-89.	1.8	65
761	DNA methylation as a transcriptional regulator of the immune system. <i>Translational Research</i> , 2019, 204, 1-18.	2.2	102
762	Somatic mutations in the human brain: implications for psychiatric research. <i>Molecular Psychiatry</i> , 2019, 24, 839-856.	4.1	29
763	Impact of aging on bone, marrow and their interactions. <i>Bone</i> , 2019, 119, 1-7.	1.4	18
765	Inherited Platelet Defects and Mutations in Hematopoietic Transcription Factor RUNX1. , 2019, , 317-325.		0
766	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. <i>Science</i> , 2019, 365, 599-604.	6.0	265
767	The role of TP53 in acute myeloid leukemia: Challenges and opportunities. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 875-888.	1.5	79
768	Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1183.	1.0	38
769	Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. <i>Cells</i> , 2019, 8, 854.	1.8	119
770	Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies. <i>Cells</i> , 2019, 8, 868.	1.8	17
772	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. <i>Blood Advances</i> , 2019, 3, 508-518.	2.5	62
773	Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1473.	3.4	237
774	Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. <i>Expert Review of Hematology</i> , 2019, 12, 833-843.	1.0	13
775	Opportunities of circulating tumor DNA in lung cancer. <i>Cancer Treatment Reviews</i> , 2019, 78, 31-41.	3.4	16
776	Characterizing Mutational Load and Clonal Composition of Human Blood. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	5
777	Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2019, 84, 106190.	0.4	9
778	Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. <i>Cell Death and Disease</i> , 2019, 10, 534.	2.7	78
779	Premalignant Clonal Hematopoietic Proliferations. <i>American Journal of Clinical Pathology</i> , 2019, 152, 347-358.	0.4	3

#	ARTICLE	IF	CITATIONS
780	Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis. <i>Annals of Laboratory Medicine</i> , 2019, 39, 509-514.	1.2	10
781	Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD. <i>Journal of the American College of Cardiology</i> , 2019, 74, 578-586.	1.2	57
782	Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 889-902.	1.5	41
783	Leukemia Stem Cells in Hematologic Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	1
784	DNA Damage Response in Quiescent Hematopoietic Stem Cells and Leukemia Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1143, 147-171.	0.8	2
785	The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia. <i>American Journal of Hematology</i> , 2019, 94, 1141-1148.	2.0	33
786	Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6546-6553.	3.2	45
787	MRD in AML: The Role of New Techniques. <i>Frontiers in Oncology</i> , 2019, 9, 655.	1.3	93
788	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. , 0, , .		0
789	Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. <i>Nature Communications</i> , 2019, 10, 2891.	5.8	36
790	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. <i>Cell Reports</i> , 2019, 28, 132-144.e3.	2.9	72
791	The roles of DNA, RNA and histone methylation in ageing and cancer. <i>Nature Reviews Molecular Cell Biology</i> , 2019, 20, 573-589.	16.1	359
792	Chronic lymphocytic leukaemia: from genetics to treatment. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 684-701.	12.5	154
793	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. <i>Blood Reviews</i> , 2019, 37, 100587.	2.8	23
794	Aging and Hematopoiesis. <i>Clinics in Geriatric Medicine</i> , 2019, 35, 285-293.	1.0	50
795	Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. <i>Blood</i> , 2019, 134, 469-479.	0.6	139
796	How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. <i>Haematologica</i> , 2019, 104, 1532-1541.	1.7	37
797	Clonal evolution of acute myeloid leukemia from diagnosis to relapse. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 839-849.	1.5	67

#	ARTICLE	IF	CITATIONS
799	GWAS of mosaic loss of chromosome Y highlights genetic effects on blood cell differentiation. Nature Communications, 2019, 10, 4719.	5.8	50
800	Experimental Modeling of Myeloproliferative Neoplasms. Genes, 2019, 10, 813.	1.0	12
801	Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. Cancer Cell, 2019, 36, 350-368.	7.7	204
802	JAK2-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure. JACC Basic To Translational Science, 2019, 4, 684-697.	1.9	114
803	Rare-variant collapsing analyses for complex traits: guidelines and applications. Nature Reviews Genetics, 2019, 20, 747-759.	7.7	147
804	Liquid biopsy tracking of lung tumor evolutions over time. Expert Review of Molecular Diagnostics, 2019, 19, 1099-1108.	1.5	50
805	De Novo Mutations Reflect Development and Aging of the Human Germline. Trends in Genetics, 2019, 35, 828-839.	2.9	80
806	The cell of origin and the leukemia stem cell in acute myeloid leukemia. Genes Chromosomes and Cancer, 2019, 58, 850-858.	1.5	50
807	The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. International Journal of Molecular Sciences, 2019, 20, 5362.	1.8	29
808	Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine. Critical Reviews in Oncology/Hematology, 2019, 144, 102827.	2.0	22
809	Clonal copy-number mosaicism in autoreactive T lymphocytes in diabetic NOD mice. Genome Research, 2019, 29, 1951-1961.	2.4	2
810	Clonal hematopoiesis in human aging and disease. Science, 2019, 366, .	6.0	590
812	Assessing Measurable Residual Disease in Acute Myeloid Leukemia. Advances in Molecular Pathology, 2019, 2, 45-58.	0.2	1
813	Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study. BMC Cancer, 2019, 19, 1072.	1.1	4
814	The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS). Current Hematologic Malignancy Reports, 2019, 14, 536-542.	1.2	29
815	Biological implications of clonal hematopoiesis. Experimental Hematology, 2019, 77, 1-5.	0.2	21
816	Somatic Variants: New Kids on the Block in Human Immunogenetics. Trends in Genetics, 2019, 35, 935-947.	2.9	29
817	Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. Cancers, 2019, 11, 1625.	1.7	19

#	ARTICLE	IF	CITATIONS
818	Mutations found in cell-free DNA s of patients with malignant lymphoma at remission can derive from clonal hematopoiesis. <i>Cancer Science</i> , 2019, 110, 3375-3381.	1.7	16
819	Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. <i>PLoS ONE</i> , 2019, 14, e0224097.	1.1	17
820	How Methods of Molecular Biology Shape Our Understanding of the Hematopoietic System. <i>Molecular Biology</i> , 2019, 53, 626-637.	0.4	1
821	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. <i>Nature Reviews Cancer</i> , 2019, 19, 553-567.	12.8	393
822	Cancer-Associated Mutations but No Cancer: Insights into the Early Steps of Carcinogenesis and Implications for Early Cancer Detection. <i>Trends in Cancer</i> , 2019, 5, 531-540.	3.8	34
823	Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH). <i>Experimental Hematology and Oncology</i> , 2019, 8, 17.	2.0	3
824	Low expression of <i>TET2</i> gene in pediatric acute lymphoblastic leukemia is associated with poor clinical outcome. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 702-709.	0.7	5
825	Updates in the management of polycythemia vera and essential thrombocythemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071987005.	1.1	25
826	CHIPing Away at Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 112, 10-11.	3.0	0
827	MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors. <i>Cell Reports</i> , 2019, 28, 2851-2865.e4.	2.9	20
828	Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. <i>Breast Cancer Research</i> , 2019, 21, 107.	2.2	51
829	Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4576.	1.8	54
830	Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <i>PLoS ONE</i> , 2019, 14, e0221941.	1.1	15
831	Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations?. <i>Frontiers in Genetics</i> , 2019, 10, 785.	1.1	3
832	Genome aging: somatic mutation in the brain links age-related decline with disease and nominates pathogenic mechanisms. <i>Human Molecular Genetics</i> , 2019, 28, R197-R206.	1.4	37
833	Clonal hematopoiesis: Pre-cancer PLUS. <i>Advances in Cancer Research</i> , 2019, 141, 85-128.	1.9	35
834	The prevalence of germline <i>DICER1</i> pathogenic variation in cancer populations. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2019, 7, e555.	0.6	24
835	Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. <i>Frontiers in Oncology</i> , 2018, 8, 669.	1.3	15

#	ARTICLE	IF	CITATIONS
836	Genetics of MDS. <i>Blood</i> , 2019, 133, 1049-1059.	0.6	241
837	The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. <i>Blood</i> , 2019, 133, 1039-1048.	0.6	172
838	MDS overlap disorders and diagnostic boundaries. <i>Blood</i> , 2019, 133, 1086-1095.	0.6	58
839	<i>DNMT3A</i> mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 1617-1625.	1.7	40
840	Mitochondrial Stress-Initiated Aberrant Activation of the NLRP3 Inflammasome Regulates the Functional Deterioration of Hematopoietic Stem Cell Aging. <i>Cell Reports</i> , 2019, 26, 945-954.e4.	2.9	98
841	Deregulated Polycomb functions in myeloproliferative neoplasms. <i>International Journal of Hematology</i> , 2019, 110, 170-178.	0.7	11
842	Premature Aging in Young Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2019, 111, 226-232.	3.0	61
843	Epigenetic Regulation of Bone Marrow Stem Cell Aging: Revealing Epigenetic Signatures associated with Hematopoietic and Mesenchymal Stem Cell Aging. , 2019, 10, 174.		51
844	Defining the impact of mutation accumulation on replicative lifespan in yeast using cancer-associated mutator phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3062-3071.	3.3	17
845	Update on the pathologic diagnosis of chronic myelomonocytic leukemia. <i>Modern Pathology</i> , 2019, 32, 732-740.	2.9	18
846	Clonal Hematopoiesis and risk of Acute Myeloid Leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 177-185.	0.7	15
847	Stem Cells Heterogeneity in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	2
848	Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019, 60, 3058-3062.	0.6	4
849	<i>DNMT3A</i> mutations are over-represented in young adults with <i>NPM1</i> mutated AML and prompt a distinct co-mutational pattern. <i>Leukemia</i> , 2019, 33, 2741-2746.	3.3	15
850	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1835-1850.	3.3	97
851	Mechanisms of leukemic transformation in congenital neutropenia. <i>Current Opinion in Hematology</i> , 2019, 26, 34-40.	1.2	28
852	Myeloid malignancies-related somatic mutations in aging individuals. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2019, 7, e683.	0.6	0
853	Somatic mosaic truncating mutations of <i>PPM1D</i> in blood can result from expansion of a mutant clone under selective pressure of chemotherapy. <i>PLoS ONE</i> , 2019, 14, e0217521.	1.1	7

#	ARTICLE	IF	CITATIONS
854	Granulopoiesis and Neutrophil Homeostasis: A Metabolic, Daily Balancing Act. <i>Trends in Immunology</i> , 2019, 40, 598-612.	2.9	67
855	RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. <i>Science</i> , 2019, 364, .	6.0	369
856	Mutated clones are the new normal. <i>Science</i> , 2019, 364, 938-939.	6.0	28
857	Cell-Free DNA. , 2019, , 11-24.		1
858	Emerging patterns in clonal haematopoiesis. <i>Journal of Clinical Pathology</i> , 2019, 72, 453-459.	1.0	2
859	Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 171-185.	0.8	0
860	Comparative analysis of clonal hematopoiesis of multipotent stem cells in healthy elderly in blood and bone marrow. <i>Leukemia Research</i> , 2019, 82, 15-18.	0.4	1
861	Concomitant and noncanonical <i>JAK2</i> and <i>MPL</i> mutations in <i>JAK2</i> V617F and <i>MPL</i> W515 positive myelofibrosis. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 747-755.	1.5	11
862	Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 108-116.	0.9	22
863	Illegitimate and Repeated Genomic Integration of Cell-Free Chromatin in the Aetiology of Somatic Mosaicism, Ageing, Chronic Diseases and Cancer. <i>Genes</i> , 2019, 10, 407.	1.0	15
864	A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3AR882) Demonstrates a Causal Relationship between Its Dominant-Negative Effect and Leukemogenesis. <i>Cancer Research</i> , 2019, 79, 3583-3594.	0.4	18
865	How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?. <i>Expert Review of Hematology</i> , 2019, 12, 473-476.	1.0	3
866	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1902-1910.	3.3	37
867	Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia. <i>Biomarker Insights</i> , 2019, 14, 117727191984645.	1.0	87
869	Molecular genetic testing in the diagnosis of myeloid neoplasms. <i>Diagnostic Histopathology</i> , 2019, 25, 249-259.	0.2	1
870	Benefits and limitations of genome-wide association studies. <i>Nature Reviews Genetics</i> , 2019, 20, 467-484.	7.7	1,226
872	Disruption of <i>asxl1</i> results in myeloproliferative neoplasms in zebrafish. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	18
873	More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 421-432.	1.8	31



#	ARTICLE	IF	CITATIONS
874	Somatic mutation panels: Time to clear their names. <i>Cancer Genetics</i> , 2019, 235-236, 84-92.	0.2	16
875	Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine. <i>Cancer Research</i> , 2019, 79, 2798-2804.	0.4	111
876	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. <i>Leukemia</i> , 2019, 33, 2842-2853.	3.3	43
877	What role can next-generation sequencing play in myelodysplastic syndrome care?. <i>Expert Review of Hematology</i> , 2019, 12, 379-382.	1.0	6
878	Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation. <i>Cell Reports</i> , 2019, 27, 2022-2028.e3.	2.9	44
879	Genomic testing in myeloid malignancy. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 117-125.	0.7	7
880	Functional characterization of novel germline <i>TP53</i> variants in Swedish families. <i>Clinical Genetics</i> , 2019, 96, 216-225.	1.0	7
881	Ageing Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. <i>Cancer Discovery</i> , 2019, 9, 1080-1101.	7.7	119
882	Genetic abnormalities and pathophysiology of MDS. <i>International Journal of Clinical Oncology</i> , 2019, 24, 885-892.	1.0	70
883	Losing Sense of Self and Surroundings: Hematopoietic Stem Cell Aging and Leukemic Transformation. <i>Trends in Molecular Medicine</i> , 2019, 25, 494-515.	3.5	84
884	CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 400-410.	1.8	58
885	Evolutionary trajectory of leukemic clones and its clinical implications. <i>Haematologica</i> , 2019, 104, 872-880.	1.7	17
886	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. <i>Hematological Oncology</i> , 2019, 37, 240-252.	0.8	8
887	Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans. <i>Nature Communications</i> , 2019, 10, 1252.	5.8	67
888	Early Detection of Myelodysplastic Syndrome/Leukemia-associated Mutations Using NGS Is Critical in Treating Aplastic Anemia. <i>Current Medical Science</i> , 2019, 39, 217-221.	0.7	3
889	Leukemia's Clonal Evolution in Development, Progression, and Relapse. <i>Current Stem Cell Reports</i> , 2019, 5, 73-81.	0.7	3
890	Clonal hematopoiesis and risk of acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 2410-2417.	1.7	73
891	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2

#	ARTICLE	IF	CITATIONS
892	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	1.7	93
893	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. <i>Blood Reviews</i> , 2019, 36, 70-87.	2.8	484
894	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. <i>Nature Communications</i> , 2019, 10, 2031.	5.8	87
895	Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. <i>Cancer Genetics</i> , 2019, 235-236, 31-38.	0.2	23
896	Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies. <i>Journal of Hepatology</i> , 2019, 71, 409-421.	1.8	31
897	Clonal hematopoiesis of indeterminate potential and its impact on patient trajectories after stem cell transplantation. <i>PLoS Computational Biology</i> , 2019, 15, e1006913.	1.5	16
898	Identification of a nine-gene panel as a prognostic indicator for recurrence with muscle-invasive bladder cancer. <i>Journal of Surgical Oncology</i> , 2019, 119, 1145-1154.	0.8	29
899	The emerging role of cell-free DNA as a molecular marker for cancer management. <i>Biomolecular Detection and Quantification</i> , 2019, 17, 100087.	7.0	375
900	Ultra-High-Frequency Reprogramming of Individual Long-Term Hematopoietic Stem Cells Yields Low Somatic Variant Induced Pluripotent Stem Cells. <i>Cell Reports</i> , 2019, 26, 2580-2592.e7.	2.9	14
901	Myeloid malignancies after treatment for solid tumours. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 40-46.	0.7	8
902	Diagnosis and Classification of Myelodysplastic Syndrome. , 0, , .		3
903	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 628-634.	2.0	16
904	Decoy fitness peaks, tumor suppression, and aging. <i>Aging Cell</i> , 2019, 18, e12938.	3.0	19
905	On fitness: how do mutations shape the biology of cancer?. <i>Biochemical Society Transactions</i> , 2019, 47, 559-569.	1.6	2
906	Detectible mosaic truncating PPM1D mutations, age and breast cancer risk. <i>Journal of Human Genetics</i> , 2019, 64, 545-550.	1.1	6
907	Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. <i>Annals of Oncology</i> , 2019, 30, 945-952.	0.6	103
908	Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer. <i>JAMA Cardiology</i> , 2019, 4, 380.	3.0	42
909	Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. <i>Cancer</i> , 2019, 125, 2233-2241.	2.0	19

#	ARTICLE	IF	CITATIONS
910	Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. <i>British Journal of Haematology</i> , 2019, 186, e31-e35.	1.2	17
911	Cell-free tumour DNA testing for early detection of cancer – a potential future tool. <i>Journal of Internal Medicine</i> , 2019, 286, 118-136.	2.7	50
912	Analysis of error profiles in deep next-generation sequencing data. <i>Genome Biology</i> , 2019, 20, 50.	3.8	196
913	Managing Clonal Hematopoiesis in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 7-11.	0.8	60
914	Clonal Hematopoiesis of Indeterminate Potential. <i>Journal of Clinical Oncology</i> , 2019, 37, 419-422.	0.8	18
915	Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2019, 186, 300-310.	1.2	9
916	Genomic subtyping and therapeutic targeting of acute erythroleukemia. <i>Nature Genetics</i> , 2019, 51, 694-704.	9.4	97
917	Translating insights into tumor evolution to clinical practice: promises and challenges. <i>Genome Medicine</i> , 2019, 11, 20.	3.6	58
918	The role of ASXL1 in hematopoiesis and myeloid malignancies. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2511-2523.	2.4	82
919	Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 868-871.	1.7	40
920	Clonal hematopoiesis and preleukemia – Genetics, biology, and clinical implications. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 828-838.	1.5	18
921	Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 2495-2505.	3.3	61
922	Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 311-331.	1.6	123
923	Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease. <i>Cell</i> , 2019, 177, 608-621.e12.	13.5	167
924	The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 mutations. <i>Modern Pathology</i> , 2019, 32, 1123-1134.	2.9	54
925	Targeted, Amplicon-Based, Next-Generation Sequencing to Detect Age-Related Clonal Hematopoiesis. <i>Methods in Molecular Biology</i> , 2019, 2045, 167-180.	0.4	8
926	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2019, 37, 375-385.	0.8	163
927	Liquid biopsy and minimal residual disease – latest advances and implications for cure. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 409-424.	12.5	671

#	ARTICLE	IF	CITATIONS
928	TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells. <i>Genome Research</i> , 2019, 29, 564-575.	2.4	66
929	Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. <i>Cancers</i> , 2019, 11, 252.	1.7	44
930	Mosaicism, aging and cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 108-113.	1.1	13
931	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 104-113.	0.7	5
932	Clonal approaches to understanding the impact of mutations on hematologic disease development. <i>Blood</i> , 2019, 133, 1436-1445.	0.6	14
933	Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 789.	1.8	50
934	Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability. <i>Scientific Reports</i> , 2019, 9, 2678.	1.6	12
935	Emerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation. <i>Immunity</i> , 2019, 50, 288-301.	6.6	106
936	Completing the genetic spectrum influencing coronary artery disease: from germline to somatic variation. <i>Cardiovascular Research</i> , 2019, 115, 830-843.	1.8	14
937	Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e579-e602.	1.6	142
938	The global clonal complexity of the murine blood system declines throughout life and after serial transplantation. <i>Blood</i> , 2019, 133, 1927-1942.	0.6	45
939	Clonal Hematopoiesis and therapy related MDS/AML. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 13-23.	0.7	17
940	A survey of the therapeutic landscape in peripheral T-cell lymphomas: the importance of expert hematopathology review in the era of targeted therapies and precision medicine. <i>Annals of Lymphoma</i> , 2019, 3, 9-9.	4.5	1
941	Articles Title ch_3. , 2019, , .		0
942	High Detection Rate of MYD88 Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	21
943	Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. <i>Blood</i> , 2019, 134, 2383-2387.	0.6	18
944	Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. <i>Blood Advances</i> , 2019, 3, 3449-3453.	2.5	7
945	Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis. <i>Blood Advances</i> , 2019, 3, 2482-2486.	2.5	89

#	ARTICLE	IF	CITATIONS
946	In vivo dynamics of human hematopoietic stem cells: novel concepts and future directions. <i>Blood Advances</i> , 2019, 3, 1916-1924.	2.5	34
947	The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. <i>Blood Advances</i> , 2019, 3, 2949-2961.	2.5	29
948	Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. <i>Blood Advances</i> , 2019, 3, 3454-3460.	2.5	5
949	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. <i>Blood Advances</i> , 2019, 3, 3962-3967.	2.5	12
950	Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. <i>Blood Advances</i> , 2019, 3, 3579-3589.	2.5	7
951	When should transplant physicians think about familial blood cancers?. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e68.	0.6	4
952	Molecular Genetics in Myelodysplasia Outcomes Prognostication. <i>Advances in Molecular Pathology</i> , 2019, 2, 35-43.	0.2	0
954	High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls. <i>Scientific Reports</i> , 2019, 9, 20158.	1.6	1
955	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. <i>Nature Communications</i> , 2019, 10, 5386.	5.8	53
956	Does early diagnosis and treatment of myelodysplastic syndromes make a difference?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101099.	0.7	3
957	DNA methylation aging clocks: challenges and recommendations. <i>Genome Biology</i> , 2019, 20, 249.	3.8	552
958	p53 involvement in clonal hematopoiesis of indeterminate potential. <i>Current Opinion in Hematology</i> , 2019, 26, 235-240.	1.2	21
959	Growing old in the age of heterogeneity: the perils of shifting clonality. <i>Current Opinion in Hematology</i> , 2019, 26, 222-227.	1.2	4
961	Application of Genomics to Clinical Practice in Haematological Malignancy. <i>Current Genetic Medicine Reports</i> , 2019, 7, 236-252.	1.9	0
962	Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients. <i>Experimental Hematology</i> , 2019, 80, 36-41.e3.	0.2	90
963	Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	3
964	The landscape of somatic mutation in normal colorectal epithelial cells. <i>Nature</i> , 2019, 574, 532-537.	13.7	468
965	The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models. <i>HemaSphere</i> , 2019, 3, e152.	1.2	8

#	ARTICLE	IF	CITATIONS
966	Shifting therapeutic paradigms in induction and consolidation for older adults with acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2019, 26, 51-57.	1.2	4
967	Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. <i>Nature Communications</i> , 2019, 10, 5649.	5.8	77
968	Heritability of skewed X-inactivation in female twins is tissue-specific and associated with age. <i>Nature Communications</i> , 2019, 10, 5339.	5.8	47
969	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	15.2	485
970	Genome Sequencing during a Patient's Journey through Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2145-2156.	13.9	50
971	Frequency and signature of somatic variants in 1461 human brain exomes. <i>Genetics in Medicine</i> , 2019, 21, 904-912.	1.1	20
972	Metabolism as master of hematopoietic stem cell fate. <i>International Journal of Hematology</i> , 2019, 109, 18-27.	0.7	71
973	Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 305-311.	1.7	56
974	Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 297-304.	1.7	33
975	DNA methylation processes in atherosclerotic plaque. <i>Atherosclerosis</i> , 2019, 281, 168-179.	0.4	49
976	Hereditary cancer testing challenges: assembling the analytical pieces to solve the patient clinical puzzle. <i>Future Oncology</i> , 2019, 15, 65-79.	1.1	4
977	<i>Smc3</i> is required for mouse embryonic and adult hematopoiesis. <i>Experimental Hematology</i> , 2019, 70, 70-84.e6.	0.2	12
978	Clinicopathological and molecular features of <i>SF3B1</i> -mutated myeloproliferative neoplasms. <i>Human Pathology</i> , 2019, 86, 1-11.	1.1	24
979	Age-related remodelling of oesophageal epithelia by mutated cancer drivers. <i>Nature</i> , 2019, 565, 312-317.	13.7	476
980	Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. <i>Haematologica</i> , 2019, 104, e200-e203.	1.7	8
981	Genomic landscape and clonal evolution of acute myeloid leukemia with <i>t(8;21)</i> : an international study on 331 patients. <i>Blood</i> , 2019, 133, 1140-1151.	0.6	96
982	Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 25.	3.0	313
983	A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease. <i>Human Molecular Genetics</i> , 2019, 28, 1369-1380.	1.4	16

#	ARTICLE	IF	CITATIONS
984	Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1204-1213.	0.4	75
985	Spontaneous & de novo germline mutations in humans and mice: rates, spectra, causes and consequences. <i>Genes and Genetic Systems</i> , 2019, 94, 13-22.	0.2	19
986	Current and future perspectives of liquid biopsies in genomics-driven oncology. <i>Nature Reviews Genetics</i> , 2019, 20, 71-88.	7.7	912
987	Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal. <i>Experimental Hematology</i> , 2019, 70, 10-23.	0.2	13
988	New generation cancer therapy: right direction for sure with some uncertainty. <i>Hepatology International</i> , 2019, 13, 22-24.	1.9	0
989	Clonal hematopoiesis: Genes and underlying mechanisms in cardiovascular disease development. <i>Journal of Cellular Physiology</i> , 2019, 234, 8396-8401.	2.0	8
990	Anemia in the Young and Old. , 2019, , .		0
991	Biological background of the genomic variations of cf-DNA in healthy individuals. <i>Annals of Oncology</i> , 2019, 30, 464-470.	0.6	75
992	The role of circulating free DNA in the management of NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 19-28.	1.1	20
993	Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. <i>Cancer Science</i> , 2019, 110, 401-407.	1.7	20
994	The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. <i>Blood</i> , 2019, 133, 1325-1334.	0.6	53
995	Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. <i>Expert Review of Hematology</i> , 2019, 12, 99-106.	1.0	5
996	Can Grail find the trail to early cancer detection?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 403-406.	1.4	9
997	Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis. <i>Human Mutation</i> , 2019, 40, 97-105.	1.1	66
998	Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms. <i>International Journal of Hematology</i> , 2019, 110, 179-186.	0.7	17
999	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.	0.4	226
1000	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 255-264.	0.5	53
1001	Cohesin-mediated NF- $\kappa$ B signaling limits hematopoietic stem cell self-renewal in aging and inflammation. <i>Journal of Experimental Medicine</i> , 2019, 216, 152-175.	4.2	56

#	ARTICLE	IF	CITATIONS
1002	Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. <i>Nature Medicine</i> , 2019, 25, 103-110.	15.2	169
1003	Plasma DNA for early cancer detection – opportunities and challenges. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 5-7.	1.5	5
1004	A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2019, 184, 176-191.	1.2	102
1005	Circulating Tumor DNA: Clinical Monitoring and Early Detection. <i>Annual Review of Cancer Biology</i> , 2019, 3, 187-201.	2.3	6
1006	Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1189-1197.	1.3	34
1007	Epigenomic drivers of immune dysfunction in aging. <i>Aging Cell</i> , 2019, 18, e12878.	3.0	60
1008	What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells. <i>International Journal of Hematology</i> , 2019, 109, 35-40.	0.7	9
1009	<i>ASXL1</i> mutations in idiopathic cytopenias: determined significance?. <i>Leukemia and Lymphoma</i> , 2019, 60, 568-570.	0.6	0
1010	Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. <i>Haematologica</i> , 2020, 105, 358-365.	1.7	5
1011	Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 665-668.	1.3	7
1012	Discovery and Characterization of Cancer Genetic Susceptibility Alleles. , 2020, , 323-336.e3.		1
1013	The Molecular Genetics of Myeloproliferative Neoplasms. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034876.	2.9	42
1015	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 823-834.	1.2	29
1016	Analysis of the clinical impact of <i>NPM1</i> mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 852-859.	1.2	13
1017	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
1018	Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 137-144.	6.1	215
1019	How Could We Slow or Reverse the Human Aging Process and Extend the Healthy Life Span with Heterochronous Autologous Hematopoietic Stem Cell Transplantation. <i>Rejuvenation Research</i> , 2020, 23, 159-170.	0.9	3
1021	Mechanisms underlying the cross-talk between heart and cancer. <i>Journal of Physiology</i> , 2020, 598, 3015-3027.	1.3	14



#	ARTICLE	IF	CITATIONS
1022	GATA3 in T-cell lymphoproliferative disorders. <i>IUBMB Life</i> , 2020, 72, 170-177.	1.5	11
1023	Circulating tumor DNA and their added value in molecular oncology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 152-161.	1.4	10
1024	Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML). <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036251.	2.9	17
1025	Recent advances in MDS mutation landscape: Splicing and signalling. <i>Advances in Biological Regulation</i> , 2020, 75, 100673.	1.4	7
1026	Cardiovascular Disease, Aging, and Clonal Hematopoiesis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 419-438.	9.6	94
1027	Low prevalence of the BCR-ABL1 fusion gene in a normal population in southern Sarawak. <i>International Journal of Hematology</i> , 2020, 111, 217-224.	0.7	1
1028	Acute Leukemias in Adults. , 2020, , 1783-1797.e1.		3
1029	Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 55-70.	1.0	35
1030	Longitudinal changes in the frequency of mosaic chromosome Y loss in peripheral blood cells of aging men varies profoundly between individuals. <i>European Journal of Human Genetics</i> , 2020, 28, 349-357.	1.4	47
1031	Large-scale analysis of acquired chromosomal alterations in non-tumor samples from patients with cancer. <i>Nature Biotechnology</i> , 2020, 38, 90-96.	9.4	27
1032	Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis. <i>Circulation</i> , 2020, 141, 124-131.	1.6	270
1033	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. <i>Gastroenterology</i> , 2020, 158, 494-505.e6.	0.6	147
1034	Clonal Hematopoiesis and Premalignant Diseases. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a035675.	2.9	10
1035	Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 605-622.	1.2	25
1036	Molecular heterogeneity unravelled by single-cell transcriptomics in patients with essential thrombocythaemia. <i>British Journal of Haematology</i> , 2020, 188, 707-722.	1.2	2
1037	A decade with whole exome sequencing in haematology. <i>British Journal of Haematology</i> , 2020, 188, 367-382.	1.2	24
1038	A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically. <i>Human Mutation</i> , 2020, 41, 203-211.	1.1	19
1039	A new opening on aortic stenosis: predicting prognosis with clonal haematopoiesis. <i>European Heart Journal</i> , 2020, 41, 940-942.	1.0	3

#	ARTICLE	IF	CITATIONS
1040	The evolving role of next generation sequencing in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2020, 188, 224-239.	1.2	11
1041	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , 2020, 105, e98-e101.	1.7	23
1042	Somatic selection of poorly differentiating variant stem cell clones could be a key to human ageing. <i>Journal of Theoretical Biology</i> , 2020, 489, 110153.	0.8	5
1044	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 322-331.e2.	0.9	30
1045	Environmental influences on clonal hematopoiesis. <i>Experimental Hematology</i> , 2020, 83, 66-73.	0.2	45
1046	The minimal that kills: Why defining and targeting measurable residual disease is the <i>“Sine Qua Non”</i> for further progress in management of acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 43, 100650.	2.8	17
1047	Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 396-404.	1.2	17
1048	Evolving Significance of Tumor-Normal Sequencing in Cancer Care. <i>Trends in Cancer</i> , 2020, 6, 31-39.	3.8	30
1049	Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 253-269.	2.7	28
1050	Somatic mosaicism: implications for the cardiovascular system. <i>European Heart Journal</i> , 2020, 41, 2904-2907.	1.0	13
1051	Clonal hematopoiesis, aging, and cardiovascular diseases. <i>Experimental Hematology</i> , 2020, 83, 95-104.	0.2	37
1052	Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells. <i>Leukemia</i> , 2020, 34, 1125-1134.	3.3	10
1053	Impact of the variant allele frequency of <i>ASXL1</i> , <i>DNMT3A</i> , <i>JAK2</i> , <i>TET2</i> , <i>TP53</i> , and <i>NPM1</i> on the outcomes of patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 765-774.	2.0	69
1054	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. <i>Nature Reviews Cancer</i> , 2020, 20, 158-173.	12.8	181
1055	Atypical CML- the role of morphology and precision genomics. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101133.	0.7	7
1056	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 183-192.	3.2	79
1057	Acute Myeloid Leukemia: Aging and Epigenetics. <i>Cancers</i> , 2020, 12, 103.	1.7	46
1058	Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. <i>International Journal of Hematology</i> , 2020, 111, 634-641.	0.7	12

#	ARTICLE	IF	CITATIONS
1059	Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 1-13.	1.6	21
1060	Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. <i>Lancet Haematology</i> , 2020, 7, e73-e81.	2.2	45
1061	Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101137.	0.7	11
1062	Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 407-414.	0.6	10
1063	Somatic inflammatory gene mutations in human ulcerative colitis epithelium. <i>Nature</i> , 2020, 577, 254-259.	13.7	202
1064	Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. <i>Current Opinion in Hematology</i> , 2020, 27, 2-10.	1.2	7
1065	Clonal hematopoiesis as a model for premalignant changes during aging. <i>Experimental Hematology</i> , 2020, 83, 48-56.	0.2	56
1066	Clonal hierarchy of main molecular lesions in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 190, 562-572.	1.2	5
1067	Acquired Resistance in Lung Cancer. <i>Annual Review of Cancer Biology</i> , 2020, 4, 279-297.	2.3	13
1068	EBV status has prognostic implication among young patients with angioimmunoblastic Tâ€cell lymphoma. <i>Cancer Medicine</i> , 2020, 9, 678-688.	1.3	23
1069	Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. <i>European Respiratory Journal</i> , 2020, 55, 1901190.	3.1	38
1070	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 1273-1283.	0.8	281
1071	AML through the prism of molecular genetics. <i>British Journal of Haematology</i> , 2020, 188, 49-62.	1.2	17
1072	Novel Approaches to Target Mutant FLT3 Leukaemia. <i>Cancers</i> , 2020, 12, 2806.	1.7	13
1073	In vivo clonal analysis of aging hematopoietic stem cells. <i>Mechanisms of Ageing and Development</i> , 2020, 192, 111378.	2.2	3
1074	Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3359-3370.	1.9	21
1075	The old and the new: DNA and RNA methylation in normal and malignant hematopoiesis. <i>Experimental Hematology</i> , 2020, 90, 1-11.	0.2	7
1076	Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. <i>Leukemia Research</i> , 2020, 98, 106454.	0.4	8

#	ARTICLE	IF	CITATIONS
1077	Advancing Leukemia Diagnostics: Role of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia. <i>Hematology Reports</i> , 2020, 12, 8957.	0.3	14
1078	Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. <i>Cells</i> , 2020, 9, 2310.	1.8	37
1079	Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. <i>Cancer Discovery</i> , 2020, 10, 1635-1644.	7.7	52
1080	Inherited causes of clonal haematopoiesis in 97,691 whole genomes. <i>Nature</i> , 2020, 586, 763-768.	13.7	376
1081	Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7140.	1.8	14
1082	Hand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis. <i>Experimental Hematology</i> , 2020, 91, 1-9.	0.2	42
1083	Clonal hematopoiesis: Molecular basis and clinical relevance. <i>Leukemia Research</i> , 2020, 98, 106457.	0.4	2
1084	Proliferation: Driver of HSC aging phenotypes?. <i>Mechanisms of Ageing and Development</i> , 2020, 191, 111331.	2.2	7
1085	The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma. <i>Theranostics</i> , 2020, 10, 7635-7644.	4.6	5
1086	Educational Updates in Hematology Book: 25th Congress of the European Hematology Association, Virtual Edition 2020. <i>HemaSphere</i> , 2020, 4, .	1.2	2
1087	A six-attribute classification of genetic mosaicism. <i>Genetics in Medicine</i> , 2020, 22, 1743-1757.	1.1	34
1088	EZH2 in Myeloid Malignancies. <i>Cells</i> , 2020, 9, 1639.	1.8	37
1089	Hematopoietic Stem Cell Metabolism during Development and Aging. <i>Developmental Cell</i> , 2020, 54, 239-255.	3.1	124
1090	SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4902.	1.8	22
1091	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2020, 116, 1820-1834.	1.8	51
1092	Older Age and High Serum Ferritin Levels Associated With the Risk of Chronic Cytopenia in Hemodialysis Patients. <i>Frontiers in Medicine</i> , 2020, 7, 568350.	1.2	2
1093	Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2020, 9, 30.	2.0	15
1094	Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1873-1884.	1.3	4

#	ARTICLE	IF	CITATIONS
1095	Immuno-Modulation of Hematopoietic Stem and Progenitor Cells in Inflammation. <i>Frontiers in Immunology</i> , 2020, 11, 585367.	2.2	16
1096	Clonal Hematopoiesis Before, During, and After Human Spaceflight. <i>Cell Reports</i> , 2020, 33, 108458.	2.9	30
1097	Molecular and cellular mechanisms of aging in hematopoietic stem cells and their niches. <i>Journal of Hematology and Oncology</i> , 2020, 13, 157.	6.9	41
1098	The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications. <i>Cells</i> , 2020, 9, 2512.	1.8	15
1099	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. <i>Nature</i> , 2020, 588, 157-163.	13.7	90
1100	Germline genomic patterns are associated with cancer risk, oncogenic pathways, and clinical outcomes. <i>Science Advances</i> , 2020, 6, .	4.7	12
1101	Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms. <i>Frontiers in Immunology</i> , 2020, 11, 604142.	2.2	5
1102	The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8885.	1.8	13
1103	Preleukemic stem cells: leave it or not?. <i>Blood Science</i> , 2020, 2, 54-58.	0.4	4
1104	Applied genomics in MPN presentation. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 434-439.	0.9	5
1105	Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 3304.	1.7	5
1106	Clinicopathological and molecular analyses of linearly expanded epithelial cells with $\beta$ -catenin alterations, $\beta$ -catenin signature, in the normal fallopian tube. <i>Histopathology</i> , 2020, 77, 880-889.	1.6	0
1107	Evidence of Clonal Hematopoiesis and Risk of Heart Failure. <i>Current Heart Failure Reports</i> , 2020, 17, 271-276.	1.3	4
1108	Discovery through clinical sequencing in oncology. <i>Nature Cancer</i> , 2020, 1, 774-783.	5.7	29
1109	Molecular and functional characteristics of megakaryocytes and platelets in aging. <i>Current Opinion in Hematology</i> , 2020, 27, 302-310.	1.2	2
1110	Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 671-684.	0.7	7
1111	High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers. <i>Blood Advances</i> , 2020, 4, 3550-3557.	2.5	38
1112	New developments and possibilities in the field of post-mortem medicine mortui vivos docent. <i>Rechtsmedizin</i> , 2020, 30, 425-429.	2.6	16

#	ARTICLE	IF	CITATIONS
1113	Advances in understanding of angioimmunoblastic T-cell lymphoma. <i>Leukemia</i> , 2020, 34, 2592-2606.	3.3	91
1114	Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma. <i>Biomarker Research</i> , 2020, 8, 27.	2.8	22
1115	Macrophages Orchestrate Hematopoietic Programs and Regulate HSC Function During Inflammatory Stress. <i>Frontiers in Immunology</i> , 2020, 11, 1499.	2.2	26
1116	A somatic evolutionary model of the dynamics of aneuploid cells during hematopoietic reconstitution. <i>Scientific Reports</i> , 2020, 10, 12198.	1.6	0
1117	TET family dioxygenases and the TET activator vitamin C in immune responses and cancer. <i>Blood</i> , 2020, 136, 1394-1401.	0.6	40
1118	Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19. <i>Cancers</i> , 2020, 12, 1992.	1.7	24
1119	Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN. <i>Cancers</i> , 2020, 12, 2038.	1.7	7
1120	Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse. <i>Haematologica</i> , 2021, 106, 2325-2333.	1.7	18
1121	Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 2100.	1.7	19
1122	Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101191.	0.7	6
1123	Clonal hematopoiesis and non-hematologic disorders. <i>Blood</i> , 2020, 136, 1606-1614.	0.6	71
1124	Clonal hematopoiesis in the inherited bone marrow failure syndromes. <i>Blood</i> , 2020, 136, 1615-1622.	0.6	26
1125	Clonal hematopoiesis and risk for hematologic malignancy. <i>Blood</i> , 2020, 136, 1599-1605.	0.6	35
1126	What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics. <i>Blood</i> , 2020, 136, 1623-1631.	0.6	23
1127	Clonal Hematopoiesis: Mechanisms Driving Dominance of Stem Cell Clones. <i>Blood</i> , 2020, 136, 1590-1598.	0.6	67
1128	Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors. <i>Journal of Translational Medicine</i> , 2020, 18, 293.	1.8	20
1129	Translating Evidence from Clonal Hematopoiesis to Cardiovascular Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2480.	1.0	16
1130	Sowing the Seeds of Clonal Hematopoiesis. <i>Cell Stem Cell</i> , 2020, 27, 195-197.	5.2	3

#	ARTICLE	IF	CITATIONS
1131	The role of clonal haematopoiesis in cardiovascular diseases: epidemiology and experimental studies. <i>Journal of Internal Medicine</i> , 2020, 288, 507-517.	2.7	10
1132	Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. <i>Cancers</i> , 2020, 12, 2194.	1.7	28
1133	In Vitro Modeling of Non-Solid Tumors: How Far Can Tissue Engineering Go?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5747.	1.8	16
1135	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020, 12, 2228.	1.7	22
1136	Inflammation mediated platelet hyperactivity in aging. <i>Annals of Blood</i> , 2020, 5, 10-10.	0.4	2
1137	Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing. <i>Haematologica</i> , 2020, 106, 313-315.	1.7	17
1138	Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues. <i>Cancers</i> , 2020, 12, 2216.	1.7	17
1140	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	9.4	367
1141	Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells. <i>Cell Reports</i> , 2020, 32, 108093.	2.9	54
1142	Single-cell mutation analysis of clonal evolution in myeloid malignancies. <i>Nature</i> , 2020, 587, 477-482.	13.7	304
1143	A mosaic analysis system with Cre or Tomato expression in the mouse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28212-28220.	3.3	3
1144	Clonal Hematopoiesis, Cardiovascular Diseases and Hematopoietic Stem Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7902.	1.8	10
1145	TET2-Loss-of-Function-Driven Clonal Hematopoiesis Exacerbates Experimental Insulin Resistance in Aging and Obesity. <i>Cell Reports</i> , 2020, 33, 108326.	2.9	117
1146	Mutations in normal tissues—some diagnostic and clinical implications. <i>BMC Medicine</i> , 2020, 18, 283.	2.3	19
1147	Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy. <i>Cancers</i> , 2020, 12, 3128.	1.7	12
1148	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <sc>Translational Research Committee</sc> of the <sc>Heart Failure Association</sc> (<sc>HFA</sc>) of the <sc>European Society of Cardiology</sc> (<sc>ESC</sc>). <i>European Journal of Heart Failure</i> . 2020. 22. 2272-2289.	2.9	92
1149	Gut microecology: Why our microbes could be key to our health. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110784.	2.5	21
1150	Murine Models of Myelofibrosis. <i>Cancers</i> , 2020, 12, 2381.	1.7	14

#	ARTICLE	IF	CITATIONS
1151	Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2020, 10, 89.	2.8	20
1152	Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach. <i>Expert Review of Hematology</i> , 2020, 13, 1289-1301.	1.0	3
1153	ctDNA as a cancer biomarker: A broad overview. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103109.	2.0	128
1154	Aplastic anemia in a patient with COVID due to NFKB1 haploinsufficiency. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005769.	0.5	3
1155	Autophagy-mTOR axis decelerates hematopoietic aging. <i>Aging Cell</i> , 2020, 19, e13232.	3.0	24
1156	Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation. <i>Haematologica</i> , 2020, 105, 2655-2658.	1.7	1
1157	Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. <i>Cancers</i> , 2020, 12, 2277.	1.7	83
1158	Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. <i>Journal of Personalized Medicine</i> , 2020, 10, 94.	1.1	12
1159	MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment. <i>Cells</i> , 2020, 9, 1901.	1.8	27
1160	Circulating Tumor DNA in Cancer Management: A Value Proposition. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 1017-1026.	0.6	0
1161	The Role of Age-Related Clonal Hematopoiesis in Genetic Sequencing Studies. <i>American Journal of Human Genetics</i> , 2020, 107, 575-576.	2.6	6
1162	Response to Holstege et al.. <i>American Journal of Human Genetics</i> , 2020, 107, 577-578.	2.6	1
1163	Unraveling Hematopoiesis through the Lens of Genomics. <i>Cell</i> , 2020, 182, 1384-1400.	13.5	96
1164	All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: driver lesion dependent effects on leukemic stem cells. <i>Cell Cycle</i> , 2020, 19, 2573-2588.	1.3	10
1165	Chasing ctDNA in Patients With Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e351-e360.	1.8	8
1166	New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. <i>Oncogenesis</i> , 2020, 9, 73.	2.1	14
1167	The road ahead in genetics and genomics. <i>Nature Reviews Genetics</i> , 2020, 21, 581-596.	7.7	118
1168	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 288.	7.1	98



#	ARTICLE	IF	CITATIONS
1169	Non-genetic Heterogeneity of Macrophages in Diseasesâ€”A Medical Perspective. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 613116.	1.8	10
1170	Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis. <i>Blood Advances</i> , 2020, 4, 6353-6363.	2.5	36
1171	Clonal Hematopoiesis in Hospitalized Elderly Patients With COVIDâ€”19. <i>HemaSphere</i> , 2020, 4, e453.	1.2	23
1172	Dietary patterns and the neoplasticâ€”prone tissue landscape of old age. <i>Aging and Cancer</i> , 2020, 1, 45-57.	0.5	2
1173	Predictors of vascular disease in myelodysplastic syndromes. <i>EJHaem</i> , 2020, 1, 467-472.	0.4	3
1174	Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes. <i>Blood Advances</i> , 2020, 4, 5232-5245.	2.5	8
1175	Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. <i>Leukemia</i> , 2020, 35, 2017-2029.	3.3	27
1176	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2441-2453.	1.1	5
1177	Clonal Hematopoiesis in Late-Stage Nonâ€”Small-Cell Lung Cancer and Its Impact on Targeted Panel Next-Generation Sequencing. <i>JCO Precision Oncology</i> , 2020, 4, 1271-1279.	1.5	19
1178	Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis. <i>Scientific Reports</i> , 2020, 10, 19037.	1.6	4
1179	Fate of Hematopoiesis During Aging. What Do We Really Know, and What are its Implications?. <i>Stem Cell Reviews and Reports</i> , 2020, 16, 1020-1048.	1.7	19
1180	Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2020, 135, 1548-1559.	0.6	58
1181	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in nonâ€”small cell lung cancer: Analysis of over 8000 cases. <i>Cancer</i> , 2020, 126, 3219-3228.	2.0	106
1182	TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3432.	1.8	25
1183	Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome. <i>Cancer Research</i> , 2020, 80, 2523-2536.	0.4	13
1184	Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 249.	1.8	29
1185	Quantitative and Qualitative QC of Next-Generation Sequencing for Detecting Somatic Variants: An Example of Detecting Clonal Hematopoiesis of Indeterminate Potential. <i>Clinical Chemistry</i> , 2020, 66, 832-841.	1.5	3
1186	Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas. <i>Advanced Biology</i> , 2020, 4, 2000029.	3.0	12

#	ARTICLE	IF	CITATIONS
1187	Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. <i>Current Oncology Reports</i> , 2020, 22, 61.	1.8	21
1188	Insights into variation in meiosis from 31,228 human sperm genomes. <i>Nature</i> , 2020, 583, 259-264.	13.7	73
1189	A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation. <i>Case Reports in Oncology</i> , 2020, 13, 449-455.	0.3	2
1190	The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. <i>PLoS ONE</i> , 2020, 15, e0231999.	1.1	36
1191	Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. <i>Nature Reviews Cancer</i> , 2020, 20, 365-382.	12.8	87
1192	Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 64.	1.1	39
1193	Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. <i>Leukemia</i> , 2020, 34, 2198-2205.	3.3	26
1194	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020, 136, 157-170.	0.6	195
1195	Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2020, 136, 36-49.	0.6	59
1196	Genetics of progression from MDS to secondary leukemia. <i>Blood</i> , 2020, 136, 50-60.	0.6	80
1197	Remethylation of <i>Dnmt3a</i> hematopoietic cells is associated with partial correction of gene dysregulation and reduced myeloid skewing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3123-3134.	3.3	27
1198	Identification of two DNA methylation subtypes of Waldenström's macroglobulinemia with plasma and memory B cell features. <i>Blood</i> , 2020, 136, 585-595.	0.6	10
1199	Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. <i>Leukemia</i> , 2020, 34, 2660-2672.	3.3	96
1200	The DNA methylation landscape of hematological malignancies: an update. <i>Molecular Oncology</i> , 2020, 14, 1616-1639.	2.1	26
1201	Clonality in haematopoietic stem cell ageing. <i>Mechanisms of Ageing and Development</i> , 2020, 189, 111279.	2.2	4
1202	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	5.8	98
1203	Large Copy-Number Variants in UK Biobank Caused by Clonal Hematopoiesis May Confound Penetrance Estimates. <i>American Journal of Human Genetics</i> , 2020, 107, 325-329.	2.6	6
1204	Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. <i>Blood Reviews</i> , 2020, 42, 100708.	2.8	10

#	ARTICLE	IF	CITATIONS
1205	Chromosomal alterations among age-related haematopoietic clones in Japan. <i>Nature</i> , 2020, 584, 130-135.	13.7	102
1206	Monogenic and polygenic inheritance become instruments for clonal selection. <i>Nature</i> , 2020, 584, 136-141.	13.7	119
1207	High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2020, 4, 2430-2438.	2.5	54
1208	Implications of Clonal Hematopoiesis for Precision Oncology. <i>JCO Precision Oncology</i> , 2020, 4, 639-646.	1.5	16
1209	Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. <i>Genes</i> , 2020, 11, 649.	1.0	29
1210	The role of host environment in cancer evolution. <i>Evolutionary Applications</i> , 2020, 13, 1756-1770.	1.5	15
1211	Intestinal stem cells heterogeneity and clonal dominance during aging: two faces of the same coin?. <i>Mechanisms of Ageing and Development</i> , 2020, 189, 111247.	2.2	2
1212	Clonal haematopoiesis and COVID-19: A possible deadly liaison. <i>International Journal of Immunogenetics</i> , 2020, 47, 329-331.	0.8	5
1213	Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2392-2403.	2.5	11
1214	CML - Not only BCR-ABL1 matters. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101194.	0.7	6
1215	The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. <i>Journal of Hematology and Oncology</i> , 2020, 13, 72.	6.9	123
1216	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. <i>Nature Reviews Urology</i> , 2020, 17, 271-291.	1.9	32
1217	RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 3597-3607.	3.2	26
1218	Interplay between Clonal Hematopoiesis of Indeterminate Potential and Metabolism. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 525-535.	3.1	23
1219	Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. <i>Leukemia</i> , 2020, 34, 3256-3268.	3.3	46
1220	Circulating tumor DNA and liquid biopsy in oncology. <i>Nature Cancer</i> , 2020, 1, 276-290.	5.7	309
1221	Novel Mutations and Decreased Expression of the Epigenetic Regulator <i>TET2</i> in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2020, 141, 1986-2000.	1.6	75
1222	The evolutionary dynamics and fitness landscape of clonal hematopoiesis. <i>Science</i> , 2020, 367, 1449-1454.	6.0	294

#	ARTICLE	IF	CITATIONS
1223	Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications. <i>Translational Lung Cancer Research</i> , 2020, 9, 61-70.	1.3	10
1224	Normal Hematopoiesis Is a Balancing Act of Self-Renewal and Regeneration. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a035519.	2.9	29
1225	Clonal Hematopoiesis From Next Generation Sequencing of Plasma From a Patient With Lung Adenocarcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 113.	1.3	3
1226	Gene constraint and genotype-phenotype correlations in neurodevelopmental disorders. <i>Current Opinion in Genetics and Development</i> , 2020, 65, 69-75.	1.5	7
1227	MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus. <i>Blood</i> , 2020, 136, 2764-2773.	0.6	15
1228	Gene mutation profile in patients with acquired pure red cell aplasia. <i>Annals of Hematology</i> , 2020, 99, 1749-1754.	0.8	9
1229	Hematopoietic alterations in chronic heart failure patients by somatic mutations leading to clonal hematopoiesis. <i>Haematologica</i> , 2020, 105, e328-e332.	1.7	19
1230	Targeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease. <i>Cells</i> , 2020, 9, 1558.	1.8	75
1231	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
1232	Cellular Therapy in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 701-714.	0.9	1
1233	Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. <i>Genes</i> , 2020, 11, 749.	1.0	30
1234	Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors. <i>Leukemia</i> , 2020, 34, 2992-3006.	3.3	14
1235	Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. <i>Blood Advances</i> , 2020, 4, 2567-2576.	2.5	37
1236	Clonal hematopoiesis in myeloma: root of all maladies!. <i>Blood</i> , 2020, 135, 2330-2331.	0.6	2
1238	Kinetics of premyelodysplastic syndromes blood values correlate with disease risk and survival. <i>Hematological Oncology</i> , 2020, 38, 782-791.	0.8	1
1239	Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity. <i>Experimental Hematology</i> , 2020, 83, 85-94.	0.2	77
1240	Clonal hematopoiesis in hematological disorders: Three different scenarios. <i>Experimental Hematology</i> , 2020, 83, 57-65.	0.2	7
1241	Hematopoietic stem cell regulation by the proteostasis network. <i>Current Opinion in Hematology</i> , 2020, 27, 254-263.	1.2	14

#	ARTICLE	IF	CITATIONS
1242	Ten-eleven translocation methyl-cytosine dioxygenase 2 deficiency exacerbates renal ischemia-reperfusion injury. <i>Clinical Epigenetics</i> , 2020, 12, 98.	1.8	8
1243	Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome. <i>American Journal of Hematology</i> , 2020, 95, E287.	2.0	6
1244	Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Haematologica</i> , 2020, 105, e264-e267.	1.7	56
1245	Clonal hematopoiesis in cancer. <i>Experimental Hematology</i> , 2020, 83, 105-112.	0.2	24
1246	Clonal hematopoiesis driven by somatic mutations: A new player in atherosclerotic cardiovascular disease. <i>Atherosclerosis</i> , 2020, 297, 120-126.	0.4	12
1247	Clonal Hematopoiesis: A New Step Linking Inflammation to Heart Failure. <i>JACC Basic To Translational Science</i> , 2020, 5, 196-207.	1.9	33
1248	Driver mutations in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2020, 27, 49-57.	1.2	44
1249	A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. <i>Journal of Biomedical Informatics</i> , 2020, 104, 103398.	2.5	5
1250	Bone marrow niches in haematological malignancies. <i>Nature Reviews Cancer</i> , 2020, 20, 285-298.	12.8	270
1251	The Role of ASXL1/2 and Their Associated Proteins in Malignant Hematopoiesis. <i>Current Stem Cell Reports</i> , 2020, 6, 6-15.	0.7	5
1252	The new biology of PTCL-NOS and AITL: current status and future clinical impact. <i>British Journal of Haematology</i> , 2020, 189, 54-66.	1.2	32
1253	Somatic mutations and T-cell clonality in patients with immunodeficiency. <i>Haematologica</i> , 2020, 105, 2757-2768.	1.7	18
1254	ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients. <i>British Journal of Haematology</i> , 2020, 189, 913-919.	1.2	11
1255	Challenges in Interpreting TP53 Pathogenic Variants With a Low Minor Allele Frequency in Germline Genetic Testing: A Case Report of a Patient With Mosaic Li-Fraumeni Syndrome. <i>JCO Precision Oncology</i> , 2020, 4, 91-95.	1.5	3
1256	Update on the classification of myeloid neoplasms: The 2016 revised World Health Organization classification of hematopoietic and lymphoid neoplasms. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e78.	0.6	1
1257	The Clinical Management of Clonal Hematopoiesis. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 357-367.	0.9	42
1258	The stochastic nature of errors in next-generation sequencing of circulating cell-free DNA. <i>PLoS ONE</i> , 2020, 15, e0229063.	1.1	6
1259	CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance. <i>British Journal of Haematology</i> , 2020, 190, 495-507.	1.2	31

#	ARTICLE	IF	CITATIONS
1260	Quantifying Hematopoietic Stem Cell Clonal Diversity by Selecting Informative Amplicon Barcodes. <i>Scientific Reports</i> , 2020, 10, 2153.	1.6	4
1261	The clinical impact of mutant <i>DNMT3A</i> R882 variant allele frequency in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e81-e86.	1.2	5
1262	Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 1.	0.6	5
1263	Cancer as a disease of old age: changing mutational and microenvironmental landscapes. <i>British Journal of Cancer</i> , 2020, 122, 943-952.	2.9	153
1264	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <i>Nature Medicine</i> , 2020, 26, 47-51.	15.2	255
1265	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	41
1266	The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. <i>Nature Communications</i> , 2020, 11, 435.	5.8	47
1267	Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 626.	1.8	42
1268	Enabling Precision Oncology Through Precision Diagnostics. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 97-121.	9.6	50
1269	ASXL1 mutation in clonal hematopoiesis. <i>Experimental Hematology</i> , 2020, 83, 74-84.	0.2	30
1270	Stem Cell DNA Damage and Genome Mutation in the Context of Aging and Cancer Initiation. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a036210.	2.3	25
1271	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. <i>Nature Communications</i> , 2020, 11, 525.	5.8	158
1272	60 Years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations. <i>Experimental Hematology</i> , 2020, 83, 2-11.	0.2	24
1273	Therapeutic targeting of preleukemia cells in a mouse model of <i>NPM1</i> mutant acute myeloid leukemia. <i>Science</i> , 2020, 367, 586-590.	6.0	145
1274	Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e013755.	1.6	37
1275	Mutational Mosaics of Cell-Free DNA from Pancreatic Cyst Fluids. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2294-2301.	1.1	6
1276	Clones assemble! The clonal complexity of blood during ontogeny and disease. <i>Experimental Hematology</i> , 2020, 83, 35-47.	0.2	10
1277	Distinctive and common features of moderate aplastic anaemia. <i>British Journal of Haematology</i> , 2020, 189, 967-975.	1.2	10

#	ARTICLE	IF	CITATIONS
1278	Understanding intrinsic hematopoietic stem cell aging. <i>Haematologica</i> , 2020, 105, 22-37.	1.7	101
1279	Hematopathology. , 2020, , 1729-2141.		0
1280	CD177 Enhances the Detection of Myelodysplastic Syndrome by Flow Cytometry. <i>American Journal of Clinical Pathology</i> , 2020, 153, 554-565.	0.4	13
1281	An Acetylation Switch of the NLRP3 Inflammasome Regulates Aging-Associated Chronic Inflammation and Insulin Resistance. <i>Cell Metabolism</i> , 2020, 31, 580-591.e5.	7.2	213
1282	EM-mosaic detects mosaic point mutations that contribute to congenital heart disease. <i>Genome Medicine</i> , 2020, 12, 42.	3.6	17
1283	Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 165-177.	0.4	19
1284	Cancer and myeloid clonal evolution in the short telomere syndromes. <i>Current Opinion in Genetics and Development</i> , 2020, 60, 112-118.	1.5	22
1285	Genetics of age-related clonal hematopoiesis and atherosclerotic cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2020, 35, 219-225.	0.8	7
1286	Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations. <i>Cancers</i> , 2020, 12, 934.	1.7	35
1287	The duality of human oncoproteins: drivers of cancer and congenital disorders. <i>Nature Reviews Cancer</i> , 2020, 20, 383-397.	12.8	44
1288	Molecular aberrations in myelodysplastic syndromes. <i>Advances in Cell and Gene Therapy</i> , 2020, 4, e83.	0.6	0
1289	Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. <i>Blood</i> , 2020, 135, 870-875.	0.6	48
1290	Baseline TP53 mutations in Adults with SCD developing Myeloid Malignancy following Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 135, 1185-1188.	0.6	29
1291	The role of circulating tumor DNA testing in breast cancer liquid biopsies: getting ready for prime time. <i>Breast Cancer Management</i> , 2020, 9, .	0.2	12
1292	Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness. <i>Stem Cell Reports</i> , 2020, 14, 551-560.	2.3	53
1293	The mutational landscape of normal human endometrial epithelium. <i>Nature</i> , 2020, 580, 640-646.	13.7	338
1294	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	3.2	74
1295	Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality. <i>Blood</i> , 2020, 135, 261-268.	0.6	47

#	ARTICLE	IF	CITATIONS
1296	Concordance for clonal hematopoiesis is limited in elderly twins. <i>Blood</i> , 2020, 135, 269-273.	0.6	38
1297	Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis. <i>Blood</i> , 2020, 135, 845-856.	0.6	27
1298	Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. <i>Blood</i> , 2020, 135, 1161-1170.	0.6	30
1299	Stem cell donors should not be screened for clonal hematopoiesis. <i>Blood Advances</i> , 2020, 4, 789-792.	2.5	27
1300	Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling. <i>Blood Advances</i> , 2020, 4, 1145-1158.	2.5	39
1301	Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 885-892.	2.5	33
1302	Clinical implications of recurrent gene mutations in acute myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2020, 9, 4.	2.0	47
1303	Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes. <i>Cancers</i> , 2020, 12, 903.	1.7	14
1304	The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a034975.	2.9	8
1305	Mouse Models of Myeloid Malignancies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a035535.	2.9	3
1306	The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 1000-1007.	1.7	9
1307	Benzene induces rapid leukemic transformation after prolonged hematotoxicity in a murine model. <i>Leukemia</i> , 2021, 35, 595-600.	3.3	8
1308	Bone marrow contribution to the heart from development to adulthood. <i>Seminars in Cell and Developmental Biology</i> , 2021, 112, 16-26.	2.3	2
1309	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification an approach to classification of patients with t-MDS. <i>Leukemia</i> , 2021, 35, 835-849.	3.3	54
1310	Immunometabolic control of hematopoiesis. <i>Molecular Aspects of Medicine</i> , 2021, 77, 100923.	2.7	22
1311	A CHIP in the Armor of Cell-Free DNA-Based Predictive Biomarkers for Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 111.	3.4	2
1312	The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. <i>Blood Reviews</i> , 2021, 46, 100744.	2.8	16
1313	Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. <i>Circulation</i> , 2021, 143, 410-423.	1.6	87



#	ARTICLE	IF	CITATIONS
1314	In Vivo Clonal Analysis of Aged Hematopoietic Stem Cells: Single-Cell Transplantation. <i>Methods in Molecular Biology</i> , 2021, 2185, 181-194.	0.4	0
1315	Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. <i>International Journal of Cancer</i> , 2021, 148, 702-712.	2.3	41
1316	Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 15-23.	3.2	20
1317	Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst. <i>Blood Reviews</i> , 2021, 47, 100760.	2.8	7
1318	Cellular heterogeneity and microenvironmental control of skin cancer. <i>Journal of Internal Medicine</i> , 2021, 289, 614-628.	2.7	8
1319	<i>TP53</i> , a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes. <i>Gut</i> , 2021, 70, 1139-1146.	6.1	10
1320	Epigenetic Regulators as the Gatekeepers of Hematopoiesis. <i>Trends in Genetics</i> , 2021, 37, 125-142.	2.9	40
1321	High frequency of clonal hematopoiesis in Erdheim-Chester disease. <i>Blood</i> , 2021, 137, 485-492.	0.6	30
1322	Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. <i>Cancer Science</i> , 2021, 112, 454-464.	1.7	15
1323	Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 142-156.	0.6	75
1324	Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. <i>Blood</i> , 2021, 137, 1145-1153.	0.6	52
1325	Cause and effect in epigenetics – where lies the truth, and how can experiments reveal it?. <i>BioEssays</i> , 2021, 43, e2000262.	1.2	3
1326	Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 199-222.	9.6	16
1327	Tumor-only sequencing for oncology management: Germline-focused analysis and implications. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 352-357.	1.5	4
1328	Principles of the Molecular and Cellular Mechanisms of Aging. <i>Journal of Investigative Dermatology</i> , 2021, 141, 951-960.	0.3	36
1329	Preleukemic and leukemic evolution at the stem cell level. <i>Blood</i> , 2021, 137, 1013-1018.	0.6	9
1330	Clonal tracking of haematopoietic cells: insights and clinical implications. <i>British Journal of Haematology</i> , 2021, 192, 819-831.	1.2	10
1331	Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone. <i>British Journal of Haematology</i> , 2021, 192, e60-e63.	1.2	3

#	ARTICLE	IF	CITATIONS
1332	TET2: A cornerstone in normal and malignant hematopoiesis. <i>Cancer Science</i> , 2021, 112, 31-40.	1.7	25
1333	Overlooking the obvious? On the potential of treatment alterations to predict patient-specific therapy response. <i>Experimental Hematology</i> , 2021, 94, 26-30.	0.2	6
1334	Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 17-33.	3.5	118
1335	Human hematopoiesis: aging and leukemogenic risk. <i>Current Opinion in Hematology</i> , 2021, 28, 57-63.	1.2	10
1336	Protein phosphatase, Mg <sup>2+</sup> /Mn <sup>2+</sup> -dependent 1D (PPM1D) mutations in haematological cancer. <i>British Journal of Haematology</i> , 2021, 192, 697-705.	1.2	7
1337	A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression. <i>British Journal of Haematology</i> , 2021, 192, e77-e81.	1.2	1
1338	Genetic complexity of chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1031-1045.	0.6	4
1339	Clonal haematopoiesis and cardiovascular disease: how low can you go?. <i>European Heart Journal</i> , 2021, 42, 266-268.	1.0	7
1340	To portray clonal evolution in blood cancer, count your stem cells. <i>Blood</i> , 2021, 137, 1862-1870.	0.6	14
1341	Paraneoplastic leukemoid reaction: Case report and review of the literature. <i>Pathology Research and Practice</i> , 2021, 217, 153295.	1.0	8
1342	Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. <i>International Journal of Cancer</i> , 2021, 148, 921-931.	2.3	13
1343	Alterations to DNMT3A in Hematologic Malignancies. <i>Cancer Research</i> , 2021, 81, 254-263.	0.4	20
1344	Towards systematic nomenclature for cell-free DNA. <i>Human Genetics</i> , 2021, 140, 565-578.	1.8	42
1345	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021, 35, 1291-1300.	3.3	5
1346	Integrating clonal haematopoiesis into geriatric oncology: The ARCH between aging, cardiovascular disease and malignancy. <i>Journal of Geriatric Oncology</i> , 2021, 12, 479-482.	0.5	2
1347	Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. <i>Nature Reviews Cardiology</i> , 2021, 18, 58-68.	6.1	187
1348	Germline DNMT3A mutation in familial acute myeloid leukaemia. <i>Epigenetics</i> , 2021, 16, 567-576.	1.3	9
1349	Pathogenic postzygotic mosaicism in the tyrosine receptor kinase pathway: potential unidentified human disease hidden away in a few cells. <i>FEBS Journal</i> , 2021, 288, 3108-3119.	2.2	7

#	ARTICLE	IF	CITATIONS
1350	Growth Factors. , 2021, , 13-21.		0
1351	Clonal hematopoiesis in adult pure red cell aplasia. <i>Scientific Reports</i> , 2021, 11, 2253.	1.6	12
1352	Diagnosis and Classification of AML: WHO 2016. <i>Hematologic Malignancies</i> , 2021, , 23-54.	0.2	1
1353	Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients. <i>Cells</i> , 2021, 10, 212.	1.8	24
1354	Stem cell epigenetics in medical therapy. , 2021, , 873-884.		0
1355	Prognostic value of absolute quantification of mutated <i>KRAS</i> in circulating tumour DNA in lung adenocarcinoma patients prior to therapy. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 209-219.	1.3	8
1356	Stem Cell Biology in Bone Marrow Transplantation. <i>Organ and Tissue Transplantation</i> , 2021, , 29-42.	0.0	0
1357	Verbascoside—A Review of Its Antitumor Activities. <i>Pharmacology &amp; Pharmacy</i> , 2021, 12, 109-126.	0.2	9
1358	Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia. <i>Frontiers of Medicine</i> , 2021, 15, 347-371.	1.5	20
1359	Telomere Length as a Marker of Biological Age: State-of-the-Art, Open Issues, and Future Perspectives. <i>Frontiers in Genetics</i> , 2020, 11, 630186.	1.1	181
1360	Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 61-70.	0.3	3
1361	Identification of Mutations in IDH1/2, DNMT3A, ASXL1 Genes of Genome Epigenetic Regulation and Their Co-Occurrence with FLT3, NPM1, RUNX1 Mutations in Acute Myeloid Leukemia. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 13-21.	0.1	3
1362	Detectable chromosome X mosaicism in males is rarely tolerated in peripheral leukocytes. <i>Scientific Reports</i> , 2021, 11, 1193.	1.6	13
1363	Maintenance therapy for <i>FLT3-ITD</i> -mutated acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 664-670.	1.7	30
1364	Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology. <i>JCO Precision Oncology</i> , 2021, 5, 107-122.	1.5	24
1365	Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. <i>JCO Precision Oncology</i> , 2021, 5, 265-274.	1.5	13
1366	Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy. <i>International Journal of Hematology</i> , 2021, 113, 936-940.	0.7	1
1367	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <i>JAMA Oncology</i> , 2021, 7, 107.	3.4	90

#	ARTICLE	IF	CITATIONS
1368	Hyperglycemia cooperates with Tet2 heterozygosity to induce leukemia driven by proinflammatory cytokine-induced lncRNA Morbid. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	18
1369	AML: Auf der Suche nach Risikofaktoren für die Anthrazyklin-induzierte Kardiomyopathie. <i>Karger Kompass Onkologie</i> , 2021, 8, 80-81.	0.0	0
1370	TP53 mutated myeloid malignancies and their treatment strategy. <i>Journal of Hematopoietic Cell Transplantation</i> , 2021, 10, 7-15.	0.1	0
1371	Acute Myeloid Leukemia. , 2021, , 110-141.		0
1372	Future Developments: Measurable Residual Disease. <i>Hematologic Malignancies</i> , 2021, , 317-337.	0.2	0
1373	Evolutionary perspectives on cancer and aging. , 2021, , 97-115.		0
1374	A New Perspective on the Origin of DNA Double-Strand Breaks and Its Implications for Ageing. <i>Genes</i> , 2021, 12, 163.	1.0	5
1375	Poor mobilization of autologous CD34 <sup>+</sup> peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminant potential. <i>British Journal of Haematology</i> , 2021, 193, 841-844.	1.2	6
1377	Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma. <i>Cancer Science</i> , 2021, 112, 1339-1347.	1.7	4
1378	Splicing alterations in healthy aging and disease. <i>Wiley Interdisciplinary Reviews RNA</i> , 2021, 12, e1643.	3.2	29
1379	Clonal expansion in non-cancer tissues. <i>Nature Reviews Cancer</i> , 2021, 21, 239-256.	12.8	133
1380	Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 373-385.	0.8	11
1381	Applications of next-generation sequencing in hematologic malignancies. <i>Human Immunology</i> , 2021, 82, 859-870.	1.2	8
1383	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. <i>Biology</i> , 2021, 10, 128.	1.3	5
1384	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. <i>JCO Precision Oncology</i> , 2021, 5, 378-388.	1.5	26
1385	High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free cfDNA in invasive gliomas after treatment. <i>International Journal of Cancer</i> , 2021, 148, 2839-2847.	2.3	19
1387	Insights into clonal hematopoiesis and its relation to cancer risk. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 63-69.	1.5	20
1388	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. <i>Nature Communications</i> , 2021, 12, 1334.	5.8	103

#	ARTICLE	IF	CITATIONS
1389	The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies?. HemaSphere, 2021, 5, e537.	1.2	0
1391	NPM1-mutant acute myeloid leukemia relapsing as acute lymphoblastic leukemia with clonal persistence of IDH1 mutation. Leukemia and Lymphoma, 2021, 62, 1790-1792.	0.6	0
1393	PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse. Leukemia, 2021, 35, 2693-2697.	3.3	2
1394	Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure. Cancers, 2021, 13, 748.	1.7	8
1395	A Translational Research in Angioimmunoblastic T-cell Lymphoma. Journal of the Society of Japanese Women Scientists, 2021, 21, 1-12.	0.0	1
1396	When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis. Journal of Clinical Medicine, 2021, 10, 1026.	1.0	6
1397	In-utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newborns. Aids, 2021, 35, 1525-1535.	1.0	2
1398	Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell, 2021, 184, 1348-1361.e22.	13.5	149
1399	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell, 2021, 28, 514-523.e9.	5.2	130
1401	High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome. PLoS ONE, 2021, 16, e0248430.	1.1	5
1402	Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 654817.	1.3	11
1403	Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nature Communications, 2021, 12, 1366.	5.8	69
1404	Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. International Journal of Molecular Sciences, 2021, 22, 2595.	1.8	10
1405	Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells. Experimental Hematology, 2021, 95, 31-45.	0.2	15
1406	Full spectrum of clonal haematopoiesisâ€ driver mutations in chronic heart failure and their associations with mortality. ESC Heart Failure, 2021, 8, 1873-1884.	1.4	26
1407	Frequent somatic <i>TET2</i> mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. Blood, 2021, 138, 662-673.	0.6	30
1408	Pre-Leukemic States: United by Difference. Cancers, 2021, 13, 1382.	1.7	0
1409	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Advances, 2021, 5, 1540-1551.	2.5	35

#	ARTICLE	IF	CITATIONS
1410	Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. <i>Nature Communications</i> , 2021, 12, 1826.	5.8	54
1411	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 46.	2.8	6
1412	Chromatin-Spliceosome Mutations in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1232.	1.7	9
1413	Large-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. <i>Blood Cancer Discovery</i> , 2021, 2, 226-237.	2.6	22
1414	When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. <i>Oncology and Therapy</i> , 2021, 9, 89-110.	1.0	36
1415	The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 635189.	1.8	13
1416	Modeling and targeting of erythroleukemia by hematopoietic genome editing. <i>Blood</i> , 2021, 137, 1628-1640.	0.6	25
1417	The association between family history and genomic burden with schizophrenia mortality: a Swedish population-based register and genetic sample study. <i>Translational Psychiatry</i> , 2021, 11, 163.	2.4	0
1419	Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms. <i>PLoS ONE</i> , 2021, 16, e0247858.	1.1	4
1420	Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 299-310.	1.5	23
1421	Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms. <i>Cell Stem Cell</i> , 2021, 28, 502-513.e6.	5.2	36
1422	Healthy Lifestyle and Clonal Hematopoiesis of Indeterminate Potential: Results From the Women's Health Initiative. <i>Journal of the American Heart Association</i> , 2021, 10, e018789.	1.6	43
1423	Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease. <i>Cancers</i> , 2021, 13, 1968.	1.7	9
1424	Dnmt3a deficiency in the skin causes focal, canonical DNA hypomethylation and a cellular proliferation phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2022760118.	3.3	6
1425	Precision medicine in myeloid malignancies. <i>Seminars in Cancer Biology</i> , 2022, 84, 153-169.	4.3	18
1426	A feedback loop: Interactions between Inflammatory Signals and Clonal Hematopoiesis in Cardiovascular Disease. <i>Molecular Biology Reports</i> , 2021, 48, 3785-3798.	1.0	5
1427	What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms. <i>Blood</i> , 2021, 138, 749-757.	0.6	23
1428	Clonal haematopoiesis and cardiovascular diseases: A growing relationship. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 316-324.	0.7	1

#	ARTICLE	IF	CITATIONS
1429	Metabolic Regulation of Stem Cells in Aging. <i>Current Stem Cell Reports</i> , 2021, 7, 72-84.	0.7	3
1430	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. <i>Biomedicines</i> , 2021, 9, 388.	1.4	6
1431	Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1747-1759.	1.2	111
1432	Assessing the Role of Rare Genetic Variation in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2021, 6, 379.	3.0	37
1433	Liquid Biopsy: From Discovery to Clinical Application. <i>Cancer Discovery</i> , 2021, 11, 858-873.	7.7	407
1434	Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years. <i>Blood Advances</i> , 2021, 5, 2115-2122.	2.5	44
1435	Stem cell concepts in myelodysplastic syndromes: lessons and challenges. <i>Journal of Internal Medicine</i> , 2021, 289, 650-661.	2.7	2
1436	<i>CBL</i> mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. <i>Blood</i> , 2021, 137, 2209-2220.	0.6	18
1437	Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i> , 2021, 23, 1179-1184.	1.1	13
1438	The changing landscape of atherosclerosis. <i>Nature</i> , 2021, 592, 524-533.	13.7	921
1439	Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns. <i>Experimental Hematology and Oncology</i> , 2021, 10, 27.	2.0	10
1441	Importance of clonal hematopoiesis in heart failure. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 198-203.	2.3	7
1442	Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma. <i>Blood Cancer Discovery</i> , 2021, 2, 216-225.	2.6	22
1443	Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy. <i>Cancers</i> , 2021, 13, 1746.	1.7	7
1445	Myeloid somatic mutation panel testing in myeloproliferative neoplasms. <i>Pathology</i> , 2021, 53, 339-348.	0.3	13
1446	Yin and Yang: The dual effects of interferons on hematopoiesis. <i>Experimental Hematology</i> , 2021, 96, 1-12.	0.2	38
1447	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. <i>Clinical Science</i> , 2021, 135, 991-1007.	1.8	18
1448	Induced pluripotent stem cell models of myeloid malignancies and clonal evolution. <i>Stem Cell Research</i> , 2021, 52, 102195.	0.3	4

#	ARTICLE	IF	CITATIONS
1449	Epigenome Chaos: Stochastic and Deterministic DNA Methylation Events Drive Cancer Evolution. <i>Cancers</i> , 2021, 13, 1800.	1.7	13
1450	Clonal haematopoiesis of emerging significance. <i>Pathology</i> , 2021, 53, 300-311.	0.3	9
1451	Genetics of Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 217-236.	0.9	13
1452	Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joining. <i>Nature Communications</i> , 2021, 12, 2455.	5.8	23
1453	MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. <i>Cancer Cell</i> , 2021, 39, 529-547.e7.	7.7	17
1454	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. <i>Blood Advances</i> , 2021, 5, 2294-2304.	2.5	60
1457	Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5042.	1.8	14
1458	Chromosomal Instability in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 2655.	1.7	14
1459	Inflammation-Induced Tumorigenesis and Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5421.	1.8	88
1460	Aged hematopoietic stem cells are refractory to bloodborne systemic rejuvenation interventions. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	48
1461	Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?. <i>Hemato</i> , 2021, 2, 305-328.	0.2	3
1462	FLT3â€”ITD mutations in acute myeloid leukaemia â€” molecular characteristics, distribution and numerical variation. <i>Molecular Oncology</i> , 2021, 15, 2300-2317.	2.1	5
1463	Somatic Mutations in â€œBenignâ€”Disease. <i>New England Journal of Medicine</i> , 2021, 384, 2039-2052.	13.9	111
1464	Genetic and Clinical Studies of Patients With Increased Multinucleated Megakaryocytes in Bone Marrow as an Isolated Finding. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, 1534-1540.	2.1	1
1465	Whole-genome sequencing analysis of semi-supercentenarians. <i>ELife</i> , 2021, 10, .	2.8	37
1466	ENVIRONMENTAL ASPECTS IN MYELODYSPLASTIC SYNDROME. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5202.	1.8	0
1467	Coronary artery disease in patients with cancer: challenges and opportunities for improvement. <i>Current Opinion in Cardiology</i> , 2021, 36, 597-608.	0.8	5
1468	Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy. <i>Cancers</i> , 2021, 13, 2231.	1.7	10



#	ARTICLE	IF	CITATIONS
1469	Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	10
1470	DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	16
1471	Splicing regulation in hematopoiesis. <i>Current Opinion in Hematology</i> , 2021, 28, 277-283.	1.2	2
1472	Germline risk of clonal haematopoiesis. <i>Nature Reviews Genetics</i> , 2021, 22, 603-617.	7.7	48
1473	Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103311.	2.0	24
1474	Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. <i>Nature Cancer</i> , 2021, 2, 527-544.	5.7	37
1475	Loss of a 7q gene, <i>CUX1</i> , disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. <i>Blood</i> , 2021, 138, 790-805.	0.6	13
1476	Liquid biopsy in lymphoma: Is it primed for clinical translation?. <i>EJHaem</i> , 2021, 2, 616-627.	0.4	6
1477	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring <i>SF3B1</i> Mutations. <i>American Journal of Clinical Pathology</i> , 2021, 156, 679-690.	0.4	10
1478	Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. <i>Leukemia</i> , 2021, 35, 3406-3420.	3.3	3
1479	Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2064-2078.	0.6	15
1480	Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2510-2517.	1.3	9
1481	Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	88
1482	Marrow failure and aging: The role of "Inflammaging". <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101283.	0.7	4
1483	Mathematical modelling of the hematopoietic stem cell-niche system: Clonal dominance based on stem cell fitness.. <i>Journal of Theoretical Biology</i> , 2021, 518, 110620.	0.8	10
1484	Clonal hematopoiesis in patients with <i>Covid-19</i> is stable and not linked to an aggravated clinical course. <i>American Journal of Hematology</i> , 2021, 96, E331-E333.	2.0	14
1485	Immature acute leukaemias: lessons from the haematopoietic roadmap. <i>FEBS Journal</i> , 2022, 289, 4355-4370.	2.2	2
1486	Mutations known from B-cell lymphoid malignancies are not found in CD34 <sup>+</sup> stem cells from patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2808-2811.	0.6	1

#	ARTICLE	IF	CITATIONS
1487	Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	113
1488	CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. <i>Blood</i> , 2021, 138, 2499-2513.	0.6	160
1489	Epigenetic deregulation in myeloid malignancies. <i>Blood</i> , 2021, 138, 613-624.	0.6	8
1490	Somatic copy number variants in neuropsychiatric disorders. <i>Current Opinion in Genetics and Development</i> , 2021, 68, 9-17.	1.5	6
1491	Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. <i>PLoS ONE</i> , 2021, 16, e0253386.	1.1	5
1492	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. <i>Leukemia</i> , 2022, 36, 257-262.	3.3	19
1493	A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms. <i>Cancer Discovery</i> , 2021, 11, 3126-3141.	7.7	17
1494	A Case-Based Approach to Understanding Complex Genetic Information in an Evolving Landscape. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e328-e338.	1.8	2
1495	CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. <i>Blood</i> , 2021, 138, 1727-1732.	0.6	58
1496	Cohesin mutations in myeloid malignancies. <i>Blood</i> , 2021, 138, 649-661.	0.6	22
1497	Clinical implementation and current advancement of blood liquid biopsy in cancer. <i>Journal of Human Genetics</i> , 2021, 66, 909-926.	1.1	16
1498	Somatic mosaicism in inherited bone marrow failure syndromes. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101279.	0.7	10
1499	Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. <i>Nature Medicine</i> , 2021, 27, 1012-1024.	15.2	109
1500	Systematic analysis of exonic germline and postzygotic de novo mutations in bipolar disorder. <i>Nature Communications</i> , 2021, 12, 3750.	5.8	15
1501	Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. <i>Blood</i> , 2021, 138, 1249-1257.	0.6	15
1502	Single-cell technologies and analyses in hematopoiesis and hematological malignancies. <i>Experimental Hematology</i> , 2021, 98, 1-13.	0.2	11
1503	HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. <i>Nature Medicine</i> , 2021, 27, 1006-1011.	15.2	62
1504	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. <i>Leukemia</i> , 2022, 36, 126-137.	3.3	10

#	ARTICLE	IF	CITATIONS
1505	Clinical relevance of clonal hematopoiesis in persons aged ≥80 years. <i>Blood</i> , 2021, 138, 2093-2105.	0.6	37
1506	Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. <i>Cancers</i> , 2021, 13, 3296.	1.7	4
1507	Anemia in older adults as a geriatric syndrome: A review. <i>Geriatrics and Gerontology International</i> , 2021, 21, 549-554.	0.7	13
1508	British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. <i>British Journal of Haematology</i> , 2021, 194, 282-293.	1.2	10
1509	Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML. <i>Cancers</i> , 2021, 13, 3190.	1.7	5
1510	Murine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease. <i>Cardiovascular Research</i> , 2022, 118, 1413-1432.	1.8	12
1511	Assessment of the gene mosaicism burden in blood and its implications for immune disorders. <i>Scientific Reports</i> , 2021, 11, 12940.	1.6	5
1512	Splicing factor mutations in hematologic malignancies. <i>Blood</i> , 2021, 138, 599-612.	0.6	40
1513	Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome. <i>Haematologica</i> , 2022, 107, 887-898.	1.7	15
1514	Induced Mitochondrial Alteration and DNA Damage via IFNGR-JAK2-STAT1-PARP1 Pathway Facilitates Viral Hepatitis Associated Hepatocellular Carcinoma Aggressiveness and Stemness. <i>Cancers</i> , 2021, 13, 2755.	1.7	11
1515	Stem Cells in the Myelodysplastic Syndromes. <i>Frontiers in Aging</i> , 2021, 2, .	1.2	4
1516	Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome. <i>Nature Communications</i> , 2021, 12, 4549.	5.8	21
1517	<i>ZBTB33</i> Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing. <i>Blood Cancer Discovery</i> , 2021, 2, 500-517.	2.6	17
1518	Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics. <i>Cancers</i> , 2021, 13, 3528.	1.7	5
1519	The Hematopoietic Bone Marrow Niche Ecosystem. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 705410.	1.8	34
1520	The Genetics of Myelodysplastic Syndromes: Clinical Relevance. <i>Genes</i> , 2021, 12, 1144.	1.0	14
1521	Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 3236-3250.	1.3	4
1522	Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. <i>Nature Medicine</i> , 2021, 27, 1239-1249.	15.2	78

#	ARTICLE	IF	CITATIONS
1523	Clonal Hematopoiesis and Incident Heart Failure Risk. <i>Journal of the American College of Cardiology</i> , 2021, 78, 53-55.	1.2	0
1524	Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021, 2, 241-254.	0.5	6
1525	DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model. <i>Cancers</i> , 2021, 13, 3587.	1.7	7
1526	Immunosenescence in Childhood Cancer Survivors and in Elderly: A Comparison and Implication for Risk Stratification. <i>Frontiers in Aging</i> , 2021, 2, .	1.2	5
1527	TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. <i>JCI Insight</i> , 2021, 6, .	2.3	37
1528	The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1501-1509.	0.7	5
1529	Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology. <i>Seminars in Cancer Biology</i> , 2022, 84, 23-31.	4.3	10
1530	Relationship between clone metrics and clinical outcome in clonal cytopenia. <i>Blood</i> , 2021, 138, 965-976.	0.6	58
1533	Cell competition in hematopoietic cells: Quality control in homeostasis and its role in leukemia. <i>Developmental Biology</i> , 2021, 475, 1-9.	0.9	4
1534	Clonal hematopoiesis and its emerging effects on cellular therapies. <i>Leukemia</i> , 2021, 35, 2752-2758.	3.3	21
1535	Next generation sequencing in therapy-related myeloid neoplasms compared to <i>de novo</i> myeloid neoplasms. <i>Acta Clinica Belgica</i> , 2022, 77, 658-663.	0.5	1
1536	Decoding and rejuvenating human ageing genomes: Lessons from mosaic chromosomal alterations. <i>Ageing Research Reviews</i> , 2021, 68, 101342.	5.0	21
1537	Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. <i>Clinical Chemistry</i> , 2021, 67, 1062-1070.	1.5	0
1538	Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations. <i>American Journal of Transplantation</i> , 2021, 21, 3894-3906.	2.6	11
1539	Is Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?. <i>TH Open</i> , 2021, 05, e338-e342.	0.7	14
1540	Genetics of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 259-265.	1.0	1
1541	Application of Data Science in Circulating Tumor DNA Detection: A Promising Avenue Towards Liquid Biopsy. <i>Frontiers in Oncology</i> , 2021, 11, 692322.	1.3	4
1542	Incidental findings from cancer next generation sequencing panels. <i>Npj Genomic Medicine</i> , 2021, 6, 63.	1.7	11

#	ARTICLE	IF	CITATIONS
1543	Incident disease associations with mosaic chromosomal alterations on autosomes, X and Y chromosomes: insights from a phenome-wide association study in the UK Biobank. <i>Cell and Bioscience</i> , 2021, 11, 143.	2.1	14
1544	Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML. <i>Bone Marrow Transplantation</i> , 2021, 56, 2834-2841.	1.3	12
1545	Cytogenetic and Genetic Advances in Myelodysplasia Syndromes. , 0, , .		0
1546	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 757-766.	1.5	4
1548	Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain. <i>Cancer Discovery</i> , 2022, 12, 172-185.	7.7	19
1549	Hematopoiesis during Ontogenesis, Adult Life, and Aging. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9231.	1.8	15
1550	Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 4116.	1.7	11
1551	Clinical implications of <i>SRSF2</i> mutations in AML patients undergoing allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, 1287-1294.	2.0	10
1553	Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality. <i>Blood Advances</i> , 2021, 5, 3266-3278.	2.5	6
1554	Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. <i>Leukemia</i> , 2022, 36, 507-515.	3.3	49
1555	The use of genetic tests to diagnose and manage patients with myeloproliferative and myelodysplastic neoplasms, and related disorders. <i>British Journal of Haematology</i> , 2021, 195, 338-351.	1.2	8
1556	Clonal Hematopoiesis: From Mechanisms to Clinical Intervention. <i>Cancer Discovery</i> , 2021, 11, 2987-2997.	7.7	30
1557	Somatic Mutations and Autoimmunity. <i>Cells</i> , 2021, 10, 2056.	1.8	7
1558	Interacting evolutionary pressures drive mutation dynamics and health outcomes in aging blood. <i>Nature Communications</i> , 2021, 12, 4921.	5.8	11
1559	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. <i>Blood Advances</i> , 2021, 5, 3066-3075.	2.5	12
1560	Engrafted Donor-Derived Clonal Hematopoiesis after Allogeneic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 662.e1-662.e9.	0.6	14
1561	Systematic Profiling of <i>DNMT3A</i> Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor. <i>Cancer Discovery</i> , 2022, 12, 220-235.	7.7	38
1562	Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 86.	1.3	10

#	ARTICLE	IF	CITATIONS
1563	Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration. <i>Leukemia</i> , 2022, 36, 394-402.	3.3	24
1564	Reprogramming enriches for somatic cell clones with small-scale mutations in cancer-associated genes. <i>Molecular Therapy</i> , 2021, 29, 2535-2553.	3.7	9
1565	Chemical Modulation of Gasdermin-Mediated Pyroptosis and Therapeutic Potential. <i>Journal of Molecular Biology</i> , 2022, 434, 167183.	2.0	22
1566	The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis. <i>Blood Advances</i> , 2021, 5, 3216-3226.	2.5	21
1567	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021, 5, 2982-2986.	2.5	45
1568	Emerging Role of Acquired Mutations and Clonal Hematopoiesis in Atherosclerosis—Beyond Conventional Cardiovascular Risk Factors. <i>Circulation Journal</i> , 2023, 87, 394-400.	0.7	4
1569	Cell competition between wild-type and JAK2V617F mutant cells in a murine model of a myeloproliferative neoplasm. <i>Experimental Hematology</i> , 2021, 100, 52-62.	0.2	4
1570	Clonal hematopoiesis and myeloid malignancies. <i>Current Opinion in Hematology</i> , 2021, Publish Ahead of Print, 347-355.	1.2	4
1573	Clonal Hematopoiesis and Cardiovascular Diseases: The Connection. <i>Current Problems in Cardiology</i> , 2021, , 100962.	1.1	5
1574	Balancing DNA repair to prevent ageing and cancer. <i>Experimental Cell Research</i> , 2021, 405, 112679.	1.2	14
1575	SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 1-16.	0.2	20
1576	Clonal hematopoiesis and associated diseases: A review of recent findings. <i>Cancer Science</i> , 2021, 112, 3962-3971.	1.7	40
1577	Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. <i>HemaSphere</i> , 2021, 5, e632.	1.2	10
1578	Brain Somatic Mutation in Aging and Alzheimer's Disease. <i>Annual Review of Genomics and Human Genetics</i> , 2021, 22, 239-256.	2.5	32
1579	Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN $\gamma$ signaling. <i>Cell Stem Cell</i> , 2021, 28, 1428-1442.e6.	5.2	164
1580	Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9867.	1.8	5
1581	Telomeres and Age-Related Diseases. <i>Biomedicines</i> , 2021, 9, 1335.	1.4	37
1582	The Role of epigenetic modifications of DNA and histones in the treatment of oncohematological diseases. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 263-279.	0.1	0

#	ARTICLE	IF	CITATIONS
1583	Update on Clonal Hematopoiesis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S32-S33.	0.2	1
1584	Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2021, 5, 1540-1553.	1.5	33
1585	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162.	2.8	32
1586	Molecular Pathology of Myeloid Neoplasms. <i>Surgical Pathology Clinics</i> , 2021, 14, 517-528.	0.7	3
1587	High-throughput characterization of mutations in genes that drive clonal evolution using multiplex adaptome capture sequencing. <i>Cell Systems</i> , 2021, 12, 1187-1200.e4.	2.9	5
1588	ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. <i>Blood Cancer Journal</i> , 2021, 11, 157.	2.8	27
1589	Clonal Hematopoiesis of Indeterminate Potential: an Expanding Genetic Cause of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2021, 23, 66.	2.0	7
1590	Increased somatic mutation burdens in normal human cells due to defective DNA polymerases. <i>Nature Genetics</i> , 2021, 53, 1434-1442.	9.4	85
1591	Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. <i>ELife</i> , 2021, 10, .	2.8	19
1592	Duplex-Repair enables highly accurate sequencing, despite DNA damage. <i>Nucleic Acids Research</i> , 2022, 50, e1-e1.	6.5	10
1593	Stress hematopoiesis induces a proliferative advantage in TET2 deficiency. <i>Leukemia</i> , 2022, 36, 809-820.	3.3	3
1594	Developmental and temporal characteristics of clonal sperm mosaicism. <i>Cell</i> , 2021, 184, 4772-4783.e15.	13.5	27
1595	Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. <i>Cancers</i> , 2021, 13, 4803.	1.7	6
1596	Utility of plasma cell-free DNA for &lt;i>de novo&/i> detection and quantification of clonal hematopoiesis. <i>Haematologica</i> , 2022, 107, 1815-1826.	1.7	3
1597	Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 573-579.	0.2	4
1598	Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 4646.	1.7	8
1599	Therapeutic targeting of the inflammasome in myeloid malignancies. <i>Blood Cancer Journal</i> , 2021, 11, 152.	2.8	17
1600	Ageing-elevated inflammation promotes DNMT3A R878H-driven clonal hematopoiesis. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 678-691.	5.7	23

#	ARTICLE	IF	CITATIONS
1602	The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large B-cell lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e03817.	0.2	2
1603	Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 751668.	1.3	2
1604	Clonal hematopoiesis in sickle cell disease. <i>Blood</i> , 2021, 138, 2148-2152.	0.6	29
1605	The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene <i>Ppm1d</i> Promotes Inflammation and Non-Ischemic Heart Failure in Mice. <i>Circulation Research</i> , 2021, 129, 684-698.	2.0	42
1606	Peripheral Blood Cytopenia and Risk of Cardiovascular Disease and Mortality. <i>Journal of the American Heart Association</i> , 2021, 10, e020809.	1.6	3
1607	Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology. <i>Leukemia Research</i> , 2021, 108, 106613.	0.4	0
1608	The Myeloid-Kidney Interface in Health and Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 323-331.	2.2	5
1609	Association of Diet Quality With Prevalence of Clonal Hematopoiesis and Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2021, 6, 1069.	3.0	43
1610	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	0.5	274
1611	Somatic mutations provide important and unique insights into the biology of complex diseases. <i>Trends in Genetics</i> , 2021, 37, 872-881.	2.9	32
1612	Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape. <i>Neoplasia</i> , 2021, 23, 1101-1109.	2.3	6
1613	Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 161, 98-105.	0.9	82
1614	Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. <i>Annals of Hematology</i> , 2021, 100, 1995-2004.	0.8	9
1615	Epidemiology and Etiology of AML. <i>Hematologic Malignancies</i> , 2021, , 1-22.	0.2	3
1616	Genomic Landscape and Clonal Evolution of AML. <i>Hematologic Malignancies</i> , 2021, , 103-118.	0.2	0
1617	Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia. <i>European Journal of Haematology</i> , 2021, 106, 500-507.	1.1	8
1618	A Single-Cell Analysis of DNMT3A-Mediated Clonal Hematopoiesis in Heart Failure. <i>Circulation Research</i> , 2021, 128, 229-231.	2.0	4
1619	TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics. <i>Seminars in Hematology</i> , 2021, 58, 27-34.	1.8	9



#	ARTICLE	IF	CITATIONS
1620	Whole Exome for the Identification of Mutations in CD8+ T-Cells. <i>Methods in Molecular Biology</i> , 2021, 2325, 155-182.	0.4	0
1621	Exploring the biological role of postzygotic and germinal de novo mutations in ASD. <i>Scientific Reports</i> , 2021, 11, 319.	1.6	5
1622	Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 659.	1.8	9
1623	Linking the KIR phenotype with <i>STAT3</i> and <i>TET2</i> mutations to identify chronic lymphoproliferative disorders of NK cells. <i>Blood</i> , 2021, 137, 3237-3250.	0.6	32
1624	A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 123-139.	1.5	155
1625	Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. <i>Recent Results in Cancer Research</i> , 2020, 215, 163-180.	1.8	26
1626	Genomic Instability of iPSCs and Challenges in Their Clinical Applications. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1201, 23-47.	0.8	40
1627	The Impact of Aging on Cancer Progression and Treatment. , 2016, , 53-83.		2
1628	Hematopoietic Stem Cell Aging and Malignant Hemopathies. , 2018, , 1-13.		2
1629	Neoplastische Bildungsstörungen der Hämatopoiese mit erhaltener Ausreifung. , 2019, , 47-87.		2
1630	Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1143, 95-128.	0.8	3
1631	Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy. <i>Current Treatment Options in Oncology</i> , 2020, 21, 8.	1.3	7
1632	Current concepts and future directions for hemato-oncologic diagnostics. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102977.	2.0	14
1633	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102978.	2.0	79
1634	Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2726-2737.	1.2	51
1635	Picking Winners and Losers: Cell Competition in Tissue Development and Homeostasis. <i>Trends in Genetics</i> , 2020, 36, 490-498.	2.9	16
1636	Extracellular serine controls epidermal stem cell fate and tumour initiation. <i>Nature Cell Biology</i> , 2020, 22, 779-790.	4.6	83
1637	The origin of leukemia: Genetic alterations and inflammatory factors in the development of premalignant clonal hematopoiesis. <i>Seminars in Hematology</i> , 2020, 57, 7-12.	1.8	4

#	ARTICLE	IF	CITATIONS
1638	Molecular/Cytogenetic Education for Hematopathology Fellows. American Journal of Clinical Pathology, 2020, 154, 149-177.	0.4	6
1639	A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. HemaSphere, 2020, 4, e502.	1.2	10
1640	Clonal hematopoiesis in hematopoietic stem cell transplantation. Current Opinion in Hematology, 2021, 28, 94-100.	1.2	7
1673	Aberrant X chromosome skewing and acquired clonal hematopoiesis in adult-onset common variable immunodeficiency. JCI Insight, 2019, 4, .	2.3	1
1674	Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction. JCI Insight, 2020, 5, .	2.3	103
1675	Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight, 2017, 2, e89473.	2.3	63
1676	Transcription factor mutations as a cause of familial myeloid neoplasms. Journal of Clinical Investigation, 2019, 129, 476-488.	3.9	47
1677	Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. Journal of Clinical Investigation, 2019, 129, 4316-4331.	3.9	143
1678	Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. Journal of Clinical Investigation, 2015, 125, 4666-4680.	3.9	116
1679	Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. Journal of Clinical Investigation, 2017, 127, 3484-3495.	3.9	41
1680	Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. Journal of Clinical Investigation, 2017, 127, 3657-3674.	3.9	80
1681	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	0.9	34
1682	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood, 2020, 135, 2375-2387.	0.6	24
1683	Mature lymphoid malignancies: origin, stem cells, and chronicity. Blood Advances, 2017, 1, 2444-2455.	2.5	13
1684	Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. Blood Advances, 2020, 4, 2261-2271.	2.5	61
1685	Clonal Hematopoiesis: The Seeds of Leukemia or Innocuous Bystander?. , 2016, 13, .		2
1686	The lethal sex gap: COVID-19. Immunity and Ageing, 2020, 17, 13.	1.8	68
1687	What do we know about the participation of hematopoietic stem cells in hematopoiesis?. F1000Research, 2015, 4, 1177.	0.8	1

#	ARTICLE	IF	CITATIONS
1688	The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals with de novo constitutive DNMT3A variants. Wellcome Open Research, 2018, 3, 46.	0.9	75
1689	Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments. PLoS Computational Biology, 2017, 13, e1005803.	1.5	26
1690	Epigenetic Aging Signatures Are Coherently Modified in Cancer. PLoS Genetics, 2015, 11, e1005334.	1.5	99
1691	The Contribution of Mosaic Variants to Autism Spectrum Disorder. PLoS Genetics, 2016, 12, e1006245.	1.5	105
1692	Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection. PLoS Medicine, 2016, 13, e1002205.	3.9	49
1693	Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study. PLoS Medicine, 2016, 13, e1002206.	3.9	83
1694	Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS ONE, 2018, 13, e0194630.	1.1	117
1695	Role of interleukin 1 in the development of atherosclerosis. Nauchno-Prakticheskaya Revmatologiya, 0, 56, 28-34.	0.2	6
1696	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	1.8	8
1697	Pre-analytical issues in liquid biopsy “where do we stand?”. Journal of Laboratory Medicine, 2020, 44, 117-142.	1.1	17
1698	Constitutional Mosaic Epimutations “a hidden cause of cancer?”. Cell Stress, 2019, 3, 118-135.	1.4	22
1700	Reduced production of laminin by hepatic stellate cells contributes to impairment in oval cell response to liver injury in aged mice. Aging, 2018, 10, 3713-3735.	1.4	3
1701	DNA hydroxymethylation combined with carotid plaques as a novel biomarker for coronary atherosclerosis. Aging, 2019, 11, 3170-3181.	1.4	14
1702	Physical activity, a modulator of aging through effects on telomere biology. Aging, 2020, 12, 13803-13823.	1.4	30
1703	Clonal evolution in therapy-related neoplasms. Oncotarget, 2017, 8, 12031-12040.	0.8	22
1704	Stat5 deficiency decreases transcriptional heterogeneity and supports emergence of hematopoietic sub-populations. Oncotarget, 2017, 8, 22477-22482.	0.8	2
1705	Chipping in on clonal hematopoiesis. Oncotarget, 2017, 8, 84637-84638.	0.8	1
1706	Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in <i>NPM1</i> mutated acute myeloid leukemia. Oncotarget, 2018, 9, 36613-36624.	0.8	26

#	ARTICLE	IF	CITATIONS
1707	<i>IDH1/2</i>but not<i>DNMT3A</i>mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. <i>Oncotarget</i> , 2015, 6, 42345-42353.	0.8	92
1708	Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. <i>Oncotarget</i> , 2016, 7, 30084-30093.	0.8	42
1709	Altered neutrophil immunophenotypes in childhood B-cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 24664-24676.	0.8	8
1710	Prognostic Value of Next-Generation Sequencing Data in Patients with Myelodysplastic Syndrome. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2020, 13, 170-175.	0.1	2
1711	The role of genomics and genetics in pulmonary arterial hypertension. <i>Global Cardiology Science &amp; Practice</i> , 2020, 2020, e202013.	0.3	5
1712	Targeting Immune Signaling Pathways in Clonal Hematopoiesis. <i>Current Medicinal Chemistry</i> , 2019, 26, 5262-5277.	1.2	6
1713	Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia. <i>Current Drug Targets</i> , 2017, 18, 296-303.	1.0	14
1714	Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia. <i>Minerva Medica</i> , 2020, 111, 386-394.	0.3	5
1715	Variants of<i>DNMT3A</i>cause transcript-specific DNA methylation patterns and affect hematopoiesis. <i>Life Science Alliance</i> , 2018, 1, e201800153.	1.3	16
1716	Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. <i>Haematologica</i> , 2021, 106, 701-707.	1.7	10
1717	Myelodysplastic syndromes: moving towards personalized management. <i>Haematologica</i> , 2020, 105, 1765-1779.	1.7	52
1718	Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate. <i>Haematologica</i> , 2021, 106, 14-25.	1.7	16
1719	Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 604391.	1.8	10
1720	The Molecular Pathogenesis of Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 9054.	0.3	9
1721	Aging: A cell source limiting factor in tissue engineering. <i>World Journal of Stem Cells</i> , 2019, 11, 787-802.	1.3	19
1722	Therapy-related myeloid neoplasms - what have we learned so far?. <i>World Journal of Stem Cells</i> , 2016, 8, 231.	1.3	15
1723	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 380-391.	2.3	314
1724	A generalized theory of age-dependent carcinogenesis. <i>ELife</i> , 2019, 8, .	2.8	45

#	ARTICLE	IF	CITATIONS
1725	Molecular testing for acute myeloid leukemia. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	3
1726	Loss Of Tet2 In T Cells Drives Translocated Pathobiont Derived Aryl Hydrocarbon Receptor Agonist-Induced Tc1 Cell Autoimmune Hepatitis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1727	Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. <i>Hematology</i> , 2021, 26, 848-859.	0.7	2
1728	Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?. <i>Seminars in Hematology</i> , 2021, 58, 226-229.	1.8	22
1729	How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101327.	0.7	2
1730	A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. <i>Cancers</i> , 2021, 13, 5128.	1.7	6
1731	Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: A Chinese pan-cancer cohort. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10279-10290.	1.6	4
1732	Inflammatory Modulation of Hematopoiesis: Linking Trained Immunity and Clonal Hematopoiesis with Chronic Disorders. <i>Annual Review of Physiology</i> , 2022, 84, 183-207.	5.6	21
1733	Somatic Mosaicism in Biology and Disease. <i>Annual Review of Physiology</i> , 2022, 84, 113-133.	5.6	5
1734	Oridonin inhibits DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia by inducing apoptosis and necroptosis. <i>Cell Death Discovery</i> , 2021, 7, 297.	2.0	8
1735	Frailty assessment in the care of older people with haematological malignancies. <i>The Lancet Healthy Longevity</i> , 2021, 2, e736-e745.	2.0	23
1736	Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease. <i>Current Opinion in Hematology</i> , 2022, 29, 1-7.	1.2	29
1737	Calibration-free NGS quantitation of mutations below 0.01% VAF. <i>Nature Communications</i> , 2021, 12, 6123.	5.8	13
1738	Tet2 deficiency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model. <i>Cancer Science</i> , 2021, 112, 4931-4943.	1.7	21
1739	Distinction of lymphoid and myeloid clonal hematopoiesis. <i>Nature Medicine</i> , 2021, 27, 1921-1927.	15.2	130
1740	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	3.4	44
1741	Taking the road less traveled – the therapeutic potential of CBP/β-catenin antagonists. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 701-719.	1.5	6
1742	Advances in acute myeloid leukemia. <i>BMJ</i> , The, 2021, 375, n2026.	3.0	177

#	ARTICLE	IF	CITATIONS
1743	The DNMT1-associated lncRNA UCA1 was upregulated in TK6 cells transformed by long-term exposure to hydroquinone and benzene-exposed workers via DNA hypomethylation. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22920.	1.4	3
1744	TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis. <i>Nature Communications</i> , 2021, 12, 6061.	5.8	47
1745	Cells with cancer-associated mutations overtake our tissues as we age. <i>Aging and Cancer</i> , 2021, 2, 82-97.	0.5	15
1746	Clonal hematopoiesis in CIN. <i>Blood</i> , 2021, 138, 1204-1206.	0.6	0
1747	TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10782.	1.8	25
1748	<i>Dnmt3a</i> -mutated clonal hematopoiesis promotes osteoporosis. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	81
1749	Next-Generation Sequencing for Measurable Residual Disease Assessment in Acute Leukemia. <i>Advances in Molecular Pathology</i> , 2021, 4, 49-63.	0.2	2
1750	Therapy-Related AML and MDS: Who Really Has It?. , 2015, 12, .		1
1751	Pre-Leukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. , 2015, 12, .		0
1752	The Origin of Therapy-Related AML Lies Deep Within. , 2015, 12, .		0
1755	Other Mutations and Gene Panel Testing in Myeloid Neoplasms. , 2016, , 3-32-3-33.		0
1756	Overview and Classification of MDS. , 2016, , 5-42-5-45.		0
1757	Genetic Mutations in Acute Myeloid Leukemia. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2016, 9, 245-256.	0.1	1
1758	Acquired Aplastic Anemia: Somatic Mutations and Eltrombopag Take the Spotlight. , 2016, 13, .		0
1761	Vitamin C Treatment Restores TET2 Deficiency and Confers Sensitivity to PARP Inhibition. , 2017, 14, .		0
1762	Existing and Emerging Molecular Technologies in Myeloid Neoplasms. <i>Molecular Pathology Library</i> , 2018, , 369-412.	0.1	0
1763	Myeloid-Derived Suppressor Cells in Aged Humans. , 2018, , 1-12.		1
1767	Inherited Genetic Variants Increase the Likelihood of Developing Clonal Hematopoiesis: Something Akin to Pre-CHIP. , 2018, 15, .		0

#	ARTICLE	IF	CITATIONS
1768	Ultra-Sensitive Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue Over a Century of Human Lifespan. SSRN Electronic Journal, 0, , .	0.4	1
1769	Somatic Mutations in Cancer-Free Individuals: A Liquid Biopsy Connection. Open Access Journal of Oncology and Medicine, 2018, 1, .	0.4	0
1770	Hematopoiesis and Aging. , 2018, , 1-24.		0
1779	PatrÃ³n clÃ³nico y citogenÃ©tico en pacientes con sÃndrome mielodisplÃsico en CÃcuta (Norte de Tj ETQq1 1 0.784314 rgBT /Over	0.0	0
1780	A perspective of novel treatment strategy for myelodysplastic syndrome. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1566-1572.	0.0	0
1782	Clonal Hematopoiesis and Cytopenias in the Elderly. , 2019, , 195-212.		0
1786	Aging and Malignant Hemopathies: A Complex Multistep Process. , 2019, , 2267-2279.		0
1788	Molecular Diagnostics in Cancer: A Fundamental Component of Precision Oncology. , 2019, , 5-31.		0
1789	Myelodysplastic Syndrome. , 2019, , 1-21.		0
1790	Myeloid-Derived Suppressor Cells in Aged Humans. , 2019, , 733-744.		0
1791	Liquid Biopsies and Critical Illness Insurance: Uncomfortable Bedfellows?. Journal of Insurance Medicine (New York, N Y), 2019, 48, 48-51.	0.1	0
1792	Attack of the Clones: CHIP in the Clinic. , 2019, 16, .		0
1793	Myelodysplastic Syndrome: An Overview. , 2019, , 149-161.		0
1794	Lymphohematopoietic Stem Cells and Their Aging. , 2019, , 995-1009.		0
1798	Biopsia lquida: una review. Rivista Italiana Della Medicina Di Laboratorio, 2019, 15, .	0.2	0
1799	The human body is a mosaic of different genomes. Nature, 0, , .	13.7	0
1800	Chronic Myeloid Neoplasms. , 2020, , 235-251.		0
1804	Molecular Mechanistic Approach of Important Antileukemic Compounds Present in Honey. , 2020, , 1-18.		0

#	ARTICLE	IF	CITATIONS
1806	A summary of the molecular testing recommended in acute myeloid leukemia. , 2020, 4, 012-017.		2
1812	Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Nature Communications, 2021, 12, 6177.	5.8	30
1813	Donor derived leukemia in allogeneic transplantation. Leukemia and Lymphoma, 2021, 62, 2823-2830.	0.6	6
1814	From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review. Diagnostics, 2021, 11, 1982.	1.3	6
1815	Enriched clonal hematopoiesis in seniors with dietary vitamin C inadequacy. Clinical Nutrition ESPEN, 2021, 46, 179-184.	0.5	8
1816	Loss of Y and clonal hematopoiesis in blood—two sides of the same coin?. Leukemia, 2022, 36, 889-891.	3.3	21
1817	Myelodysplastic Syndrome. , 2020, , 479-499.		0
1819	Epidemiology, Etiology, and Clinical Presentation of Myelodysplastic Syndromes. , 2020, , 3-17.		2
1820	CLL dedifferentiation to clonally related myeloid cells. Blood Advances, 2020, 4, 6169-6174.	2.5	1
1822	Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells. Current Opinion in Hematology, 2021, 28, 50-56.	1.2	6
1823	Stem Cell Biology in Bone Marrow Transplantation. Organ and Tissue Transplantation, 2021, , 1-14.	0.0	0
1824	Some characteristics of patients with myelodysplastic syndrome. Medical Herald of the South of Russia, 2020, 11, 32-42.	0.2	0
1825	Identification and lineage restriction analyses of preleukemia cells in a sporadic biallelic <i>CEBPA</i> mutated acute myeloid leukemia patient. International Journal of Laboratory Hematology, 2021, 43, e145-e147.	0.7	1
1826	OUP accepted manuscript. Journal of Crohn's and Colitis, 2021, , .	0.6	6
1827	Hematopoietic Stem Cell Aging and Malignant Hemopathies. , 2020, , 169-181.		0
1828	Identification of Malignant Cell Populations Years Before Development of Treatment-related Leukemia in Patients With Myeloma. , 2020, 17, .		0
1829	Molecular Landscape of MDS. , 2020, , 73-90.		0
1830	Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant <i>De Novo</i> Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor. Journal of Hematology (Brossard, Quebec), 2020, 9, 140-146.	0.4	6



#	ARTICLE	IF	CITATIONS
1831	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
1832	Hematopoiesis and Aging. , 2020, , 305-328.		0
1835	The Mutagenic Impact of Environmental Exposures in Human Cells and Cancer: Imprints Through Time. Frontiers in Genetics, 2021, 12, 760039.	1.1	12
1836	Aged healthy mice acquire clonal hematopoiesis mutations. Blood, 2022, 139, 629-634.	0.6	13
1837	Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation. American Journal of Hematology, 2021, , .	2.0	2
1838	EXCELLENT PROGNOSIS OF LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DETECTABLE MYELOID-RELATED MUTATIONS. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	0
1839	Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science, 2021, 374, 768-772.	6.0	93
1840	Synonymous mutations reveal genome-wide levels of positive selection in healthy tissues. Nature Genetics, 2021, 53, 1597-1605.	9.4	33
1841	Evaluation of <i>TP53</i> Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic <i>TP53</i> Variants. JCO Precision Oncology, 2021, 5, 1677-1686.	1.5	7
1842	Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. Stroke, 2022, 53, 788-797.	1.0	88
1843	The Role and Impact of Minimal Residual Disease in NSCLC. Current Oncology Reports, 2021, 23, 136.	1.8	13
1845	Acute Myeloid Leukemia: Epidemiology and Etiology. Hematologic Malignancies, 2021, , 3-9.	0.2	2
1846	Deciphering the role of Wnt signaling in acute myeloid leukemia prognosis: how alterations in DNA methylation come into play in patientsâ€™ prognosis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3097-3109.	1.2	4
1849	No Differences in Outcomes Between JAK2 V617F-Positive Patients with Variant Allele Fraction <math>\leq 2\%</math> Versus 2-10%: A 6-Year Province-wide Retrospective Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e569-e578.	0.2	3
1851	Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. Cancer Biology and Medicine, 2016, 13, 41-54.	1.4	9
1852	THE GORDON WILSON LECTURE EVOLUTION OF CLINICAL CANCER GENETICS. Transactions of the American Clinical and Climatological Association, 2016, 127, 127-139.	0.9	1
1853	Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach. Oncology, 2016, 30, 330, 333.	0.4	0
1854	Mutation detection using plasma circulating tumor DNA (ctDNA) in a cohort of asymptomatic adults at increased risk for cancer. International Journal of Molecular Epidemiology and Genetics, 2018, 9, 1-12.	0.4	10

#	ARTICLE	IF	CITATIONS
1855	Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 56-66.	0.3	10
1856	The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 6462-6474.	0.0	14
1863	Next generation sequencing guided treatment modulation and prognosis in Acute myeloid leukemia: Case vignettes. <i>American Journal of Blood Research</i> , 2020, 10, 134-144.	0.6	0
1864	Aging and leukemic evolution of hematopoietic stem cells under various stress conditions. <i>Inflammation and Regeneration</i> , 2020, 40, 29.	1.5	6
1865	Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	0
1866	Employing the CRISPR-Cas System for Clonal Hematopoiesis Research. <i>International Journal of Physical Medicine &amp; Rehabilitation</i> , 2021, 9, .	0.5	1
1868	Aging, Bone Marrow and Next-Generation Sequencing (NGS): Recent Advances and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12225.	1.8	11
1869	Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9. <i>Leukemia</i> , 2022, 36, 1102-1110.	3.3	14
1871	<i>DNMT3A</i> overgrowth syndrome is associated with the development of hematopoietic malignancies in children and young adults. <i>Blood</i> , 2022, 139, 461-464.	0.6	9
1872	Azacytidine Treatment for VEXAS Syndrome. <i>HemaSphere</i> , 2021, 5, e661.	1.2	45
1873	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. <i>Journal of Clinical Oncology</i> , 2022, 40, 189-201.	0.8	79
1874	Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. <i>Nature Communications</i> , 2021, 12, 6770.	5.8	105
1875	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. <i>Blood Advances</i> , 2022, 6, 2230-2235.	2.5	10
1876	<i>TET2</i> mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. <i>Blood Advances</i> , 2022, 6, 100-107.	2.5	12
1877	Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials. <i>Haematologica</i> , 2022, 107, 2051-2063.	1.7	8
1878	Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. <i>Diagnostics</i> , 2021, 11, 2171.	1.3	26
1879	At the dawn: cell-free DNA fragmentomics and gene regulation. <i>British Journal of Cancer</i> , 2022, 126, 379-390.	2.9	27
1880	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. <i>JCO Precision Oncology</i> , 2021, 5, 1768-1776.	1.5	12

#	ARTICLE	IF	CITATIONS
1881	Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors. <i>Cancer Research</i> , 2022, 82, 199-209.	0.4	11
1882	Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. <i>Cancer Discovery</i> , 2021, 11, 2968-2986.	7.7	116
1884	Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity. <i>Genetics in Medicine</i> , 2022, 24, 673-680.	1.1	4
1885	Why Single-Cell Sequencing Has Promise in MDS. <i>Frontiers in Oncology</i> , 2021, 11, 769753.	1.3	2
1886	Clonal hematopoiesis and its role in the development of hematological diseases. <i>Gematologiya i Transfuziologiya</i> , 2021, 66, 580-592.	0.1	0
1887	Clonal hematopoiesis: Molecular and clinical implications. <i>Leukemia Research</i> , 2022, 113, 106787.	0.4	15
1888	Next-Generation Sequencing Analysis in Posttransplant Relapsed Acute Myeloid Leukemia Reveals Clonal Evolution and Donor-Derived Germline Variant Indicating Bone Marrow Chimerism. <i>AJSP Review and Reports</i> , 2019, 24, 260-262.	0.0	0
1889	Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	4
1891	Molecular Diagnostics in Bone Marrow Haematopathology. , 2020, , 362-417.		0
1893	Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells. <i>Annual Review of Medicine</i> , 2022, 73, 307-320.	5.0	5
1894	Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application. <i>Leukemia and Lymphoma</i> , 2022, 63, 1524-1533.	0.6	0
1896	Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2022, 28, 73-77.	1.0	6
1897	The Mechanism of Stem Cell Aging. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 1281-1293.	1.7	18
1898	Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2022, 97, 411-420.	2.0	11
1899	Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia. <i>Seminars in Hematology</i> , 2022, 59, 47-53.	1.8	3
1901	ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 523.	1.8	18
1904	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. <i>Nature Biomedical Engineering</i> , 2022, 6, 232-245.	11.6	56
1905	Genetic alterations in patients with chronic leucocytosis and persistent thrombocytosis. <i>Journal of Genetics</i> , 2022, 101, 1.	0.4	1

#	ARTICLE	IF	CITATIONS
1906	An update on clinical applications of iPSCs from a genomic point of view. , 2022, , 147-175.		0
1907	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 1614-1627.	3.2	4
1908	The German Uranium Minersâ€™ Biobankâ€”A Biobank for OMICs Radiation Research. <i>Radiation</i> , 2022, 2, 62-77.	0.6	1
1909	Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 1211-1226.	1.7	8
1910	COPD makes CHIP less indeterminate. <i>Blood</i> , 2022, 139, 310-311.	0.6	0
1911	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 19-26.	0.8	5
1912	TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. <i>Cell Stem Cell</i> , 2022, 29, 298-314.e9.	5.2	23
1913	Hypoxia signalling in the regulation of innate immune training. <i>Biochemical Society Transactions</i> , 2022, 50, 413-422.	1.6	1
1914	Somatic Mutations in Cardiovascular Disease. <i>Circulation Research</i> , 2022, 130, 149-161.	2.0	32
1915	The â€œotherâ€™ big complication: how chronic kidney disease impacts on cancer risks and outcomes. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1071-1079.	0.4	16
1917	Patience is a virtue. <i>Blood</i> , 2022, 139, 481-482.	0.6	0
1918	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. <i>Scientific Reports</i> , 2022, 12, 577.	1.6	27
1919	Life histories of myeloproliferative neoplasms inferred from phylogenies. <i>Nature</i> , 2022, 602, 162-168.	13.7	140
1920	Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study. <i>Kidney International Reports</i> , 2022, 7, 876-888.	0.4	13
1921	Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments. <i>Experimental Hematology</i> , 2022, 107, 51-59.	0.2	1
1923	Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood</i> , 2022, 139, 2347-2354.	0.6	131
1924	A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. <i>Lung Cancer</i> , 2022, 165, 34-42.	0.9	20
1925	The roles of sex and genetics in the MPN. <i>International Review of Cell and Molecular Biology</i> , 2022, 366, 1-24.	1.6	3

#	ARTICLE	IF	CITATIONS
1926	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. <i>International Review of Cell and Molecular Biology</i> , 2022, 366, 83-124.	1.6	12
1927	CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression. <i>Cancer Science</i> , 2022, 113, 1182-1194.	1.7	17
1928	Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review. <i>Cells</i> , 2022, 11, 580.	1.8	7
1929	JAK2V617F Mutant Megakaryocytes Contribute to Hematopoietic Aging in a Murine Model of Myeloproliferative Neoplasm. <i>Stem Cells</i> , 2022, 40, 359-370.	1.4	4
1930	Shared genetic and epigenetic changes link aging and cancer. <i>Trends in Cell Biology</i> , 2022, 32, 338-350.	3.6	20
1931	Hematologic malignancies magnify the effect of body mass index on insulin resistance in cancer survivors. <i>Blood Advances</i> , 2022, 6, 1981-1990.	2.5	5
1932	Clonal hematopoiesis and vascular disease. <i>Seminars in Immunopathology</i> , 2022, 44, 303-308.	2.8	6
1933	Genetic and non-genetic mechanisms of inflammation may promote transformation in leukemia. <i>Cell Stem Cell</i> , 2022, 29, 184-186.	5.2	2
1934	SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data. <i>Bioinformatics</i> , 2022, 38, 2088-2095.	1.8	4
1935	Clonal hematopoiesis of indeterminate potential in the companion dog. <i>Leukemia</i> , 2022, 36, 1401-1403.	3.3	2
1936	What Clonal Hematopoiesis Can Teach Us About MDS. <i>Frontiers in Oncology</i> , 2022, 12, 794021.	1.3	1
1937	Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F. <i>Journal of Cardiology</i> , 2023, 81, 3-9.	0.8	7
1938	Aging and Clonal Behavior of Hematopoietic Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1948.	1.8	11
1939	Aging and leukemic evolution of hematopoietic stem cells under various stress conditions. <i>Inflammation and Regeneration</i> , 2020, 40, 29.	1.5	16
1940	Clonal Hematopoiesis and Hematological Disorders. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 301-307.	0.0	0
1941	A Multilevel Approach to the Causes of Genetic Instability in Stem Cells. , 2022, , 1-55.		0
1942	Exploring the Associations Between Clonal Hematopoiesis of Indeterminate Potential, Myeloid Malignancy, and Atherosclerosis. <i>Methods in Molecular Biology</i> , 2022, 2419, 73-88.	0.4	3
1945	Granulomatous Dermatitis Heraldng Myelodysplastic/Myeloproliferative Neoplasms. Neoplastic or Reactive Cells? A Study of 2 Cases. <i>American Journal of Dermatopathology</i> , 2022, Publish Ahead of Print, .	0.3	1

#	ARTICLE	IF	CITATIONS
1946	Clonal hematopoiesis as a pitfall in germline variant interpretation in the context of Mendelian disorders. <i>Human Molecular Genetics</i> , 2022, 31, 2386-2395.	1.4	7
1947	Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 985-995.	3.0	45
1949	DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. <i>Frontiers in Oncology</i> , 2022, 12, 849376.	1.3	9
1950	A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency. <i>Experimental Hematology</i> , 2022, 109, 11-17.	0.2	6
1951	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	1.5	33
1952	Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial. <i>Blood</i> , 2022, 139, 1593-1597.	0.6	21
1953	Peripheral T-Cell Lymphomas of the T Follicular Helper Type: Clinical, Pathological, and Genetic Attributes. <i>Hemato</i> , 2022, 3, 268-286.	0.2	0
1954	Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations. <i>JACC: CardioOncology</i> , 2022, 4, 38-49.	1.7	14
1955	Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective. <i>Leukemia</i> , 2022, 36, 1203-1214.	3.3	8
1957	Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3177.	1.8	5
1958	Cancer progression as a learning process. <i>IScience</i> , 2022, 25, 103924.	1.9	8
1959	The burden of rare protein-truncating genetic variants on human lifespan. <i>Nature Aging</i> , 2022, 2, 289-294.	5.3	6
1960	Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. <i>Genes and Development</i> , 2022, 36, 259-277.	2.7	19
1961	A clinician's handbook for using ctDNA throughout the patient journey. <i>Molecular Cancer</i> , 2022, 21, 81.	7.9	43
1962	Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity. <i>Haematologica</i> , 2022, 107, 1703-1708.	1.7	8
1963	Increasing Complexity of Molecular Landscapes in Human Hematopoietic Stem and Progenitor Cells during Development and Aging. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3675.	1.8	5
1964	A comparative knowledge base development for cancerous cell detection based on deep learning and fuzzy computer vision approach. <i>Multimedia Tools and Applications</i> , 2022, 81, 24799-24814.	2.6	2
1965	Genome-wide association studies identify novel genetic loci for epigenetic age acceleration among survivors of childhood cancer. <i>Genome Medicine</i> , 2022, 14, 32.	3.6	12

#	ARTICLE	IF	CITATIONS
1967	Leukemia and Heart Disease. JACC: CardioOncology, 2022, 4, 50-52.	1.7	0
1968	Postnatal conservation of human blood- and marrow-specific CD34+ hematopoietic phenotypes. Experimental Hematology, 2022, , .	0.2	0
1970	Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents. Cancers, 2022, 14, 1689.	1.7	6
1971	RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations. Cells, 2022, 11, 854.	1.8	3
1972	Liquid Profiling for Cancer Patient Stratification in Precision Medicine—Current Status and Challenges for Successful Implementation in Standard Care. Diagnostics, 2022, 12, 748.	1.3	9
1973	Role of p53 in regulation of hematopoiesis in health and disease. Current Opinion in Hematology, 2022, 29, 194-200.	1.2	3
1974	Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations. Experimental Hematology, 2022, , .	0.2	2
1975	Advances in understanding the molecular basis of clonal hematopoiesis. Trends in Molecular Medicine, 2022, 28, 360-377.	3.5	5
1976	Maladaptive trained immunity and clonal hematopoiesis as potential mechanistic links between periodontitis and inflammatory comorbidities. Periodontology 2000, 2022, 89, 215-230.	6.3	13
1977	Somatic Mutations of Hematopoietic Cells Are an Additional Mechanism of Body Aging, Conducive to Comorbidity and Increasing Chronification of Inflammation. Biomedicines, 2022, 10, 782.	1.4	3
1978	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. British Journal of Haematology, 2022, 198, 103-113.	1.2	7
1979	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nature Medicine, 2022, 28, 468-471.	15.2	19
1980	Longitudinal study of 2 patients with cyclic thrombocytopenia, <i>STAT3</i> and <i>MPL</i> mutations. Blood Advances, 2023, 7, 190-194.	2.5	5
1981	Sulfur Amino Acid Supplementation Abrogates Protective Effects of Caloric Restriction for Enhancing Bone Marrow Regrowth Following Ionizing Radiation. Nutrients, 2022, 14, 1529.	1.7	1
1982	Mantle cell lymphoma and the evidence of an immature lymphoid component. Leukemia Research, 2022, 115, 106824.	0.4	1
1983	Cellular and Molecular Mechanisms Involved in Hematopoietic Stem Cell Aging as a Clinical Prospect. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-13.	1.9	9
1985	Myeloid Toxicity of Radionuclide Cancer Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 164-172.	0.7	2
1986	<i>Txnip</i> Enhances Fitness of <i>Dnmt3a</i> -Mutant Hematopoietic Stem Cells via <i>p21</i> . Blood Cancer Discovery, 2022, 3, 220-239.	2.6	7

#	ARTICLE	IF	CITATIONS
1987	MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. <i>Blood Advances</i> , 2022, 6, 5702-5706.	2.5	3
1988	Somatic Dnmt3a inactivation leads to slow, canonical DNA methylation loss in murine hematopoietic cells. <i>iScience</i> , 2022, 25, 104004.	1.9	2
1989	The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. <i>Annals of Hematology</i> , 2022, 101, 1227-1237.	0.8	5
1990	<i>TET2</i>-Driven Clonal Hematopoiesis and Response to Canakinumab. <i>JAMA Cardiology</i> , 2022, 7, 521.	3.0	125
1991	Cancer: More than a geneticistâ€™s Pandoraâ€™s box. <i>Journal of Biosciences</i> , 2022, 47, .	0.5	2
1992	NPM1 gene mutations can be confidently identified in blood DNA months before de novo AML onset. <i>Blood Advances</i> , 2022, 6, 2409-2413.	2.5	3
1993	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. <i>Science Advances</i> , 2022, 8, eabl6579.	4.7	36
1994	Interleukin-1 (IL-1) and the inflammasome in cancer. <i>Cytokine</i> , 2022, 153, 155850.	1.4	30
1995	Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. <i>Cancer Research</i> , 2022, 82, 749-763.	0.4	20
1996	Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective. <i>Frontiers in Oncology</i> , 2021, 11, 790004.	1.3	11
1997	Have we reached a molecular era in myelodysplastic syndromes?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 418-427.	0.9	23
1998	Driving mosaicism: somatic variants in reference population databases and effect on variant interpretation in rare genetic disease. <i>Human Genomics</i> , 2021, 15, 71.	1.4	5
1999	Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer. <i>ClÃnica E InvestigaciÃ³n En Arteriosclerosis</i> , 2023, 35, 35-41.	0.4	1
2000	Clonal Hematopoiesisâ€™ Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 565-570.	3.0	17
2002	A Vicious Circle of Clonal Haematopoiesis of Indeterminate Potential and Cardiovascular Disease. <i>Hamostaseologie</i> , 2021, 41, 443-446.	0.9	0
2003	CD8+ cell somatic mutations in multiple sclerosis patients and controlsâ€™ Enrichment of mutations in STAT3 and other genes implicated in hematological malignancies. <i>PLoS ONE</i> , 2021, 16, e0261002.	1.1	15
2004	When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 399-404.	0.9	10
2006	Impaired myelopoiesis in congenital neutropenia: insights into clonal and malignant hematopoiesis. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 514-520.	0.9	2



#	ARTICLE	IF	CITATIONS
2009	Topological indices of novel drugs used in blood cancer treatment and its QSPR modeling. <i>AIMS Mathematics</i> , 2022, 7, 11829-11850.	0.7	17
2010	Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma – a critical review and evaluation of the existing evidence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3247-3256.	3.3	11
2011	A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms. <i>Cancer Research Communications</i> , 2022, 2, 258-276.	0.7	0
2012	Clinical application of liquid biopsy in cancer patients. <i>BMC Cancer</i> , 2022, 22, 413.	1.1	3
2013	Cell origin-dependent cooperativity of mutant <i>Dnmt3a</i> and <i>Npm1</i> in clonal hematopoiesis and myeloid malignancy. <i>Blood Advances</i> , 2022, 6, 3666-3677.	2.5	8
2014	A predictive model for bone marrow disease in cytopenia based on noninvasive procedures. <i>Blood Advances</i> , 2022, 6, 3541-3550.	2.5	2
2015	Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1435-1442.	1.8	3
2016	Bone Marrow Niches of Hematopoietic Stem and Progenitor Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4462.	1.8	19
2017	Somatic genomic changes in single Alzheimer's disease neurons. <i>Nature</i> , 2022, 604, 714-722.	13.7	92
2024	Can aggressive cancers be identified by the aggressiveness of their chromatin?. <i>BioEssays</i> , 2022, , 2100212.	1.2	2
2025	Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies. <i>Cancer Letters</i> , 2022, 538, 215691.	3.2	4
2033	Screening of early-staged colorectal neoplasia by clonal hematopoiesis-based liquid biopsy and machine-learning. <i>American Journal of Cancer Research</i> , 2022, 12, 1088-1101.	1.4	0
2036	The History and Future of Basic and Translational Cell-Free DNA Research at a Glance. <i>Diagnostics</i> , 2022, 12, 1192.	1.3	5
2037	Circulating cell-free DNA for cancer early detection. <i>Innovation(China)</i> , 2022, 3, 100259.	5.2	35
2038	Genetics of smoking and risk of clonal hematopoiesis. <i>Scientific Reports</i> , 2022, 12, 7248.	1.6	25
2039	Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3767-3778.	2.5	13
2040	Ageing and cancer: a research gap to fill. <i>Molecular Oncology</i> , 2022, 16, 3220-3237.	2.1	7
2041	Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2022, 12, 1690-1701.	7.7	84

#	ARTICLE	IF	CITATIONS
2042	The Cell Type-Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 346-367.	2.6	16
2043	The Field of Cell Competition Comes of Age: Semantics and Technological Synergy. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	4
2044	Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. <i>Cell Stem Cell</i> , 2022, 29, 760-775.e10.	5.2	29
2045	Quiescence regulation by normal haematopoietic stem cells and leukaemia stem cells. <i>FEBS Journal</i> , 2023, 290, 3708-3722.	2.2	3
2046	Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 61-68.	1.2	14
2047	Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 711-728.	1.8	12
2048	DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022030.	0.5	2
2049	Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals. <i>Blood Advances</i> , 2022, 6, 4174-4184.	2.5	8
2050	Epigenetic traits inscribed in chromatin accessibility in aged hematopoietic stem cells. <i>Nature Communications</i> , 2022, 13, 2691.	5.8	22
2051	Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?. <i>Basic Research in Cardiology</i> , 2022, 117, 28.	2.5	9
2053	The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103725.	2.0	1
2054	Automated next-generation profiling of genomic alterations in human cancers. <i>Nature Communications</i> , 2022, 13, .	5.8	8
2055	Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	20
2057	Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors. <i>Thrombosis Research</i> , 2022, 213, S107-S112.	0.8	4
2059	TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	1
2060	Clinical implications of homologous recombination repair mutations in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	4
2061	Clonal hematopoiesis: Mutation-specific adaptation to environmental change. <i>Cell Stem Cell</i> , 2022, 29, 882-904.	5.2	34
2062	The longitudinal dynamics and natural history of clonal haematopoiesis. <i>Nature</i> , 2022, 606, 335-342.	13.7	136

#	ARTICLE	IF	CITATIONS
2063	Somatic Mutations and Clonal Hematopoiesis as Drivers of Age-Related Cardiovascular Risk. <i>Current Cardiology Reports</i> , 2022, 24, 1049-1058.	1.3	9
2064	Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional <i>TP53</i> Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1621-1629.	1.1	2
2065	Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 3160.	1.0	2
2066	Clonal dynamics of haematopoiesis across the human lifespan. <i>Nature</i> , 2022, 606, 343-350.	13.7	160
2067	Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk. <i>Current Hematologic Malignancy Reports</i> , 0, , .	1.2	0
2068	Specification of hematopoietic stem cells in mammalian embryos: A rare or frequent event?. <i>Blood</i> , 0, , .	0.6	1
2069	PPM1D in Solid and Hematologic Malignancies: Friend and Foe?. <i>Molecular Cancer Research</i> , 2022, 20, 1365-1378.	1.5	6
2070	CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis. <i>Leukemia Research Reports</i> , 2022, 17, 100334.	0.2	1
2071	The rising tide of cell-free DNA profiling: from snapshot to temporal genome analysis. <i>Laboratoriums Medizin</i> , 2022, 46, 207-224.	0.1	7
2072	<i>TET2</i> -mutant clonal hematopoiesis and risk of gout. <i>Blood</i> , 2022, 140, 1094-1103.	0.6	57
2073	Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis. <i>Aids</i> , 2022, 36, 1521-1531.	1.0	10
2074	A macaque clonal hematopoiesis model demonstrates expansion of <i>TET2</i> -disrupted clones and utility for testing interventions. <i>Blood</i> , 2022, 140, 1774-1789.	0.6	13
2075	Mechanisms that regulate the activities of TET proteins. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	27
2076	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	0
2078	Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock. <i>European Journal of Heart Failure</i> , 2022, 24, 1573-1582.	2.9	20
2079	Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma. <i>Blood Reviews</i> , 2022, 56, 100986.	2.8	6
2080	Therapy-Related Clonal Hematopoiesis. <i>Heart Failure Clinics</i> , 2022, 18, 349-359.	1.0	1
2081	Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. <i>European Journal of Cancer</i> , 2022, 171, 44-54.	1.3	14

#	ARTICLE	IF	CITATIONS
2082	The Impact of Clonal Hematopoiesis of Indeterminate Potential on Advanced Heart Failure. , 2022, 2, 218-221.		0
2083	Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer. Haematologica, 2023, 108, 161-170.	1.7	2
2084	Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma. Cancers, 2022, 14, 3222.	1.7	5
2085	Myelodysplastic Syndrome: Diagnosis and Screening. Diagnostics, 2022, 12, 1581.	1.3	4
2087	Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications. Diagnostics, 2022, 12, 1659.	1.3	1
2088	PU.1-Dependent Enhancer Inhibition Separates <i>Tet2</i> -Deficient Hematopoiesis from Malignant Transformation. Blood Cancer Discovery, 2022, 3, 444-467.	2.6	10
2089	Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia. Journal of Internal Medicine, 2022, 292, 262-277.	2.7	7
2090	Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects. Nature Medicine, 2022, 28, 1439-1446.	15.2	36
2092	Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy. EJHaem, 0, , .	0.4	0
2093	Somatic mutations in acquired pure red cell aplasia. Seminars in Hematology, 2022, , .	1.8	4
2094	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2022, 33, 750-768.	0.6	204
2095	Liquid profiling for cancer patient stratification in precision medicine“ current status and challenges for successful implementation in standard care. Laboratoriums Medizin, 2022, 46, 225-236.	0.1	1
2096	Ecoevolutionary biology of pancreatic ductal adenocarcinoma. Pancreatology, 2022, , .	0.5	2
2097	Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease. Diagnostics, 2022, 12, 1613.	1.3	4
2098	Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. Blood, 2022, 140, 1650-1655.	0.6	10
2099	Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nature Genetics, 2022, 54, 1155-1166.	9.4	109
2100	Targeted sequencing of candidate gene regions for myelofibrosis in dogs. Journal of Veterinary Internal Medicine, 0, , .	0.6	2
2101	Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell, 2022, 40, 850-864.e9.	7.7	82

#	ARTICLE	IF	CITATIONS
2102	Ageing and rejuvenation of tissue stem cells and their niches. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 45-62.	16.1	96
2103	Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	27
2104	A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology. <i>Cancers</i> , 2022, 14, 3663.	1.7	3
2105	Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy. , 2022, 1, .		0
2106	ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. <i>Leukemia</i> , 2022, 36, 2242-2249.	3.3	14
2107	Hypertension in Cancer Survivors. <i>Current Hypertension Reports</i> , 0, , .	1.5	0
2108	In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia—A Narrative Review of Current Knowledge. <i>Journal of Clinical Medicine</i> , 2022, 11, 4283.	1.0	0
2109	Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia. <i>Leukemia</i> , 2022, 36, 2328-2337.	3.3	19
2110	PCR-Fluorescence-Activated Cell Sorting (PCR-FACS) : A fast, sensitive and inexpensive complementary method to detect ASXL1 mutations in haematological malignancies. <i>International Journal of Laboratory Hematology</i> , 0, , .	0.7	0
2111	Hematopoyesis Clonal de Potencial Indeterminado (HCPI): mÃ¡s allÃ¡ de un modelo de campo de cancerizaciÃ³n. <i>Revista Colombiana De CancerologÃa</i> , 2021, 25, 210-221.	0.0	0
2112	Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. <i>Leukemia</i> , 2022, 36, 2151-2164.	3.3	24
2114	Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. <i>Cancers</i> , 2022, 14, 3674.	1.7	3
2115	Religious fasting and the vascular health. <i>Indian Heart Journal</i> , 2022, , .	0.2	0
2116	The mythological chimera and new era of relapse prediction post-transplant. <i>Blood Reviews</i> , 2023, 57, 100997.	2.8	3
2117	Discovering the drivers of clonal hematopoiesis. <i>Nature Communications</i> , 2022, 13, .	5.8	33
2119	Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	8
2120	Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm. <i>Life</i> , 2022, 12, 1135.	1.1	6
2121	Effect of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV. <i>Experimental Hematology</i> , 2022, 114, 18-21.	0.2	7

#	ARTICLE	IF	CITATIONS
2122	Clonal hematopoiesis of indeterminate potential: clinical relevance of an incidental finding in liquid profiling. <i>Laboratoriums Medizin</i> , 2022, 46, 301-310.	0.1	3
2123	Pathological and Molecular Features of Nodal Peripheral T-Cell Lymphomas. <i>Diagnostics</i> , 2022, 12, 2001.	1.3	5
2124	CHIPing away the progression potential of CHIP: A new reality in the making. <i>Blood Reviews</i> , 2023, 58, 101001.	2.8	6
2126	Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?. <i>Seminars in Hematology</i> , 2022, 59, 150-155.	1.8	3
2127	DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages. <i>Immunity</i> , 2022, 55, 1386-1401.e10.	6.6	27
2128	Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq). <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	1
2129	Somatic mutations in VEXAS Syndrome and Erdheim-Chester disease: Inflammatory myeloid diseases. <i>Seminars in Hematology</i> , 2022, 59, 156-166.	1.8	4
2130	Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men. <i>Human Molecular Genetics</i> , 2023, 32, 489-495.	1.4	1
2131	Novel modes of MPL activation in triple-negative myeloproliferative neoplasms. <i>Pathology</i> , 2022, , .	0.3	0
2133	Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells. <i>Nature Genetics</i> , 2022, 54, 1406-1416.	9.4	31
2134	Bioplatfroms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. <i>Biotechnology and Genetic Engineering Reviews</i> , 2022, 38, 339-383.	2.4	8
2135	Genomic profiling for clinical decision making in lymphoid neoplasms. <i>Blood</i> , 2022, 140, 2193-2227.	0.6	63
2136	The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome. <i>Seminars in Hematology</i> , 2022, 59, 123-130.	1.8	7
2137	Donor-derived Acute Myeloid Leukemia in solid organ transplantation. <i>American Journal of Transplantation</i> , 0, , .	2.6	1
2138	Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia. <i>Haematologica</i> , 0, , .	1.7	1
2139	Mechanisms involved in hematopoietic stem cell aging. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	6
2141	Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 3078-3086.	2.6	7
2142	Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	8

#	ARTICLE	IF	CITATIONS
2143	Fibroblast testing can inform medical management in individuals with mosaic variants detected on hereditary cancer panels. <i>Cancer Genetics</i> , 2022, 266-267, 86-89.	0.2	0
2144	HIV accelerates clonal hematopoiesis and cardiovascular aging. <i>Aids</i> , 2022, 36, 1599-1601.	1.0	0
2145	Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection. <i>Trends in Immunology</i> , 2022, 43, 693-695.	2.9	1
2146	Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis.. <i>Cancer Epidemiology</i> , 2022, 80, 102238.	0.8	1
2148	Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Journal of Clinical Oncology</i> , 2023, 41, 132-142.	0.8	27
2149	Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma. <i>American Journal of Hematology</i> , 2022, 97, 1538-1547.	2.0	3
2150	Role of DNA Damage, Somatic Mutations, Telomere Shortening, and Epigenetic Alterations in Aging and Age-Related Disease. , 2022, , .		0
2151	Myeloproliferative Neoplasms. , 2022, , .		0
2152	Somatic mutations in "benign" blood diseases. <i>Seminars in Hematology</i> , 2022, 59, 121-122.	1.8	0
2153	New progress in diagnosis and treatment of pulmonary arterial hypertension. <i>Journal of Cardiothoracic Surgery</i> , 2022, 17, .	0.4	6
2154	Detection of <i>BRCA1</i> , <i>BRCA2</i> , and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. <i>Clinical Cancer Research</i> , 2023, 29, 81-91.	3.2	19
2155	Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor Malignancies. <i>Cancer Research</i> , 2022, 82, 4107-4113.	0.4	8
2156	CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022069.	0.5	1
2159	Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19. <i>Blood</i> , 2022, 140, 1993-1997.	0.6	8
2160	Tet2 helps blood cells balance in air. <i>Blood</i> , 2022, 140, 1186-1187.	0.6	0
2161	Clonal hematopoiesis and differential outcomes after immune checkpoint blockade. <i>Cancer Cell</i> , 2022, 40, 1071-1072.	7.7	4
2162	Clinical implementation of genetic testing in adults for hereditary hematologic malignancy syndromes. <i>Genetics in Medicine</i> , 2022, 24, 2367-2379.	1.1	3
2163	The research progress of targeted therapy in acute myeloid leukemia based on bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
2164	New Perspectives on the Importance of Cell-Free DNA Biology. <i>Diagnostics</i> , 2022, 12, 2147.	1.3	24
2165	Patient perspectives on testing for clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2022, 6, 6151-6161.	2.5	3
2166	Genomic profiling for clinical decision making in amyloid neoplasms and acute leukemia. <i>Blood</i> , 2022, 140, 2228-2247.	0.6	72
2167	Sleep exerts lasting effects on hematopoietic stem cell function and diversity. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	26
2169	Inferring the initiation and development of myeloproliferative neoplasms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	12
2170	Whole-exome sequencing in 415,422 individuals identifies rare variants associated with mitochondrial DNA copy number. <i>Human Genetics and Genomics Advances</i> , 2023, 4, 100147.	1.0	2
2171	Molecular Diagnostic Testing for Hematopoietic Neoplasms. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 325-347.	0.7	5
2172	Individual Genetic Heterogeneity. <i>Genes</i> , 2022, 13, 1626.	1.0	3
2174	Diagnosis and Treatment of Myelodysplastic Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 872.	3.8	44
2175	Somatic variation in normal tissues: friend or foe of cancer early detection?. <i>Annals of Oncology</i> , 2022, 33, 1239-1249.	0.6	12
2176	International expert group collaboration for developing an adverse outcome pathway for radiation induced leukemia. <i>International Journal of Radiation Biology</i> , 0, , 1-14.	1.0	2
2177	Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation. <i>Nature Genetics</i> , 2022, 54, 1514-1526.	9.4	50
2178	Clonal hematopoiesis of indeterminate potential and cardiovascular disease. <i>Translational Research</i> , 2023, 255, 152-158.	2.2	3
2179	Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease. <i>Nature Communications</i> , 2022, 13, .	5.8	25
2180	The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. <i>Molecular Cancer</i> , 2022, 21, .	7.9	4
2181	Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells. <i>Nature Communications</i> , 2022, 13, .	5.8	20
2182	Distinct Tumor Necrosis Factor Alpha Receptors Dictate Stem Cell Fitness versus Lineage Output in DNMT3A-Mutant Clonal Hematopoiesis. <i>Cancer Discovery</i> , 2022, 12, 2763-2773.	7.7	23
2183	Cell competition in development, homeostasis and cancer. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 221-236.	16.1	33



#	ARTICLE	IF	CITATIONS
2184	Role of ASXL1 in Hematopoiesis and Myeloid Diseases. <i>Experimental Hematology</i> , 2022, , .	0.2	4
2185	Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 762-778.	4.1	51
2187	Hypothesis: can transfer of primary neoplasm-derived extracellular vesicles and mitochondria contribute to the development of donor cellâ€derived hematologic neoplasms after allogeneic hematopoietic cell transplantation?. <i>Cytotherapy</i> , 2022, 24, 1169-1180.	0.3	1
2188	Compartment-specific mutational landscape of clonal hematopoiesis. <i>Leukemia</i> , 2022, 36, 2647-2655.	3.3	6
2189	The role of aging in cancer. <i>Molecular Oncology</i> , 2022, 16, 3213-3219.	2.1	7
2190	Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	4
2191	Clonal hematopoiesis, somatic mosaicism, and age-associated disease. <i>Physiological Reviews</i> , 2023, 103, 649-716.	13.1	21
2192	All that glitters is not LGL Leukemia. <i>Leukemia</i> , 2022, 36, 2551-2557.	3.3	8
2193	Lysosomes and Their Role in Regulating the Metabolism of Hematopoietic Stem Cells. <i>Biology</i> , 2022, 11, 1410.	1.3	3
2195	Nuclear-embedded mitochondrial DNA sequences in 66,083 human genomes. <i>Nature</i> , 2022, 611, 105-114.	13.7	69
2196	Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60Âyears. <i>GeroScience</i> , 2023, 45, 543-553.	2.1	5
2197	Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	6
2198	The role of epigenetics in T-cell lymphoma. <i>International Journal of Hematology</i> , 2022, 116, 828-836.	0.7	6
2199	Increased prevalence of clonal hematopoiesis of indeterminate potential in hospitalized patients with COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2200	Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis. <i>PLoS ONE</i> , 2022, 17, e0275399.	1.1	1
2201	IPSS-M has greater survival predictive accuracy compared with IPSS-R in personsâ60Âyears with myelodysplastic syndromes. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	17
2202	Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 181-197.	1.2	2
2203	SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis. <i>Leukemia</i> , 2022, 36, 2894-2902.	3.3	12

#	ARTICLE	IF	CITATIONS
2204	Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities. JCI Insight, 2022, 7, .	2.3	5
2205	The International Consensus Classification of myelodysplastic syndromes and related entities. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2023, 482, 39-51.	1.4	6
2206	Clonal Hematopoiesis of Indeterminate Potential and Kidney Function Decline in the General Population. American Journal of Kidney Diseases, 2023, 81, 329-335.	2.1	13
2207	The Role of ctDNA in Gastric Cancer. Cancers, 2022, 14, 5105.	1.7	11
2209	Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study. Blood Advances, 0, , .	2.5	0
2211	Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia. Frontiers in Oncology, 0, 12, .	1.3	5
2214	Neutrophils in aging and aging-related pathologies. Immunological Reviews, 2023, 314, 357-375.	2.8	17
2215	The genetics of myelodysplastic syndromes and the opportunities for tailored treatments. Frontiers in Oncology, 0, 12, .	1.3	4
2216	Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer. JAMA Oncology, 2022, 8, 1830.	3.4	39
2217	Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia, 2022, 36, 2939-2946.	3.3	14
2218	Acute deletion of TET enzymes results in aneuploidy in mouse embryonic stem cells through decreased expression of Khdc3. Nature Communications, 2022, 13, .	5.8	3
2219	Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood, 2023, 141, 380-390.	0.6	4
2220	A Multilevel Approach to the Causes of Genetic Instability in Stem Cells. , 2022, , 1445-1498.		0
2221	Cellular heterogeneity and clonal hematopoiesis of immune system cells in atherosclerosis. Russian Journal of Cardiology, 2022, 27, 5228.	0.4	0
2222	Aging drives Tet2 clonal hematopoiesis via IL-1 signaling. Blood, 2023, 141, 886-903.	0.6	29
2223	Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood, 2023, 141, 1909-1921.	0.6	31
2224	Clonal hematopoiesis and bone marrow inflammation. Translational Research, 2023, 255, 159-170.	2.2	3
2225	Factors associated with clonal hematopoiesis and interaction with marrow environment. Journal of Bone and Mineral Metabolism, 0, , .	1.3	0

#	ARTICLE	IF	CITATIONS
2226	Molecular Pathogenesis of Myeloproliferative Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 319-329.	1.2	11
2227	Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2023, 43, 3-14.	1.1	10
2229	Clonal hematopoiesis and cardiovascular disease: deciphering interconnections. <i>Basic Research in Cardiology</i> , 2022, 117, .	2.5	11
2230	Recurrent missense variants in clonal hematopoiesis-related genes present in the general population. <i>Clinical Genetics</i> , 2023, 103, 247-251.	1.0	2
2231	Genetic Modifiers of Sickle Cell Disease. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 1097-1124.	0.9	4
2232	Topological Indices and QSPR Modeling of New Antiviral Drugs for Cancer Treatment. <i>Polycyclic Aromatic Compounds</i> , 2023, 43, 8147-8170.	1.4	9
2233	EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2023, 7, 1308-1311.	2.5	3
2234	Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes. <i>Cancers</i> , 2022, 14, 5656.	1.7	9
2235	Risk factors for clonal hematopoiesis of indeterminate potential and mosaic chromosomal alterations. <i>Translational Research</i> , 2023, 255, 171-180.	2.2	5
2236	Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211439.	1.4	3
2237	Management of Adult Patients with Myelodysplastic Syndromes. <i>European Medical Journal Hematology</i> , 0, , 104-112.	0.0	0
2238	Somatic Mutations in Myelodysplastic Syndrome Patients in the Context of Allogeneic Stem Cell Transplantation. <i>European Medical Journal Oncology</i> , 0, , 122-129.	0.0	0
2239	The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms. <i>Cancers</i> , 2022, 14, 5690.	1.7	3
2240	A Case Report of <i>HER2</i> -Amplification in the Breast Without Histological Abnormality. <i>International Journal of Surgical Pathology</i> , 2023, 31, 801-804.	0.4	0
2241	Clonal Hematopoiesis and Its Impact on Human Health. <i>Annual Review of Medicine</i> , 2023, 74, 249-260.	5.0	18
2242	Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
2243	Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke. <i>Blood</i> , 2023, 141, 787-799.	0.6	21
2244	Age acquired skewed X chromosome inactivation is associated with adverse health outcomes in humans. <i>ELife</i> , 0, 11, .	2.8	9

#	ARTICLE	IF	CITATIONS
2245	Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	16
2246	Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes. <i>Hematological Oncology</i> , 2023, 41, 463-473.	0.8	0
2247	Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. <i>Biomedicines</i> , 2022, 10, 3008.	1.4	0
2248	The Role of Cell-Free DNA in Cancer Treatment Decision Making. <i>Cancers</i> , 2022, 14, 6115.	1.7	10
2249	Prognostic value of <i>ASXL1</i> mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, .	0.7	3
2250	Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms. <i>Leukemia</i> , 0, , .	3.3	0
2252	Frequent somatic mosaicism in T lymphocyte subsets in individuals with and without multiple sclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2253	Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias. <i>Seminars in Oncology</i> , 2022, 49, 465-475.	0.8	5
2254	Spatial biology of cancer evolution. <i>Nature Reviews Genetics</i> , 2023, 24, 295-313.	7.7	42
2255	<i>Asxl1</i> deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors. <i>Leukemia</i> , 0, , .	3.3	1
2256	The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 0, , .	1.2	0
2257	Clonal Hematopoiesis and Risk of Incident Lung Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 1423-1433.	0.8	10
2258	CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors. <i>Clinical Cancer Research</i> , 2023, 29, 1403-1411.	3.2	9
2259	Genetic causes and cardiovascular consequences of clonal hematopoiesis in the UK Biobank. , 2023, 2, 13-15.		2
2260	Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 266-271.	0.9	5
2261	Cancer Genomics. <i>Archives of Medical Research</i> , 2022, 53, 723-731.	1.5	5
2263	The attack of the clones to the cardiovascular system. <i>European Journal of Heart Failure</i> , 2023, 25, 14-16.	2.9	0
2265	Genetic landscape of chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2023, 117, 30-36.	0.7	12

#	ARTICLE	IF	CITATIONS
2266	Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. <i>Blood Advances</i> , 0, , .	2.5	2
2267	Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry. <i>Prostate</i> , 2023, 83, 454-461.	1.2	1
2270	Tumor fractions deciphered from circulating cell-free DNA methylation for cancer early diagnosis. <i>Nature Communications</i> , 2022, 13, .	5.8	13
2271	Is it the time to integrate novel sequencing technologies into clinical practice?. <i>Current Opinion in Hematology</i> , 0, Publish Ahead of Print, .	1.2	0
2272	A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential. <i>Molecular Biology Reports</i> , 0, , .	1.0	0
2273	Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors. <i>Annals of Hematology</i> , 0, , .	0.8	2
2274	TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. , 2023, 2, 144-158.		25
2275	Clonal hematopoiesis and associated cardiovascular diseases. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
2276	Clonal Hematopoiesis in Nonhuman Primates: Harnessing Shared Evolution to Model Clonal Selection in Human Disease. , 2023, 20, .		0
2278	Myocardial infarction in women under 50: Possible implication of clonal haematopoiesis of indetermined potential. <i>Archives of Cardiovascular Diseases</i> , 2023, 116, 106-108.	0.7	0
2279	Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic <i>TP53</i> -Mutant Clonal Hematopoiesis. <i>Blood Cancer Discovery</i> , 2023, 4, 134-149.	2.6	4
2281	Meta-hallmarks of aging and cancer. <i>Cell Metabolism</i> , 2023, 35, 12-35.	7.2	80
2282	State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, , .	0.2	1
2283	Mesenchymal stromal cell senescence in haematological malignancies. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 277-296.	2.7	11
2284	Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution. <i>ELife</i> , 0, 12, .	2.8	9
2285	Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy. <i>Current Oncology</i> , 2023, 30, 1146-1150.	0.9	2
2286	Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome. <i>International Journal of Hematology</i> , 2023, 117, 919-924.	0.7	4
2288	Diagnostic accuracy of circulating-free DNA for the determination of hepatocellular carcinoma: a systematic review and meta-analysis. <i>Expert Review of Molecular Diagnostics</i> , 2023, 23, 63-69.	1.5	1

#	ARTICLE	IF	CITATIONS
2291	Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study. <i>Leukemia Research</i> , 2023, 125, 107007.	0.4	6
2292	Clonal hematopoiesis and inflammation â€” the perpetual cycle. <i>Trends in Cell Biology</i> , 2023, 33, 695-707.	3.6	5
2294	Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease. <i>Translational Research</i> , 2023, 256, 87-94.	2.2	3
2295	Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2023, 30, 38-44.	1.2	3
2296	Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	8
2297	Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR. <i>Clinical Research in Cardiology</i> , 2023, 112, 585-593.	1.5	3
2299	Causes of Clonal Hematopoiesis: a Review. <i>Current Oncology Reports</i> , 2023, 25, 211-220.	1.8	1
2300	Distinct and opposite effects of leukemogenic <i>Idh</i> and <i>Tet2</i> mutations in hematopoietic stem and progenitor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	7
2301	The NOTCH-RIPK4-IRF6-ELOVL4 Axis Suppresses Squamous Cell Carcinoma. <i>Cancers</i> , 2023, 15, 737.	1.7	3
2302	Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population. <i>HemaSphere</i> , 2023, 7, e821.	1.2	3
2303	Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-transplant Follow-Up: The Role of Next-Generation Sequencing. <i>Biomedicines</i> , 2023, 11, 359.	1.4	0
2304	Increased Inflammasome Activation Is Associated with Aging and Chronic Myelomonocytic Leukemia Disease Severity. <i>Journal of Immunology</i> , 2023, 210, 580-589.	0.4	8
2306	Liquid biopsy: a right tool in a right context?. , 2023, , 31-45.		0
2308	NPM 1 Mutations in AMLâ€”The Landscape in 2023. <i>Cancers</i> , 2023, 15, 1177.	1.7	5
2309	Increased clonal hematopoiesis involving DNA damage response genes in patients undergoing lung transplantation. <i>JCI Insight</i> , 2023, 8, .	2.3	2
2310	Intestinal Microbes and Hematological Malignancies. <i>Cancers</i> , 2023, 15, 2284.	1.7	1
2311	Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. <i>Nature</i> , 2023, 616, 755-763.	13.7	19
2312	Multiomics of Bohring-Opitz syndrome truncating ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation. <i>JCI Insight</i> , 2023, 8, .	2.3	6

#	ARTICLE	IF	CITATIONS
2313	Clonal haematopoiesis and risk of chronic liver disease. <i>Nature</i> , 2023, 616, 747-754.	13.7	40
2314	Clonal Hematopoiesis: Origins and determinants of evolution. <i>Leukemia Research</i> , 2023, 129, 107076.	0.4	2
2315	Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms. <i>Leukemia Research</i> , 2023, 126, 107020.	0.4	0
2317	Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes – A potential prognostic marker?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2318	Germline TP53 pathogenic variants and breast cancer: A narrative review. <i>Cancer Treatment Reviews</i> , 2023, 114, 102522.	3.4	5
2319	Leukemic stem cells and therapy resistance in acute myeloid leukemia. <i>Haematologica</i> , 2023, 108, 353-366.	1.7	26
2320	Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers. <i>JAMA Network Open</i> , 2023, 6, e2254221.	2.8	1
2321	Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up. <i>Haematologica</i> , 2023, 108, 1817-1826.	1.7	4
2322	Synthetic lethal targeting of <i>TET2</i> mutant haematopoietic stem and progenitor cells by <i>XPO1</i> inhibitors. <i>British Journal of Haematology</i> , 2023, 201, 489-501.	1.2	0
2323	Dynamics of Age- versus Therapy-Related Clonal Hematopoiesis in Long-term Survivors of Pediatric Cancer. <i>Cancer Discovery</i> , 2023, 13, 844-857.	7.7	12
2324	From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers. <i>Leukemia Research</i> , 2023, 127, 107038.	0.4	5
2325	Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. <i>Blood Reviews</i> , 2023, 60, 101056.	2.8	2
2326	Clonal Hematopoiesis Mutations Are Present in Atherosclerotic Lesions in Peripheral Artery Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3962.	1.8	2
2327	The etiology of clonal mosaicism in human aging and disease. <i>Aging and Cancer</i> , 2023, 4, 3-20.	0.5	2
2328	Clonal Hematopoiesis: Connecting Aging and Inflammation in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2023, 25, 105-111.	2.0	1
2329	Clonal hematopoiesis: the nonhereditary genetics of age-associated cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2023, 38, 201-206.	0.8	0
2330	Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer. <i>Clínica e Investigaci3n En Arteriosclerosis (English Edition)</i> , 2023, 35, 35-41.	0.1	0
2331	Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors. <i>JCO Precision Oncology</i> , 2023, , .	1.5	4

#	ARTICLE	IF	CITATIONS
2332	Interplay between chronic inflammation and clonal haematopoiesis of indeterminate potential in Behçet's disease. <i>Arthritis Research and Therapy</i> , 2023, 25, .	1.6	2
2333	Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4790.	1.8	5
2334	Malignancy and viral infections in Sub-Saharan Africa: A review. <i>Frontiers in Virology</i> , 0, 3, .	0.7	1
2335	Emerging Therapies in CLL in the Era of Precision Medicine. <i>Cancers</i> , 2023, 15, 1583.	1.7	4
2336	Defining clonal hematopoiesis of indeterminate potential: evolutionary dynamics and detection under aging and inflammation. <i>Journal of Physical Education and Sports Management</i> , 2023, 9, a006251.	0.5	2
2337	Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes. <i>Blood Advances</i> , 0, , .	2.5	0
2338	Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). <i>Blood Reviews</i> , 2023, 60, 101072.	2.8	7
2339	Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	11
2340	Clinical Circulating Tumor DNA Testing for Precision Oncology. <i>Cancer Research and Treatment</i> , 2023, 55, 351-366.	1.3	6
2341	Mosaic chromosomal alterations detected in men living with HIV and the relationship to non-Hodgkin lymphoma. <i>Aids</i> , 0, Publish Ahead of Print, .	1.0	0
2342	Patterns of mosaicism for sequence and copy-number variants discovered through clinical deep sequencing of disease-related genes in one million individuals. <i>American Journal of Human Genetics</i> , 2023, 110, 551-564.	2.6	3
2343	Interplay between hereditary and acquired factors determines the neutrophil counts in older individuals. <i>Blood Advances</i> , 2023, 7, 3232-3243.	2.5	1
2344	Clonal Evolution in Healthy and Premalignant Tissues: Implications for Early Cancer Interception Strategies. <i>Cancer Prevention Research</i> , 2023, 16, 369-378.	0.7	3
2345	Acquired crizotinib-resistant pulmonary adenocarcinoma and subsequent primary gallbladder cancer: A case report. <i>Medicine (United States)</i> , 2023, 102, e33162.	0.4	1
2346	Hematopoietic Stem Cells and the Immune System in Development and Aging. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5862.	1.8	7
2347	COVID-19 and the Genetics of Inflammation. <i>Critical Care Medicine</i> , 2023, 51, 817-825.	0.4	3
2348	Topological Descriptors and QSPR Models of Drugs used in Blood Cancer. <i>The Punjab University Journal of Mathematics</i> , 2023, , 27-43.	0.8	1
2349	An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6031.	1.8	1



#	ARTICLE	IF	CITATIONS
2350	Recent advances in targeted therapies in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	23
2351	RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2023, 64, 951-961.	0.6	1
2352	Clonal haematopoiesis and dysregulation of the immune system. <i>Nature Reviews Immunology</i> , 2023, 23, 595-610.	10.6	18
2354	Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 776-783.	1.1	1
2355	Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway. <i>JCI Insight</i> , 0, , .	2.3	1
2356	Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. <i>Blood Advances</i> , 2023, 7, 3624-3636.	2.5	9
2358	The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action. <i>HemaSphere</i> , 2023, 7, e872.	1.2	6
2359	Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	11
2360	Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer. <i>Biomedicines</i> , 2023, 11, 1069.	1.4	1
2361	Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. <i>Leukemia</i> , 2023, 37, 957-963.	3.3	2
2362	Toward a systems-level probing of tumor clonality. <i>IScience</i> , 2023, 26, 106574.	1.9	1
2363	Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia. <i>Seminars in Hematology</i> , 2023, 60, 90-96.	1.8	3
2364	DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells. <i>Nature Cell Biology</i> , 2023, 25, 528-539.	4.6	9
2365	Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
2366	Microbiota influences on hematopoiesis and blood cancers: New Horizons?. <i>Blood Cancer Discovery</i> , 0, , .	2.6	0
2367	Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy. <i>Journal of the National Cancer Institute</i> , 2023, 115, 981-988.	3.0	3
2368	TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Biomedicines</i> , 2023, 11, 1152.	1.4	2
2369	The origins and functional effects of postzygotic mutations throughout the human life span. <i>Science</i> , 2023, 380, .	6.0	6

#	ARTICLE	IF	CITATIONS
2370	Epigenetic regulation by ASXL1 in myeloid malignancies. <i>International Journal of Hematology</i> , 2023, 117, 791-806.	0.7	4
2371	DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age. <i>Nature Communications</i> , 2023, 14, .	5.8	2
2372	Administration of glucocorticoids prior to liquid biopsy dramatically reduces the detection rate of MYD88 L265P mutation in cerebrospinal fluid of primary CNS lymphoma patients. <i>Leukemia and Lymphoma</i> , 2023, 64, 1219-1222.	0.6	0
2373	Exposure to microbial products followed by loss of Tet2 promotes myelodysplastic syndrome via remodeling HSCs. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	1
2374	Obesity-induced inflammation exacerbates clonal hematopoiesis. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	16
2375	Biomarkers of aging. <i>Science China Life Sciences</i> , 2023, 66, 893-1066.	2.3	60
2376	Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing. <i>JCO Precision Oncology</i> , 2023, , .	1.5	2
2377	Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies. <i>Experimental Hematology</i> , 2023, 122, 10-18.	0.2	1
2378	Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort. <i>Annals of Hematology</i> , 2023, 102, 1409-1420.	0.8	7
2379	Clinical implications of myeloid malignancy-related somatic mutations in aplastic anemia. <i>Clinical and Experimental Medicine</i> , 2023, 23, 4473-4482.	1.9	1
2380	Potential utility of risk stratification for multicancer screening with liquid biopsy tests. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	1
2384	Hallmarks of cardiovascular ageing. <i>Nature Reviews Cardiology</i> , 2023, 20, 754-777.	6.1	28
2453	Cancers make their own luck: theories of cancer origins. <i>Nature Reviews Cancer</i> , 2023, 23, 710-724.	12.8	14
2482	Clonal haematopoiesis - a novel entity that modifies pathological processes in elderly. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	0
2484	Liquid biopsy: creating opportunities in brain space. <i>British Journal of Cancer</i> , 2023, 129, 1727-1746.	2.9	1
2486	Diagnostic and prognostic molecular pathology of lymphoid malignancies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 0, , .	1.4	1
2487	Clonal evolution in leukemia: preleukemia, evolutionary models, and clinical implications. <i>Genome Instability &amp; Disease</i> , 2023, 4, 227-238.	0.5	0
2493	Molecular tumour boards – current and future considerations for precision oncology. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 843-863.	12.5	6

#	ARTICLE	IF	CITATIONS
2515	Bone Marrowâ€œResident Stem Cells. , 2024, , 357-379.		0
2518	Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention. <i>International Review of Neurobiology</i> , 2023, , 237-284.	0.9	0
2519	Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia. , 2023, , 119-128.		0
2520	Molecular Techniques in the Diagnosis and Monitoring of Acute and Chronic Leukaemias. , 2023, , 23-45.		0
2521	Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia. , 2023, , 61-89.		0
2522	Therapy-Related MDS/AML and the Role of Environmental Factors. , 2023, , 409-420.		0
2536	Molecular testing in myeloproliferative neoplasms. , 2024, , 569-587.		1
2538	Molecular testing in myelodysplastic syndromes. , 2024, , 589-596.		0
2541	Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2024, 38, 198-201.	3.3	1
2542	Clonal haematopoiesis, ageing and kidney disease. <i>Nature Reviews Nephrology</i> , 2024, 20, 161-174.	4.1	1
2544	Precision Nutrition and Cancer. , 2024, , 277-298.		1
2546	Molecular mechanisms in colitis-associated colorectal cancer. <i>Oncogenesis</i> , 2023, 12, .	2.1	3
2549	DNA methylation controls hematopoietic stem cell aging. <i>Nature Aging</i> , 2023, 3, 1320-1322.	5.3	0
2562	Liquid Biopsies for Pancreatic Cancer: Is It Ready for Prime Time?. , 2023, , 147-157.		0
2593	Ten-Eleven-Translocation Genes in Cancer. <i>Cancer Treatment and Research</i> , 2023, , 363-373.	0.2	0
2622	Immune System Influence on Hematopoietic Stem Cells and Leukemia Development. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 125-135.	0.8	0
2624	Ageing, Causes, and Rejuvenation of Hematopoietic Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 201-210.	0.8	0
2625	The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 65-83.	0.8	0

#	ARTICLE	IF	CITATIONS
2667	Alternative DNA structures in hematopoiesis and adaptive immunity. <i>Advances in Immunology</i> , 2024, , .	1.1	0